• KOL
    • Charles L Loprinzi
    • Charles L Loprinzi

      Charles L Loprinzi

      Mayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ...

       

       

      Kol CV for Charles L Loprinzi

      Year
      2022

      Mayo Clinic, Rochester, MN;

      2021

      Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address:

      Mayo Clinic, Rochester, MN, USA

      2020

      Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America

      Division of Medical Oncology, Mayo Clinic, Rochester, USA

      North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota

      Mayo Clinic, Rochester, MN, United States.

      2019

      Department of Oncology; Mayo Clinic; Rochester, Minnesota

      Mayo Clinic Rochester, Florida, USA

      Medical Oncology

      2018

      Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA

      Division of Medical Oncology, Mayo Clinic, Rochester, MN

      2017

      Division of Medical Oncology, Mayo Clinic, Rochester, MN.

      Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX.

      Mayo Clinic Minnesota Department of Oncology Rochester Minnesota

      The Cancer Center

      2016

      Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN

      Mayo Clinic Cancer Center, Rochester, Minnesota

      2015

      Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA

      Mayo Clinic Division of Medical Oncology Rochester Minnesota

      2014

      Mayo Clinic Cancer Center Rochester MN

      2013

      From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN.

      Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA

      2012

      Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA

      Mayo Clinic, Rochester, MN, United States

       

       

      Charles L Loprinzi: Påvirke statistikk

      Prøve av konsepter som Charles L Loprinzi er blant de beste ekspertene i verden.
      Concept World rank
      effects cipn #1
      balance gait testing #1
      hot flash relief #1
      outcomes study points #1
      patients paclitaxel polyneuropathy #1
      weight loss investigation #1
      day cisplatin therapy #1
      preliminary evidence improvement #1
      flashes treatment #1
      preceding 2 months #1
      vaginal dehydroepiandrosterone dhea #1
      topical cannabinoids #1
      antacid mouthwash #1
      neuropathy 20 #1
      1year survival trials #1
      flashes stellate #1
      cipn methods #1
      purposepaclitaxel #1
      deprivation therapy patients #1
      magnesium camg #1
      cipn trials #1
      numerical analogue scale #1
      cancers prevalence #1
      stellate ganglion block #1
      records adult patients #1
      oral cryotherapy #1
      nonfluid weight gain #1
      1 month appetite #1
      oral cryotherapy patients #1
      neuropathic pain difficulty #1
      pregenplus #1
      bothersome hot flashes #1
      n08c3 #1
      amines antidepressive #1
      attribution treatment #1
      safety progestational agents #1
      toxicities opioids #1
      weeks hot #1
      agents humans clinicians #1
      recommended colorectal #1
      n08cb #1
      middle aged minocycline #1
      adam vte trial #1
      placebo mouthwash #1
      patients hot flashes #1
      flashes prospective #1
      therapy hot #1
      hot flash #1
      cinv day #1
      n08ca association #1
      fsfi 95 #1
      oral mucosa study #1
      antiemetic prescribing #1
      prognosis items #1
      cipn function #1
      evidence cipn #1
      placebo arm gabapentin #1
      gabapentin aminobutyric acid #1
      alliance a151724 #1
      lidocaine antacid #1
      studies cyproheptadine #1
      cipn phase iii #1
      rs9657362 #1
      life cipn #1
      flash therapies #1
      polyneuropathy allelic variability #1
      peripheral neuropathy #1
      hot flash scores #1
      pilot trial hands #1
      ambulatory patients opioids #1
      placebo oral mucositis #1
      pharmacologic therapeutics #1
      score baseline values #1
      oral mucositisrelated pain #1
      duloxetine response #1
      motor subscales #1
      darbepoetin alfa head #1
      painful oxaliplatininduced cipn #1
      isaes #1
      pilot trials efficacy #1
      female services tpn #1
      extreme phenotyping #1
      cipnmethodspatients #1
      isae #1
      cipn agents #1
      n08cb alliance #1
      prevent oxaliplatin #1
      suggested gabapentin #1
      cachexia studies #1
      prtmethodsdata #1
      sensory neuropathy symptoms #1
      joints syndrome #1
      tpn death #1
      illness neuropathic symptoms #1
      leap rom #1
      adjuvant numeracy calculators #1
      olanzapine projects vomiting #1
      oral mucositis alopecia #1
      baseline assessment week #1
      baseline neuropathic pain #1
      combination chemotherapy hec #1
      acetate hot #1
      aes placebo arm #1
      paclitaxel polyneuropathy #1
      flaxseed bar lignans #1
      appetite stimulation patients #1
      subsequent chemotherapy cycles #1
      pilot trials citalopram #1
      cipn common #1
      a151408 study data #1
      cipn20 questionnaire #1
      understanding potential benefits #1
      5fu adjuvant #1
      items positive indication #1
      compassionate honesty #1
      grade peripheral neuropathy #1
      megestrol acetate nausea #1
      patients placebo pellet #1
      bridging editorial #1
      baseline week followup #1
      patients 25 micrograms #1
      cinv neoplasms vomiting #1
      management hot #1
      bakplo #1
      pharmacological targeting oct2 #1
      supportive nsclc #1
      topical keratolytic #1
      natural postural instability #1
      attribution percentage #1
      treatment hot #1
      diseases pilot #1
      adt cyclohexanecarboxylic acids #1
      numeracy benefit #1
      treatment cipn #1
      oil nasal #1
      nonhormonal agents treatment #1
      acute symptoms cycle #1
      suggestion oral cryotherapy #1
      overview crci #1
      arhgef10 cipn #1
      flash scores #1
      patients megestrol acetate #1
      enoxaparin cvte #1
      ocular ice #1
      hormone deprivation cancer #1
      recommendation prevention #1
      purposehot #1
      head therapeutic equivalency #1
      gas menopause patient #1
      postural instability chemotherapy #1
      week tamoxifen #1
      toxicity agent #1
      doubleblinded manner #1
      background hot #1
      uniscale qol baseline #1
      antibiotic lozenge #1
      antiemetic prescribing practices #1
      leucovorin breast #1
      anorexia antineoplastic agents #1
      life leap #1
      extensive animal data #1
      lymphedema incidence intervention #1
      tested interventions lymphedema #1
      postsurgical neuropathic pain #1
      estimated benefit dfs #1
      stomatitis administration #1
      iii double #1
      induced cipn #1
      numbness hands #1
      historical placebo response #1
      management hot flashes #1
      ulabtka #1
      cipn topical gel #1
      oncologists competence 95ci #1
      placebo 15 points #1
      cryotherapy auc #1
      topical cannabinoids patients #1
      relatedness treatment #1
      male megestrol megestrol #1
      newer antidepressants gabapentin #1
      cyproheptadine appetite #1
      response relationship odc #1
      longitudinal continuation #1
      fluorouracilinduced stomatitis #1
      rs17683288 #1
      prevention paps #1
      chemotherapy regimen type #1
      drowsiness unpleasant taste #1
      lignans 6 weeks #1
      cachexia cyproheptadine #1
      isae anthracycline #1
      drowsiness doxepin mouthwash #1
      cachexia dexamethasone #1
      alleviate hot #1
      neoplasms climacteric #1
      inadequate hot #1
      cipn paps #1
      5fuinduced ocular toxicity #1
      baseline prognosis values #1
      cyclohexanols female #1
      mascc isoo evidence #1
      81 patients patients #1
      alliance n08c1 #1
      testosterone improvements #1
      balance impairments patients #1
      efficacy gabapentin #1
      gene arhgef10 #1
      neuropathic symptoms breast #1
      alliance study a221102 #1
      flashes venlafaxine #1
      purposehot flashes #1
      δ − 95 #1
      20 data patients #1
      underdescribers weeks #1
      baseline prognosis #1
      nonestrogenic management #1
      oestrogen hot flashes #1
      subcutaneous testosterone improvements #1
      points diphenhydramine #1
      difference cipn20 scores #1
      n08ca patients #1
      managing hot #1
      aminobutyric acid hec #1
      cipn postural control #1
      placebo arms percentage #1
      95 increased difficulty #1
      preliminary promising data #1
      cancerassociated anorexia cachexia #1
      altered sensory organization #1
      trust oncologists competence #1
      infliximab lung #1
      acetate anorexia #1
      ulabtka placebo cream #1
      5 weeks device #1
      gabapentin hot flashes #1
      cancer hot #1
      guidelineendorsed treatment #1
      doxepin mouthwash placebo #1
      nasal vestibulitis #1
      data clinical histories #1
      toxicity gabapentin #1
      acetate appetite #1
      cipn adult #1
      tingling #1
      antidepressant gabapentin #1
      rs9657362 previous study #1
      accru trial #1
      n08ca #1
      neuropathy data #1
      numbness scores #1
      a151408 #1
      underdescribing #1
      disease patient factors #1
      nonhormonal therapies paroxetine #1
      male megestrol life #1
      cryotherapy hands #1
      sae δ − #1
      cipnsummarythere #1
      hfs trial #1
      agents cipn #1
      patients 10 range #1
      accru study ru221408i #1
      weeks hot flashes #1
      discrepancies clinicians assessment #1
      glutamine toxicity #1
      12 months anticoagulation #1
      authors 115 patients #1
      oncologists competence #1
      nonhormonal hot #1
      2007 guidelines guideline #1
      patients spray product #1
      bortezomib alters #1
      nonfluid weight #1
      udi scores baseline #1
      initiation tpn #1
      taxane infusion #1
      rest psychostimulants #1
      43 oral complications #1
      underdescribers #1
      data hot #1
      study dmc assay #1
      treatments modalities #1
      peripheral neuropathy paclitaxel #1
      symptom intervention #1
      alliance trial #1
      mouthwash diphenhydramine #1
      n00cb #1
      hot flash score #1
      ganglion surveys humans #1
      acetate dexamethasone #1
      neuropathy randomized #1
      ssc device prototype #1
      tpn longterm survival #1
      flash score #1
      complete response authors #1
      cipn clinical trial #1
      oestrogen survivors #1
      or1 year patients #1
      infliximab cancer #1
      leap lymphedema #1
      hormone deprivation symptoms #1
      mascc isoo guidelines #1
      oncologists prognostic #1
      populations neurologic humans #1
      methylphenidate cancer patients #1
      patient followup studies #1
      sham acupuncture participants #1
      institutional guidelines patients #1
      oxybutynin hot flashes #1
      phase iii evaluation #1
      leap 12 months #1
      individuals cipn #1
      pilot evaluation #1
      rs2294039 #1
      benefit fluoxetine #1
      symptoms cipn #1
      bellergal #1
      isae data #1
      current trial #1
      receiving fluorouracil #1
      women 65 day #1
      weight megestrol acetate #1
      qlq cipn20 #1
      small cell continuity #1
      pilot study minocycline #1
      daily questionnaires #1
      flashes common #1
      benefit 5fu #1
      venous toxicity fosaprepitant #1
      induced neurotoxicity oct2 #1
      lymphedema prevention education #1
      toxicity prospective trial #1
      cvte rivaroxaban #1
      daily hot #1
      cipn nervous diseases #1
      isae patients #1
      reduction hot #1
      doxepin mouthwash patients #1
      aimss life #1
      nonhormonal agents #1
      decrease hot #1
      cipn data #1
      week hot #1
      prevention cipn #1
      hot flashes quality #1
      snv rs9657362 #1
      95 neuropathic pain #1
      patients subcutaneous testosterone #1
      prominent toxicity #1
      lenolidamide #1
      placebo drowsiness #1
      hormone deprivation #1
      acetate doses #1
      patientreported nasal symptoms #1
      n01c9 #1
      leucovorin breast cancer #1
      adam vte #1
      flaxseed hot flashes #1
      oral cryotherapy prevention #1
      rom leap #1
      dronabinol megestrol acetate #1
      nonfluid bodyweights #1
      deprivation symptoms #1
      life study arms #1
      cipn20 #1
      bakplo placebo #1
      patients dosing guidelines #1
      gabapentin antidepressant #1
      recurrences clinical histories #1
      drug humans interferons #1
      slight appetite stimulation #1
      digital melt curve #1
      auc cryotherapy #1
      agents cyclohexanecarboxylic #1
      tools oncologists #1
      patients cancer anorexia #1
      ctcae grade #1
      hot flash mechanism #1
      prominent clinical problem #1
      supportive cytotoxic chemotherapy #1
      n08c1 #1
      humans ganglion surveys #1
      items uncertain gbu #1
      prestudy hypothesis #1
      ganglion surveys #1
      association arhgef10 #1
      authors 30 minutes #1
      hfs symptoms patients #1
      suggestion toxicity #1
      patients nasal vestibulitis #1
      burning pain #1
      qol reported difficulty #1
      hot flash control #1
      duloxetine response patients #1
      control hot flashes #1
      nociceptors putative mechanism #1
      antibiotic lozenge placebo #1
      gabapentin baseline week #1
      gait testing patients #1
      differences neuropathy syndromes #1
      megestrol acetate #1
      survivors genitourinary syndrome #1
      acetate versus #1
      chemotherapy treatment chemotherapy #1
      hot flashes treatment #1
      bakplo symptoms #1
      ocular ice packs #1
      anthracycline data #1
      vte recurrence enoxaparin #1
      centrally active agent #1
      median δ qs #1
      topic rectum surveys #1
      taxane treatment development #1
      regional hypothermia burden #1
      treatment attribution #1
      uncertain gbu gbu #1
      single snv rs9657362 #1
      therapy numbness #1
      antineoplastic agents nrs #1
      ru221408i #1
      baseline fsfi score #1
      individual patients understanding #1
      uncertain gbu #1
      95 doxepin mouthwash #1
      ulabtka hfs #1
      resected cutaneous melanomas #1
      placebo anecdotal observations #1
      lymphedemafree rates groups #1
      severe stomatitis #1
      anecdotal observations gabapentin #1
      tools hypothetical scenarios #1
      residual hot flashes #1
      olanzapine arm emesis #1
      cipn20 sensory #1
      lymphedema hrqol outcomes #1
      metastatic disease initiation #1
      placebo pilot trials #1
      feet oxaliplatin #1
      65 day #1
      developed mucositis #1
      flashes objective #1
      aps paclitaxel #1
      crc patients 95 #1
      fluoxetine hot #1
      points doxepin #1
      toxicity anecdotal observations #1
      flashes gabapentin #1
      based chemotherapy isae #1
      life qlqcipn20 #1
      nsclc response rate #1
      acceptability ssc device #1
      eortc cipn20 #1
      fosaprepitant isae #1
      prevention oral cryotherapy #1
      women inadequate control #1
      reducing hot #1
      nonhormonal #1
      compliance institutional guidelines #1
      chamomile mouthwash #1
      treatment hot flashes #1
      oncology providers crci #1
      modalities cancer patients #1
      hot flashes weeks #1
      tpn initiation death #1
      suggestion pregabalin #1
      tpn female services #1
      neoplasms placebos #1
      lymphedemafree rates #1
      flashes pilot #1
      creatine placebo groups #1
      5 methylphenidate #1
      dmc assay #1
      flashes quality #1
      active nonhormonal #1
      device 5 weeks #1
      established cipn #1
      dronabinol combination #1
      symptoms hormone deprivation #1
      burden alopecia #1
      myalgias arthralgias #1
      dfs predictions adjuvant #1
      treating hot #1
      cachexia cancer anorexia #1
      glutathione cipn #1
      supportive cryotherapy #1
      nonfluid #1
      positive indication prognosis #1
      mouthwash placebo #1
      alopecia ocular toxicity #1
      coasting phenomenon #1
      relatedness treatment arms #1
      patients dfs predictions #1
      paclitaxel weekly cryotherapy #1
      aes relatedness #1
      cipn development severity #1
      antiserotonergic drug #1
      ncctg n08c1 #1
      vitamin cipn #1
      stomatitis scores #1
      discrepancies women #1
      trial n00cb #1
      balance patientreported outcomes #1
      women megestrol acetate #1
      symptoms feet #1
      n06ca #1
      pain chemotherapy #1
      flashes patients #1
      skin dermatitis trials #1
      acute pain syndrome #1
      efficacy agent #1
      revisitation doc #1
      placebo 30 points #1
      tingling numbness #1
      numbness tingling #1
      neuronal uptake transporters #1
      inadequate control antidepressant #1
      ulabtka arm #1
      symptoms hands #1
      sensory subscale #1
      gsm fsfi #1
      premenopause radiotherapy #1
      gabapentin hot #1
      minocycline cipn #1
      137 patients cycle #1
      hot flash frequency #1
      difficulty neuropathic pain #1
      phytotherapy vitamin #1
      cachexia trial #1
      dmc samples #1
      paresthesia peripheral #1
      treatment symptom intervention #1
      hec cisplatin therapy #1
      breakthrough nausea patients #1
      placebos pregabalin quality #1
      anorexia appetite #1
      patientcompleted questionnaires #1
      qolconclusionsthe #1
      megestrol acetate patients #1
      therapeutic targets cipn #1
      cytotoxic chemotherapy supportive #1
      patients gabapentin #1
      ncctg trial n06ca #1
      improvements hot flashes #1
      topic peripheral neuropathy #1
      eortc qlqcipn20 instrument #1
      eortc cipn #1
      antidepressants gabapentin #1
      flaxseed bar #1
      baseline week gabapentin #1
      flashes prostate #1
      managing hot flashes #1
      hot flashes #1
      intervention leap #1
      treating institution intervention #1
      hot flashes day #1
      cachexia megestrol #1
      prevention induced cipn #1
      doxepin mouthwash #1
      agents antihypertensive agents #1
      incurable cancer records #1
      − fsfi #1
      hot flashes women #1
      hot flashes gabapentin #1
      cancer anorexia cachexia #1
      dfs 5fu #1
      effects hot flashes #1
      hours nighttime sleep #1
      2007 guidelines suggestion #1
      2 study arms #1
      oral cryotherapy management #1
      conducted studies hrt #1
      magnesium oxaliplatininduced neurotoxicity #1
      accru study #1
      fsfi udi #1
      pregabalin paps #1
      individuals impaired balance #1
      dmc mutations #1
      routine feces sensitivity #1
      hfs ulabtka #1
      hot flashes acceptability #1
      chemotherapy neuropathy #1
      aminobutyric acid adt #1
      pilot trials venlafaxine #1
      adjuvant numeracy #1
      hot flash activity #1
      patients highdose interferon #1
      safety oestrogen #1
      5fuinduced stomatitis #1
      loe prevention #1
      udi δ − #1
      life megestrol acetate #1
      favor placebo #1
      women male megestrol #1
      paclitaxel favor #1
      fractures infertility #1
      antidepressive agents gamma #1
      vaginal dehydroepiandrosterone #1
      alliance n08ca #1
      cancerrelated fatigue interventions #1
      nonhormonal agent #1
      neoplasm recurrence apixaban #1
      pregabalin paclitaxel #1
      flashes week #1
      increased difficulty patients #1
      purpose hot #1
      highdose melphalan intervention #1
      treatment alteration #1
      neuropathy prevention #1
      physical consequences cipn #1
      impaired postural control #1
      compounded topical gel #1
      gabapentin arm #1
      patients ulabtka #1
      hot flashes patients #1
      numeracy adjuvant #1
      randomized study lymphedema #1
      patients underdescribers #1
      cryotherapy mucositis #1
      placebo 15 glutathione #1
      study stool samples #1
      oxybutynin doses #1
      fourth treatment week #1
      judicious tpn #1
      hot flash data #1
      cachexia carcinoma life #1
      effects limited efficacy #1
      papsmethodspatients #1
      toxicity ocular #1
      ncctg n08c3 #1
      arthralgia breast life #1
      cisplatin therapy cinv #1
      paclitaxel coasting phenomenon #1
      overview oncology providers #1
      patients physical examinations #1
      rose geranium #1
      paclitaxel acute #1
      time publication attitude #1
      cipn20 data #1
      shooting burning #1
      8week observation period #1
      survival tpn initiation #1
      newer antidepressants #1
      hormonal ablation andropause #1
      education lymphedema prevention #1
      chemotherapy response rates #1
      patientreported outcomes balance #1
      diphenhydraminelidocaineantacid #1
      alleviating hot #1
      anecdotal observations #1
      replacement testosterone andropause #1
      flashes androgen #1
      22 nonestrogenic management #1
      flashes women #1
      qolresultsfrom #1
      management genital symptoms #1
      paps fatigue #1
      attribution clinical trials #1
      backgrounddehydroepiandrosterone #1
      cyclohexanecarboxylic acids gamma #1
      30 points 95 #1
      megestrol acetate weeks #1
      flashes breast #1
      bothersome hot #1
      chamomile mouthwash toxicity #1
      compliance institutional guideline #1
      bupropion nicotine dependence #1
      education lymphedema education #1
      vaginal cytology women #1
      paclitaxel study arms #1
      progestational agents patients #1
      npy levels groups #2
      humans postmenopause pregabalin #2
      hot flash frequencies #2
      allopurinol mouthwash #2
      sensitivity cold items #2
      “use vitamin #2
      patients oxybutynin doses #2
      epoetin alfa 40000 #2
      monthly intervals appetite #2
      cpmp scrambler therapy #2
      time randomized study #2
      scrambler #2
      ctcae differences #2
      hot flashes dehydroepiandrosterone #2
      hot flashes citalopram #2
      baseline week day #2
      vitamin hot #2
      cdf score #2
      hemoccultsensa hemoccult #2
      previous hot flashes #2
      cipn cases #2
      bupropion nicotine inhaler #2
      postural instability individuals #2
      life illness tetracycline #2
      patients black cohosh #2
      conceppt #2
      improvement hot flashes #2
      dhea 4 weeks #2
      qol crc #2
      hot flashes pregabalin #2
      oxybutynin doses placebo #2
      surveys repeated measures #2
      study arms conclusions #2
      advancedstage cancer #2
      improvement hot #2
      design considerations recommendations #2
      46 screenrelevant neoplasms #2
      nicotine inhaler bupropion #2
      vte recurrence doacs #2
      patients cipn #2
      desipramine hot flashes #2
      120k arm patients #2
      nutrition scores physicians #2
      patients treating institution #2
      longitudinal studies postmenopause #2
      shark cartilage product #2
      supplementary n03cb #2
      intervention 18 months #2
      patients difluoromethylornithine #2
      time ncctg alliance #2
      placebo hf frequency #2
      hemoccultsensa sensitivity #2
      pa outcomes pros #2
      15 points 95 #2
      single snv #2
      inadequate benefit #2
      folfox auc p0·0001 #2
      oral iron 46 #2
      skindex16 itching #2
      symptoms skin toxicity #2
      postmenopausal women previous #2
      40000 40k arm #2
      females cessation treatment #2
      cipn cancer treatment #2
      placebo breast radiotherapy #2
      shark cartilage placebo #2
      hemoccultsensa detection #2
      pregabalin arms #2
      doses megestrol #2
      ncctg trial #2
      tens 2 weeks #2
      original report time #2
      conclusions sunscreen #2
      positive doseresponse #2
      colonoscopically normal patients #2
      hot flashes bupropion #2
      hot flashes data #2
      anabolic corticosteroid appetite #2
      pregabalin treatments placebo #2
      hot flash studies #2
      46 adenomas 1 #2
      flashes placebo #2
      appearing pilot data #2
      cachexia pentoxifylline #2
      nonestrogenic hot #2
      symptomatic cipn #2
      pilocarpine vaginal dryness #2
      topic estrogen #2
      fatigue improvement methylphenidate #2
      nutrition scores 95 #2
      oxaliplatin hands #2
      ctcae pruritus #2
      woman quality #2
      nonestrogenic therapies #2
      physicians kps #2
      pilocarpine vaginal #2
      cipn peripheral neuropathy #2
      cancerassociated anorexia #2
      lmwh arms #2
      breast cancer venlafaxine #2
      weekly epoetin #2
      descriptive manner #2
      week baseline week #2
      placebo bar #2
      outcome measures ctcae #2
      day baseline week #2
      cisplatin polymerase inhibitors #2
      subsequent mucositis #2
      study n08cb alliance #2
      trial suggestion #2
      lmwh arms 7 #2
      reduce hot #2
      screenrelevant neoplasms 16 #2
      questionnaires antineoplastic agents #2
      life venlafaxine hydrochloride #2
      oral megestrol #2
      cipn primary outcomes #2
      data relative benefits #2
      cipn prevention trials #2
      kps nutrition score #2
      evaluating gabapentin #2
      folfox auc analysis #2
      tamoxifen percentage reduction #2
      oxybutynin women #2
      vitamin hot flashes #2
      placebo vaginal dryness #2
      flash diary #2
      megestrol acetate dexamethasone #2
      sdt2 sdt1 #2
      ferric gluconate darbepoetin #2
      illness tetracycline egfr #2
      16 hemoccult #2
      4 treatment weeks #2
      versus megestrol #2
      lvef 1000 #2
      npy anorexia cholecystokinin #2
      sulfate prevent #2
      reducing chemotherapy #2
      real patients treatment #2
      treatment baseline week #2
      anabolic corticosteroid #2
      mometasone time #2
      type chemotherapy drug #2
      patient‐physician disagreement #2
      rash incidence severity #2
      dronabinoltreated patients #2
      autonomic scales #2
      lessons cipn #2
      starting tamoxifen women #2
      nutrition score disagreement #2
      kps nutrition scores #2
      treatment alterations #2
      target doses placebo #2
      incidence severity stomatitis #2
      hot flashes aprepitant #2
      cycle folfox #2
      800 liquid suspension #2
      time toxt analysis #2
      provider assessed #2
      neuropathy paclitaxel #2
      49 venlafaxine #2
      venlafaxine gabapentin #2
      14 hot flashes #2
      iii randomized #2
      locoregional event #2
      feet 18 months #2
      women rom #2
      experience hot flashes #2
      clinically deficient fatigue #2
      anorexia severity #2
      hot flash quality #2
      peripheral neuropathy cipn #2
      tetracycline rash incidence #2
      anemia caa #2
      receiving megestrol #2
      receive parenteral #2
      stat erythema #2
      patients 40k arm #2
      study treatment citalopram #2
      coriat #2
      cipn #2
      108±11 #2
      appetite improvement #2
      postchemotherapy rheumatism #2
      40k arm 120000 #2
      induced peripheral #2
      treatment arm mmf #2
      breakthrough cinv #2
      infliximab docetaxel #2
      sdt2 hemoccult #2
      prevent paclitaxel #2
      sdt2 #2
      central cancer #2
      fluoxymesterone treatment #2
      ncctg n10c1 #2
      piroxantrone women #2
      established chemotherapy #2
      anabolic corticosteroid treatment #2
      trial acetate doses #2
      disagreement increased risk #2
      irox folfox auc #2
      life cancerrelated fatigue #2
      topical aged antimetabolites #2
      alternative treatment regimen #2
      ≤ moderate correlations #2
      ecog nutrition score #2
      dhea vaginal symptoms #2
      vte recurrence dalteparin #2
      treatment minority smokers #2
      cachexia decision #2
      preventive therapies cipn #2
      treatment cycles cycle #2
      induced peripheral neuropathy #2
      neoplasms double #2
      paclitaxel chronic neuropathy #2
      stomatitis sex #2
      120k arm #2
      gabapentin 4 weeks #2
      venlafaxine oxaliplatin neurotoxicity #2
      antidepressant hot flashes #2
      patients shark cartilage #2
      arms conclusions #2
      standard arm rate #2
      appetite cachexia #2
      moderate correlations ≤ #2
      time toxt approach #2
      treatment smoking abstinence #2
      tingling shooting #2
      intermediate term efficacy #2
      n0993 #2
      clinical trials n9741 #2
      adjuvant 5fu models #2
      middle aged survivors #2
      original report mometasone #2
      increased risk cipn #2
      oxaliplatin induced neurotoxicity #2
      hf frequency placebo #2
      guaninemethyltransferase #2
      prevent radiation #2
      paclitaxel induced #2
      patients 120k arm #2
      tens global impression #2
      patients chemotherapyassociated anemia #2
      singleagent megestrol acetate #2
      data gabapentin #2
      poor qol 95 #2
      fsfi score baseline #2
      patients monthly intervals #2
      dalteparin lowest risk #2
      pregabalin hot flashes #2
      week black cohosh #2
      n06c4 #2
      newer antidepressants trials #2
      months randomized #2
      120000 epoetin alfa #2
      advanced cancer anorexia #2
      placebo situ carcinoma #2
      infliximab 5 day #2
      acttionconsortium #2
      cipn antineoplastic agents #2
      hot flashes humans #2
      management genitourinary symptoms #2
      cipn clinical #2
      appetite dissent disputes #2
      egfr inhibitor tetracycline #2
      indirect comparison apixaban #2
      life scrambler therapy #2
      scrambler therapy treatment #2
      mmf itching #2
      detection screenrelevant neoplasms #2
      predictors disagreement #2
      alliance folfox #2
      1 oral megestrol #2
      cipn20 factor analysis #2
      glutamine placebo preparation #2
      sdt1 hemoccult #2
      real real patients #2
      day study week #2
      induced arthralgias #2
      glutathione prevention #2
      oxaliplatin doses trends #2
      lamotrigine neuropathic symptoms #2
      trials newer antidepressants #2
      participants 3 stools #2
      phytogenic female humans #2
      neuropathy caused #2
      n01c4 #2
      depomedroxyprogesterone #2
      cohosh treatment #2
      dna markers participants #2
      cycle chronic neurotoxicity #2
      tamoxifenassociated hot flashes #2
      qol hb increment #2
      coumarin placebo #2
      suggested agents #2
      decreasing stomatitis #2
      folfox alliance #2
      study arms tetracycline #2
      5fuinduced mucositis #2
      disagreement patients #2
      cck8 anorexia severity #2
      product hot flashes #2
      trials suggested #2
      placebo combination therapy #2
      sunscreen arms #2
      rcts preventive therapies #2
      patients receiving fluorouracil #2
      efficacy scrambler therapy #2
      scrambler therapy management #2
      shark cartilage patients #2
      tamoxifen medications #2
      circulating concentrations npy #2
      randomized receive #2
      flash studies #2
      venlafaxine control #2
      sensitivity screenrelevant neoplasms #2
      women hot flashes #2
      cipn cancer survivors #2
      n03cb #2
      cipn paclitaxel #2
      scrambler therapy #2
      stat itching #2
      acknowledged loss #2
      pilot citalopram #2
      daily mmf radiotherapy #2
      95 oral placebo #2
      study arms #2
      cipn cohort #2
      mucositis 5fubased chemotherapy #2
      01 mmf #2
      life 4week intervention #2
      fosaprepitant patients #2
      declining qol #2
      cold items 71 #2
      treatment aprepitant #2
      palliative communications #2
      flashes citalopram #2
      symptoms surveys #2
      pruritus pros #2
      dronabinol versus #2
      34—vitamin #2
      stomatitis women #2
      aprepitan #2
      worse survivorship #2
      weekly hf score #2
      docetaxel serum concentrations #2
      aprepitant 4 weeks #2
      hot flash trials #2
      day average pain #2
      survival 3915 patients #2
      citalopram hot flashes #2
      life cipn20 #2
      150 groups patients #2
      infertility ovarian failure #2
      evaluate weight #2
      patients daily mmf #2
      979254 #2
      80 anorexia #2
      hot flash management #2
      stage disease 5fu #2
      levetiracetam 4 weeks #2
      40k arm #2
      natural paps #2
      methylphenidate cancer #2
      gabapentin venlafaxine hydrochloride #2
      placebo arms women #2
      injections hot flashes #2
      hot flashes efficacy #2
      pain ≥4 10 #2
      120 arm #2
      global impression life #2
      hemoccultsensa sdt2 #2
      tingling patients #2
      gabapentin symptoms #2
      3 months bupropion #2
      detection dna markers #2
      eortc qlqcipn20 #2
      conclusions original report #2
      week breast cancer #2
      cipn interventions #2
      mometasone cream #2
      average stomatitis sex #2
      differences mometasone #2
      7 control arms #2
      duloxetine hydrochloride humans #2
      chronic chemotherapy #2
      patients adjuvant 5fu #2
      substantial hot flashes #2
      skindex16 ctcae #2
      dexamethasone fluoxymesterone #2
      95 indirect estimates #2
      cancerassociated wasting #2
      guidelines recommendation #2
      dermatitis symptom evolution #2
      life venlafaxine #2
      screenrelevant neoplasms #2
      135±19 #2
      treatment breakthrough cinv #2
      chemotherapyassociated anemia caa #2
      leucovorin women #2
      local antineoplastic agents #2
      women stomatitis #2
      life treatment weeks #2
      numeracy prognosis #2
      magnesium oxaliplatin #2
      life aimss #2
      folfox symptoms #2
      cipn20 scores #2
      control arms rate #2
      thiophenes treatment life #2
      dronabinol combination therapy #2
      cachexia acetate #2
      hemoccultsensa sdt1 #2
      humans citalopram cyclohexanols #2
      chemotherapy peripheral neuropathy #2
      manuscript “use #2
      432 smokers treatment #2
      nonhormonal management #2
      historic controls npy #2
      citalopram cyclohexanols humans #2
      weight concerns 26 #2
      placebo oxybutynin doses #2
      anorexia antineoplastic #2
      hot flash diary #2
      appetite dissent #2
      75 49 venlafaxine #2
      treating chemotherapy #2
      5fubased chemotherapy mucositis #2
      starting tamoxifen #2
      venlafaxine treatment 75 #2
      older age bupropion #2
      anthraquinones agents breast #2
      antidepressants hot #2
      patients olanzapine arm #2
      therapy hot flashes #2
      trial baseline week #2
      scrambler therapy tens #2
      toxicity profiles time #2
      16 sdt2 #2
      treatment target doses #2
      usual breathing #2
      pilocarpine arms #2
      smokers nicotine inhaler #2
      randomized study mometasone #2
      mometasone surveys #2
      subject global impression #2
      prevalence weight concerns #2
      failure prior chemotherapy #2
      placebo pregabalin treatments #2
      evaluating venlafaxine #2
      tamoxifen metabolism evidence #2
      anthrapyrazoles piroxantrone #2
      study arms quality #2
      neuropathy cipn #2
      treatment week placebo #2
      ductal mometasone furoate #2
      dosing zoledronic #2
      rash prevention #3
      oncology colorectal #3
      anorexia anorexia appetite #3
      real day #3
      survival cancerassociated wasting #3
      general subscale mfsisf #3
      eventual sensory patients #3
      51 female age #3
      median δ #3
      cachexia decision humans #3
      corticosteroid medications #3
      clonidine randomized trials #3
      flutamide hgpin #3
      cipn biological targets #3
      neurotoxic chemotherapies #3
      sham acupuncture week #3
      pts stage iii #3
      patients lidocaine patch #3
      traditional ctcae #3
      gwas mayo clinic #3
      cancer patients drugs #3
      ctcae grades patients #3
      cumulative neurotoxicity oxaliplatin #3
      additional 4 weeks #3
      placebo preparation #3
      cmt genes oxaliplatin #3
      advanced cancer standard #3
      baseline hot #3
      months bupropion #3
      trial bmd #3
      oxaliplatinbased therapy #3
      completed diaries #3
      depression somnolence #3
      eightyone randomized women #3
      delayed treatment arm #3
      n08ca paclitaxel #3
      toxicities selfreport #3
      physiologic pilot #3
      paps scores #3
      inhibitorinduced rash #3
      cartilage shark #3
      cmtassociated genes #3
      cyclohexanecarboxylic acids #3
      centrally active agents #3
      data pilot trials #3
      preventing peripheral #3
      feet 15 #3
      alfa compared #3
      pros differences #3
      primary endpoint gwas #3
      cipn mcbdr population #3
      qol placebotreated patients #3
      blind trial #3
      ctpm experts #3
      trials newer #3
      female gabapentin #3
      ginseng arm #3
      cmt gene #3
      life hospice patients #3
      minocycline prevention #3
      delayed zoledronic #3
      cipn evidence #3
      crossover methodology #3
      paps scores dose #3
      placebo prostate adenocarcinoma #3
      starting letrozole #3
      questionnaires syndrome paclitaxel #3
      95 40 points #3
      upfront arm #3
      oxaliplatin cipn #3
      centric decision #3
      patients upfront arm #3
      reported rash #3
      relationship numbness #3
      average severity #3
      snv charcotmarietooth disease #3
      hot flashes trial #3
      management cancer cachexia #3
      rash symptoms #3
      ” numbness #3
      incurable cancers #3
      vaginal dhea #3
      male megestrol #3
      chemotherapy‐associated anemia #3
      20 calories #3
      mucositis scores #3
      qlqcipn20 traditional ctcae #3
      asco guideline management #3
      hgb rbc transfusions #3
      canada collaborative effort #3
      hands burning pain #3
      burning pain patients #3
      dhea hot flashes #3
      neuropathy chemotherapy #3
      1 month cytokines #3
      genetic factors patients #3
      epoetintreated patients #3
      bacterial agents life #3
      baseline general subscale #3
      ≤−20 #3
      snv cmtassociated genes #3
      experts cipn #3
      cipn snv #3
      weekly arm differences #3
      genetic predictors cipn #3
      10 weeks therapy #3
      paps dose #3
      study population mcbdr #3
      longitudinal adverse #3
      life antineoplastic agents #3
      middle aged pilot #3
      receive placebo #3
      hemoccultsensa #3
      epoetintreated patients incidence #3
      patients paps scores #3
      bit hands #3
      neoplasms vomiting #3
      apixaban lowest risk #3
      asco surveillance #3
      combinationtreated arms #3
      chlorhexidine mouthwash #3
      cipn ctpm #3
      neuropathy trials #3
      patient completed #3
      pilot trial pregabalin #3
      n08ca n08cb study #3
      undergoing androgen ablation #3
      topical ceramides #3
      chemotherapy gabapentin #3
      projects prospective #3
      patients antiemetic #3
      n05c4 #3
      toxicity agents #3
      trials n9741 #3
      acetate treated #3
      topic mayo clinic #3
      hemoccult hemoccultsensa #3
      mcbdr #3
      egfr inhibitorinduced rash #3
      placebo breast #3
      thirdline hormonal therapy #3
      hgpin chemoprevention trial #3
      “use #3
      controls singleton snv #3
      study antidepressive agents #3
      recommendations dietary counseling #3
      measures peripheral #3
      subcutaneous weekly #3
      relationship response rate #3
      epoetin alfa hgb #3
      evidence prostate adenocarcinoma #3
      tingling burning pain #3
      epoetintreated patients study #3
      methodologic lessons #3
      prevent epidermal #3
      patients cyproheptadine #3
      numeracy patients #3
      combinationtreated arms survival #3
      chemotherapyassociated anemia #3
      qlqcipn20 #3
      mouthwash patients #3
      tamoxifen fluoxetine #3
      dalteparin vte #3
      methylphenidate patients #3
      cold items #3
      bivariate construct #3
      patients scrambler therapy #3
      egfr inhibitor patients #3
      treatment bother #3
      osteoporosis osteopenia letrozole #3
      95 udi #3
      follow fsfi #3
      carboplatin gwas #3
      controlled double #3
      radiation‐induced mucositis #3
      shooting burning pain #3
      life dronabinol #3
      hot flashes placebo #3
      acute neuropathy #3
      rash conclusions #3
      cipn n08cx population #3
      oral megestrol acetate #3
      40000 units #3
      life eortc qlq #3
      repeated measures analyses #3
      n03cc #3
      drug toxicity patients #3
      hormonal ablation #3
      mfsisf 4 weeks #3
      mcbdr primary endpoint #3
      qlqcipn20 scores #3
      chemotherapy induced #3
      patients chemotherapy cycle #3
      etanercept current trial #3
      data ginseng #3
      patients baseline week #3
      vitamin prevention #3
      cvte #3
      thromboembolism secondary #3
      chemotherapy increases #3
      intravenous calcium magnesium #3
      mastectomy rates #3
      iii controlled #3
      interventions cancerrelated fatigue #3
      cyproheptadine patients #3
      gabapentin management #3
      chronic neuropathy patients #3
      epa combinationtreated arms #3
      oxaliplatin primary endpoint #3
      purposefosaprepitant #3
      ctcae grading arms #3
      neurotoxic chemotherapy cipn #3
      prophylactic tetracycline #3
      classic sums #3
      survivors gsm #3
      upfront treatment arm #3
      pilot evaluation gabapentin #3
      aminobutyric acid gabapentin #3
      purposeoxaliplatin #3
      ssc device #3
      fluoxetine arm #3
      selfreport ctcae grading #3
      cipn cmtassociated genes #3
      week chemotherapy dose #3
      rash study arms #3
      mpa single dose #3
      iii evaluation #3
      experience greater #3
      stomatitis sucralfate #3
      ctcae pros #3
      survival epa #3
      baseline treatment day #3
      patients cancerassociated wasting #3
      3 weeks 80k #3
      frequency hot #3
      ginseng crf #3
      genetic predictors paclitaxel #3
      week venlafaxine therapy #3
      oxaliplatininduced neuropathy #3
      fasting chemotherapy #3
      qol hgb #3
      n08cx #3
      severe stomatitis leukopenia #4
      chemotherapy‐induced peripheral #4
      900 dose #4
      endorsed treatment #4
      risk reduction therapy #4
      severity sexes #4
      receive oral #4
      doubleblind manner #4
      based chemotherapy severity #4
      ctx odx #4
      day paroxetine #4
      chronic neuropathy #4
      colorectal cancer asco #4
      guidelines oral #4
      appetite stimulation #4
      bupropion 3 #4
      single dose venlafaxine #4
      oxybutynin placebo #4
      topic survivors #4
      95 oral iron #4
      cutaneous electrostimulation #4
      measurable metastatic disease #4
      treatment ncctg #4
      qol performance score #4
      secondary vte prevention #4
      to100 #4
      addition letrozole #4
      survivors hot #4
      rash incidence #4
      nsclc trials #4
      trpa1 cisplatin #4
      doxepin female head #4
      1093 women #4
      flaxseed placebo #4
      anorexia weight #4
      therapy aimss #4
      aimss #4
      rash study #4
      prominent problem #4
      control hot #4
      arm breast neoplasms #4
      predictors duloxetine response #4
      symptoms individual patients #4
      intrapatient difference #4
      numbness toes #4
      vaginal assessment scale #4
      bupropion 3 months #4
      cipn20 ctcae #4
      6 months bupropion #4
      backgroundhistorically #4
      recommendation ctx #4
      fluorouracilbased chemotherapy #4
      therapy oncologists #4
      weekly toxicity #4
      parenteral iron #4
      general subscale #4
      flash frequency #4
      surgery lymphedema #4
      hot flashes week #4
      nonabsorbable antibiotic #4
      hemoccult #4
      ais biomarkers #4
      appetite quality #4
      logistic regression incidence #4
      paced breathing #4
      iron arm #4
      tpn initiation #4
      gabapentin day #4
      oral cryotherapy mucositis #4
      achievements ncctg #4
      egfr inhibitor rash #4
      cco guideline followup #4
      anorexia cholecystokinin #4
      based chemotherapy women #4
      benefits adjuvant #4
      recommended endorsement #4
      loss syndrome #4
      dietician #4
      odx ctx #4
      treatment cancer anorexia #4
      odc activity mice #4
      anorectic cancer patients #4
      baseline fatigue survival #4
      followup surveillance protocol #4
      toxt analysis #4
      3915 patients #4
      hec cisplatin #4
      hfs quality #4
      daily baseline #4
      major doselimiting toxicity #4
      publication antiemetics humans #4
      outcomes olanzapine #4
      weight loss syndrome #4
      odc odc activity #4
      doac dalteparin #4
      administration parp inhibitor #4
      hot flashes therapy #4
      apr dex #4
      cancer acute vte #4
      nonestrogenic #4
      cachexia purpose #4
      qol baseline fatigue #4
      women greater toxicity #4
      40000 #4
      placebo arms #4
      or1 year #4
      additional meta analysis #4
      placebo hot #4
      aged mouthwashes #4
      inhibitor induced #4
      oral cavity mucosa #4
      controls imbalance #4
      suggested efficacy #4
      hgpin antineoplastic agents #4
      mastectomy rates patients #4
      calgb 70305 #4
      breast medical oncologists #4
      treatment benefits sex #5
      ongoing clinical trial #5
      cipnrelated symptoms #5
      epa supplement #5
      3 stools #5
      nutrition scores #5
      nodal status stage #5
      hb increment #5
      current trial patients #5
      models ttr #5
      study dmc #5
      aapro #5
      cancerrelated fatigue patients #5
      gabapentin trial #5
      trials lessons #5
      kps ecog #5
      appetite enhancement #5
      neuropeptide leptin #5
      neuropathy acute #5
      cipn participants #5
      receiving paclitaxel #5
      colorectal cancer surveillance #5
      vasomotor hot flashes #5
      ajcc external validation #5
      life epa #5
      cyclohexanecarboxylic #5
      physicianreported #5
      reported hot #5
      cancer anorexia #5
      trial hot #5
      additional 8 weeks #5
      trials cytotoxic chemotherapy #5
      combination electroacupuncture #5
      race ttr #5
      colorectal cancer society #5
      treating postmenopausal #5
      acetate neoplasms #5
      ttr cindices #5
      neuropathic pain qol #5
      ttr ajcc #5
      cumulative neurotoxicity #5
      life lmwh #5
      mucositis allopurinol #5
      trial developed #5
      cachexia anorexia #5
      numeracy tools #5
      agents basis #5
      disputes female humans #5
      intravenous calcium #5
      editor manuscript #5
      grade model estimates #5
      oxantrazole #5
      higher drug doses #5
      3 patients 4 #5
      postsurgical neuropathic #5
      difference control arm #5
      cipn numbness #5
      ajcc version staging #5
      patient outcomes numeracy #5
      impaired postural #5
      nodal status grade #5
      pain scores dose #5
      medical oncology outpatients #5
      ajcc tools #5
      odx #5
      patients lmwh injections #5
      centrally active #5
      cindices ajcc #5
      trial gabapentin #5
      induced stomatitis #5
      subsets treatment benefits #5
      reduce chemotherapy #5
      placebo exposed #5
      women 5fu #5
      libido #5
      olanzapine arm #5
      crc cancers #5
      neoplasm diagnostic tests #5
      cisplatin ganglia #5
      progestational agent #5
      sham real #5
      iron oral #5
      discontinuation aimss #5
      gabapentin patients #5
      crc cancer types #5
      bone loss osteopenia #5
      groups leptin concentrations #5
      neoplasms compared #5
      tools numeracy #5
      cancer survivors symptoms #5
      cipn effects #5
      questionnaires pregabalin #5
      numeracy online clinical #5
      flashes data #5
      acetate placebo #5
      death communication humans #5
      physicians predictive ttr #5
      digital melt #5
      rectal cancer surveillance #5
      fluoxymesterone patients #5
      fiftynine percent #5
      fosaprepitant prevention #5
      5fu trials #5
      ttr variables #5
      acetate neoplasms quality #5
      major outcome measure #5
      mucositis caused #5
      genetic quality life #5
      5fu folfox #6
      background chemotherapy #6
      loe guidelines #6
      staging patient outcomes #6
      agents breast #6
      hospitalized oncology patients #6
      proportion aes #6
      imidazoles letrozole #6
      5fubased chemotherapy #6
      north central #6
      smoking abstinence rates #6
      bf qol #6
      versus combination #6
      placebo arm patients #6
      71 sensitivity #6
      death kps #6
      pharmaceutic aged aged #6
      apixaban cancer patients #6
      megestrol #6
      studies vomiting #6
      methylo #6
      depomedroxyprogesterone acetate #6
      sadenosyllmethionine treatment #6
      participants sham acupuncture #6
      olanzapine prevention #6
      hrqol breast neoplasms #6
      alliance clinical #6
      daily diary questionnaires #6
      rs11572080 #6
      sensory scale #6
      severity data #6
      active malignancy #6
      severity neuropathic symptoms #6
      4week intervention #6
      placebo hot flashes #6
      fatigue pilot study #6
      highly emetogenic chemotherapy #6
      wisconsin ginseng #6
      life toxicity #6
      therapy 10 weeks #6
      nci ctcae #6
      selective poly #6
      500 mcg #6
      nicotine inhaler #6
      nonanthracycline chemotherapy #6
      flashes humans #6
      her2directed therapy #6
      induced sensory #6
      cancerrelated fatigue life #6
      intervention lymphedema #6
      mri trends #6
      neurological safety #6
      data supporting #6
      breakthrough nausea #6
      predictive illness surveys #6
      paclitaxel peripheral neuropathy #6
      placebo hfs #6
      cipn treatment #6
      medical acupuncture #6
      inhaler bupropion #6
      longacting methylphenidate #6
      menopause hot #7
      fluoxetine clinical trials #7
      neuropathy oxaliplatin #7
      mucositis placebo #7
      illness antimetabolites #7
      cyclophosphamidedoxorubicin #7
      throat discomfort #7
      follow year #7
      nausea cancer patients #7
      blind study #7
      minority smokers #7
      cancer patients anorexia #7
      model estimates survival #7
      pregabalin prevention #7
      12 treatment arms #7
      toxic polyneuropathy #7
      sensitivity fecal #7
      scheduled receive #7
      study drug trial #7
      appetites #7
      patient anthracycline #7
      mpa arm #7
      lymphedema education #7
      1week baseline period #7
      prevalence moderatetosevere #7
      intervention lymphedema status #7
      skindex16 #7
      study arms difference #7
      induced rash #7
      patients oral cryotherapy #7
      chronic postmastectomy pain #7
      venlafaxine day #7
      pain cipn #7
      weight concerns smokers #7
      paclitaxel peripheral #7
      cream versus #7
      adjuvant interferon patients #7
      patients hb response #7
      weekly epoetin alfa #7
      placebocontrolled trial #7
      hemoquant #7
      vte recurrence doac #7
      incidence rbc transfusion #7
      transdermal clonidine #7
      cryotherapy arm #7
      outcomes primary outcomes #7
      lower extremity symptoms #7
      5fu based chemotherapy #7
      rs10509681 #7
      intermediate odx #7
      stage nodal status #7
      bupropion relapse #7
      odx score #7
      hemoccult hemoquant #7
      nutrition score #7
      accru #7
      induced neuropathy #7
      20 percent placebo #7
      week followup #7
      smoking 3 #7
      venlafaxine therapy #7
      uniscale qol #7
      symptom subscale #7
      patients product #7
      serum concentrations cytokines #7
      citalopram cyclohexanols #7
      uniscale #7
      letrozole differences #7
      venlafaxine versus #7
      cmt genes #7
      fuinduced #7
      raw data trials #8
      cancer survivors cipn #8
      efficacy newer antidepressants #8
      cycle capecitabine #8
      severe hot flashes #8
      70305 #8
      1355 #8
      stomatitis patients #8
      venlafaxine hot flashes #8
      recurrence colon cancer #8
      topic antineoplastic #8
      oxaliplatin paclitaxel #8
      libido women #8
      neuropathic symptoms #8
      evidence pharmacologic interventions #8
      mouth sores #8
      smokers weight concerns #8
      18 months symptoms #8
      induced painful #8
      administered systemically #8
      venous toxicity #8
      nonhormonal treatments #8
      epa survival #8
      symptoms neuropathy #8
      cpmp #8
      direct oral factor #8
      pros aes #8
      series clinical trials #8
      oral placebo #8
      agents newer #8
      greater toxicity #8
      sdt1 #8
      prior chemotherapy exposure #8
      oral iron placebo #8
      treatment cinv #8
      factors cipn #8
      placebo pilot study #8
      chronic neurotoxicity #8
      opioids moderate pain #8
      paclitaxel severity #8
      neuropathy pain #8
      antidepressant patients #8
      tamoxifeninduced hot flashes #8
      oxaliplatin neuropathy #8
      progestational #8
      odx risk #8
      fecal blood #8
      folfox dfs #8
      paclitaxel pain #8
      life antibodies #8
      anecdotal #8
      flutamide placebo #8
      women hfs #8
      placebo suggestion #8
      neuropathy scale #8
      cutaneous aged anesthetics #9
      aged pilot #9
      baseline week week #9
      lymphedema prevention #9
      lmwh injections #9
      sensory axonopathy #9
      skindex16 scores #9
      incurable disease #9
      lymphedema hrqol #9
      trial paroxetine #9
      cipn patients #9
      questionnaires syndrome #9
      numbness fingers #9
      mometasone furoate placebo #9
      medications evidence #9
      fosaprepitant #9
      5 nausea #9
      oxaliplatin placebo #9
      neuropathic symptoms patients #9
      radiationinduced esophagitis #9
      fatigue methylphenidate #9
      appetite weight #9
      topical antimetabolites #9
      disease receive #9
      apixaban lower rate #9
      study treatment arm #9
      vitality subscale #9
      surgical year #9
      lamotrigine pain #9
      incidence colorectal adenomas #9
      relapse relapse prevention #9
      prevention vomiting #9
      patients provided #9
      ambulatory analgesics #9
      cancer patients cipn #9
      letrozole day #9
      acid amines #9
      dose dfmo #9
      hot flashes tamoxifen #9
      patients hot #9
      disease recurrence recurrence #9
      flash control #9
      43 trials #9
      antiemetic properties #9
      mucositis pain #9
      genistein tumor growth #9
      flashes hot #9
      follow tests #9
      trials demonstrated #10
      asco guideline #10
      life topic reproducibility #10
      frequency hot flashes #10
      recommendations general population #10
      neoplasms neuralgia #10
      qol anemia #10
      patients neurotoxic chemotherapy #10
      vaginal dryness #10
      flash data #10
      data relatedness #10
      humans megestrol #10
      oxaliplatin peripheral #10
      factes #10
      differences 5 years #10
      cancerassociated anemia #10
      scrambler therapy patients #10
      life dietary supplements #10
      ecog kps #10
      venlafaxine arm #10
      nonhormonal therapies #10
      gabapentin #10
      oxaliplatin trpa1 #10
      adult cancers #10
      advanced cancer life #10
      doses citalopram #10
      chemotherapy‐induced #10
      cognitive chemotherapy #10
      symptomatic malignant ascites #10
      inhibit cyp2d6 #10
      40 arm #10
      qol total #10
      randomized placebo #10
      nonhormonal treatment #10
      shark cartilage #10
      phase iii #10
      pain medications patients #10
      antineoplastic agents humans #10
      physical consequences #10
      patients treatment period #10
      controlled randomized #10
      cancerrelated fatigue fatigue #10
      minocycline reduction #10
      δ − #10
      folfox 5fu #10
      aprepitant treatment #10
      ctcae grades #10
      combination therapy relapse #10
      sensitivity cancer #10
      incidence stomatitis #10
      megestrol acetate quality #10
      anorexia cachexia #10
      ginseng placebo #11
      cancer undergoing #11
      translational component #11
      promising data #11
      physicians increased risk #11
      flashes #11
      efficacy black cohosh #11
      fsfi female #11
      institutional guideline #11
      differences study arms #11
      gbu #11
      curve assay #11
      sensory neurotoxicity #11
      anastrozole 10 #11
      prevalence neuropathic pain #11
      diphenhydramine lidocaine #11
      difficulty patients #11
      erythropoietic response #11
      reported incidences #11
      qol uniscale #11
      dalteparin major bleeding #11
      nicotine patch therapy #11
      electroanalgesia #11
      melt curve #11
      vomiting cancer patients #11
      ativan #11
      combination treated #11
      hydrazine sulfate #11
      olanzapine chemotherapy #11
      antiemetic guidelines #11
      rash quality #12
      individuals advanced adenomas #12
      toxicity 4 weeks #12
      apixaban dalteparin #12
      capsaicin cream #12
      adjuvant communication decision #12
      cipn development #12
      venlafaxine hydrochloride #12
      cachexia clinical trials #12
      venlafaxine women #12
      hot flashes 95 #12
      recurrence comparisons #12
      patients cipn symptoms #12
      valerian placebo #12
      reported peripheral #12
      hb response #12
      pilot trial levetiracetam #12
      neurotoxic chemotherapy #12
      toxicities groups #12
      irox folfox #12
      oxaliplatin induced #12
      pluronic lecithin organogel #12
      breast cancer letrozole #12
      −307 #12
      ctpm #12
      completed daily #12
      leptin cck8 #12
      cycles drugs #12
      probability prospective studies #12
      gait testing #12
      decreased libido #12
      andropause #13
      abh gel #13
      bmd 1 year #13
      oral anesthetics #13
      months smoking #13
      acute treatment vte #13
      patients diphenhydramine #13
      flashes day #13
      patients breakthrough cinv #13
      severity hot flashes #13
      megestrol acetate therapy #13
      ais women #13
      initial 3 months #13
      life neoplasm recurrence #13
      median hb #13
      rs3213619 #13
      venlafaxine life #13
      adjuvant colon cancer #13
      newer antidepressants placebo #13
      patients advancedstage cancer #13
      anemia life #13
      trial support #13
      education clinical practice #13
      adjuvant benefit #13
      hot flashes baseline #13
      40 points 95 #13
      nausea patients #13
      major bleeding doac #13
      weight cachexia #13
      therapy benefits #13
      troubling #13
      10 range #13
      ncctg #13
      neuropathy outcome #13
      2000 update #13
      life investigation #13
      treatment advanced cancer #13
      venlafaxine paroxetine #13
      paroxetine hot flashes #13
      neuropathic pain surgery #13
      improve cancer #13
      incident exposure #13
      adenomas aspirin #13
      autonomic scale #13
      troublesome symptoms #13
      estimates prognosis #13
      common toxicity #13
      valerian sleep #13
      marked toxicity #14
      smokers placebo #14
      benefit toxicity #14
      stool dna #14
      phase 3 months #14
      5fu surgery #14
      prophylactic agent #14
      flash activity #14
      oral iron #14
      based topical #14
      fluoxymesterone #14
      diagnosis localized disease #14
      palliate #14
      patients pain scores #14
      oxaliplatin vivo #14
      provided data #14
      biomarkers bone formation #14
      recurrences patients #14
      life anemia #14
      genital symptoms #14
      highly emetogenic #15
      life life survivors #15
      sternal skin conductance #15
      oxaliplatininduced neurotoxicity #15
      aes treatment #15
      folfox irox #15
      persistent incisional pain #15
      academic oncologists #15
      lidocaine patch #15
      16–28 #15
      triazoles zoledronic #15
      syndromes peripheral #15
      grade age #15
      week baseline #15
      monoclonal carcinoma antibodies #15
      prognosis quality life #15
      adjuvant aromatase #15
      therapy nicotine #15
      acceptability device #15
      advanced malignant disease #15
      agents life #15
      acute diarrhea patients #15
      trials gabapentin #15
      vaginal dryness dyspareunia #15
      androgen ablation therapy #15
      taste alterations #15
      mastectomy irradiation #15
      duloxetine cipn #15
      bfq #15
      suggestion guideline #15
      advanced cancer methods #15
      clinician perception #15
      treatment weeks patients #15
      week darbepoetin #15
      evidence treatment options #15
      diarrhoea time #16
      premenopausal women chemotherapy #16
      breast gynecologic cancer #16
      female cancer survivors #16
      product time #16
      patients venlafaxine #16
      patch therapy #16
      rash pruritus #16
      paclitaxel oxaliplatin #16
      stool dna test #16
      vte apixaban #16
      dalteparin 95 #16
      antiemetic agent #16
      randomized trial aspirin #16
      endpoints baseline #16
      induced hot #16
      advancedstage cancer patients #16
      findings education #16
      measurable evaluable disease #16
      loss appetite #16
      treatment cancer vte #16
      symptoms numbness #16
      tingling pain #16
      venlafaxine patients #16
      mfsi #16
      study tetracycline #17
      recommendation suggestion #17
      vaginal symptoms #17
      screen detection #17
      oxaliplatin doses #17
      reduction fatigue #17
      oxaliplatin treated #17
      dfs folfox #17
      rs11849538 #17
      18 months women #17
      arthralgias #17
      breast cancer oestrogen #17
      institute common #17
      786 patients #17
      leap study #17
      women metastatic #17
      adenomas 1 #17
      inadequate control #17
      venlafaxine #17
      cancer menopause #17
      fractional co2 #17
      device women #17
      leptin concentrations groups #17
      arhgef10 #17
      flashes tamoxifen #17
      crc patients patients #17
      patients informed decisions #18
      placebo 04 #18
      sternal skin #18
      symptoms hormone #18
      prophylactic antiemetic therapy #18
      oncology providers patients #18
      mri mastectomy #18
      menopausal problems #18
      postmenopausal women letrozole #18
      standard prognostic #18
      data followup #18
      sigmoidoscopy tomography #18
      flash frequencies #18
      patients overview #18
      120000 #18
      baseline 4 #18
      severity cipn #18
      intervention guidelines #18
      secondary endpoint analysis #18
      randomized trials women #18
      patients irox #18
      severity hot #18
      patients hb #18
      oral dronabinol #18
      5 adjuvant #18
      subsets age #18
      treatment osteopenia #18
      receiving head #18
      physician reported #19
      ncdf #19
      double blinded #19
      oxaliplatin carboplatin #19
      induced mucositis #19
      folfox fluorouracil #19
      evidence status #19
      bmd neoplasms chemotherapy #19
      panax quinquefolius #19
      7 outcomes #19
      95 46 #19
      rs7349683 #19
      previous colorectal #19
      unpleasant taste #19
      oxaliplatin neurotoxicity #19
      treatment mastectomy #19
      patients based chemotherapy #19
      flash reduction #19
      mastectomy methotrexate #19
      minimal adverse effects #19
      groups infliximab #19
      life gabapentin #19
      n6 n5 #19
      acute cancer #19
      neoplasms peripheral #19
      numbness #20
      palliating #20
      fatigue 4 #20
      reducing pain #20
      baseline week #20
      diseases randomized #20
      surveillance protocol #20
      appetite nutritional status #20
      advanced cancer study #20
      study ginseng #20
      cancer cancer therapy #20
      placebo cream #20
      moderate pain patients #20
      major bleeding treatment #20
      fecal occult #20
      life skindex16 #20
      revisitation #20
      placebo smokers #20
      emetogenic chemotherapy #20
      progestational agents #20
      pilot trials #20
      receiving pelvic #20
      therapeutic options treatment #20
      cipn symptoms #21
      receptorpositive breast cancer #21
      substantial problem #21
      female menopause #21
      oral mucositis pain #21
      treatment options women #21
      management cachexia #21
      metastatic breast carcinoma #21
      trial 12 months #21
      crossover analysis #21
      refractory cachexia #21
      cancer starting #21
      studies methylphenidate #21
      acetate patients #21
      therapy adverse effects #21
      routine test #21
      radiationinduced dermatitis #21
      chemotherapy agents #21
      npy leptin #22
      150 groups #22
      pharmacokinetics infliximab #22
      optumlabs #22
      guideline intervention #22
      patients 5 weeks #22
      emetogenic #22
      location stage #22
      patients testosterone #22
      projects quality #22
      n9741 #22
      gain patients #22
      crossover phase #22
      median time initiation #22
      candidate single #22
      doc time #22
      asco panel #22
      severity adverse events #22
      subcutaneous testosterone #22
      scores ≤ #22
      mcf7 cells genistein #23
      fsdsr #23
      stool dna testing #23
      aes qol #23
      followup tests #23
      sucralfate patients #23
      potential toxicities #23
      acupuncture hot #23
      versus delayed #23
      acetate middle #23
      decision adjuvant #23
      mascc isoo #23
      detecting recurrence #23
      life ascites #23
      5 pounds #23
      ortho biotech #24
      design rcts #24
      mirtazapine patients #24
      weeks primary #24
      aged anorexia #24
      aged amines #24
      n56 #24
      prevention chemotherapy #24
      replacement testosterone #24
      tamoxifen octreotide #24
      pilot clinical #24
      day chemotherapy #24
      adjuvant decision making #24
      apixaban treatment #24
      hrt survival #24
      topic design severity #24
      randomized 1 #24
      every3 #24
      female hot #24
      abstract5fluorouracil #24
      prevention nausea #25
      placebo arm treatment #25
      criteria adverse #25
      women adjuvant tamoxifen #25
      mmf placebo #25
      nausea olanzapine #25
      doses schedules #25
      trial pilot #25
      recommendations basis #25
      lymphedema incidence #25
      qol tools #25
      neoplasia screening #25
      severe nausea vomiting #25
      vte trial #25
      institutional guidelines #25
      cancerassociated weight loss #25
      cco guideline #25
      bpisf #25
      antiepileptic agent #25
      undergoing adjuvant #26
      aiinduced #26
      receiving oxaliplatin #26
      syndrome menopause #26
      treatment arms #26
      dose gabapentin #26
      cachexia carcinoma #26
      combination weight loss #26
      irradiation mastectomy #26
      prior week #26
      joints muscles #26
      mfsisf #26
      2005 update #26
      clinical trials chemotherapy #26
      neoplasms estrogens #26
      regional breast #26
      colorectal adenomas patients #26
      induced musculoskeletal #26
      oncology journals #26
      nci ctc #26
      agents prevention #26
      trial evaluate #26
      lmwh survival #27
      adjuvant 5fu #27
      smoking bupropion #27
      hot flashes hf #27
      antiemetic #27
      prophylactic antiemetic #27
      valerian #27
      neuropathy symptoms #27
      series trials #27
      patients short term #27
      events ctcae #27
      fubased #27
      lymphedema arm #27
      nurse survey #27
      recommendations trials #27
      fluoxetine citalopram #28
      gynecologic cancer survivors #28
      chest rays #28
      describers #28
      matched general population #28
      prevent colorectal adenomas #28
      alliance #28
      treatment hot flushes #28
      mastectomy rate #28
      definitively #28
      newer #28
      muscles joints #28
      standard prognostic factors #28
      primary endpoint proportion #28
      lidocaine patches #28
      intractable palliative #28
      biological predictors #29
      statistical controversies #29
      feet hands #29
      asco guideline update #29
      blood screening #29
      chemotherapy cipn #29
      placebo arm #29
      efficacy venlafaxine #29
      survival arms #29
      smokers bupropion #29
      mucositis study #29
      patients paclitaxel #29
      citalopram placebo #29
      taxanebased chemotherapy #29
      paclitaxel cipn #29
      difluoromethylornithine dfmo #29
      pain cancer survivors #29
      vitamin incidence #29
      points study #29
      middle aged postmenopause #30
      month duration #30
      anthrapyrazoles #30
      management oral mucositis #30
      small pilot #30
      usual oncology #30
      postmenopause predictive #30
      cipn pain #30
      mild nausea #30
      development cipn #30
      contralateral axillary #30
      pain oral #30
      loss postmenopausal #30
      alfa darbepoetin #30
      benadryl #30
      phase iii comparison #30
      twoyear followup #30
      diseases peripheral #30
      treatment acute vte #31
      sixtysix patients #31
      arms placebo #31
      management menopausal symptoms #31
      middle aged perimenopause #31
      efficacy methylphenidate #31
      patients secondary analysis #31
      term rectal #31
      patients races #31
      treatment paclitaxel #31
      ixabepilone patients #31
      pain quality life #31
      benefit dfs #31
      calcium magnesium #31
      prevention oral mucositis #31
      symptomatic ascites #31
      mastectomy mri #31
      guideline endorsement #32
      doubleblind trial #32
      receiving highly #32
      breast cancer symptoms #32
      oncologist patients #32
      camg #32
      vera gel #32
      delayed chemotherapy #32
      women lymphedema #32
      evidencebased guidance #32
      rash severity #32
      female services #32
      pursuant #33
      blind manner #33
      4week followup #33
      painful cipn #33
      isoo #33
      aloe vera gel #33
      patients taxol #33
      toxicity breast #33
      patients cinv #33
      neuropathy patients #33
      smokers randomized #33
      week treatment #33
      breast neoplasms life #33
      hands feet #33
      acupuncture hot flashes #33
      neoplasms carboplatin #33
      sensitivity polyps #33
      increased difficulty #33
      chemotherapeutic regimens #33
      dose megestrol #33
      therapy bupropion #33
      survival advanced cancer #33
      fingers hands #33
      questionnaires total #33
      instruments life #33
      continuation study #34
      patients acitretin #34
      patients nausea #34
      chemotherapy hec #34
      toxicity fluorouracil #34
      prevention chemotherapyinduced nausea #35
      inhibitors venlafaxine #35
      primary outcomes trials #35
      cipn severity #35
      patients tools #35
      4 week #35
      levels week #35
      cancer international society #35
      major bleeding lmwh #35
      moderatetosevere patients #35
      carcinoembryonic antigen levels #35
      treating cancer #35
      stomatitis #35
      united states hrqol #35
      trial designed #35
      dawley statistics #35
      formal consensus process #35
      doxepin #36
      pyrexia patients #36
      lymphedema treatment #36
      stages colorectal cancer #36
      myalgias #36
      nk1ras #36
      cohosh #36
      mometasone placebo #36
      head neck radiotherapy #36
      secondary prevention measures #36
      pain pilot #36
      tnfα study #36
      study intravenous #37
      nausea neoplasms #37
      cancerrelated fatigue #37
      topic humans life #37
      mc5 #37
      chronic nausea #37
      planned sample size #37
      p00052 #37
      ctcae #37
      survival supportive #37
      alleviation #37
      global impression #37
      topic stomatitis #37
      early integrated #37
      symptoms cancer #37
      tests controlled trials #38
      illness purpose #38
      trial conducted #38
      women metastatic disease #38
      fluorouracil based #38
      sensitization nociceptors #38
      5ht3ras #38
      patients taxanes #38
      individual item #38
      oncology providers #38
      relationships populations #38
      patients highdose melphalan #38
      3 agents #39
      trials oncology #39
      arm difference #39
      treatment breakthrough #39
      chi2 tests #39
      european organisation cancer #39
      menopause gsm #39
      cohort type #39
      grade 2 toxicity #39
      acids drug #39
      qol clinical trials #39
      crushed ice #39
      arm placebo #39
      blind crossover #39
      study double #39
      arthralgia breast #40
      initial mastectomy #40
      single dose placebo #40
      method fatigue #40
      treatment analyses #40
      terminology criteria #40
      appetite patients #40
      patients lamotrigine #40
      cachexia clinical #40
      difluoromethylornithine #40
      topic reproducibility surveys #40
      mastectomy chemotherapy #40
      prevent colorectal #40
      treatment period #41
      drug evaluation studies #41
      united states guidelines #41
      relapse 3 months #41
      smokers weight #41
      cure recurrence #41
      undergoing androgen #41
      zoledronic acid bmd #41
      bupropion smokers #41
      trial performed #41
      symptoms 12 months #41
      gabapentin placebo #41
      oral gabapentin #42
      patients incurable #42
      patients completed #42
      nortriptyline placebo #42
      placebo venlafaxine #42
      chemotherapy day #42
      treating institution #42
      randomized doubleblind trial #42
      neuronal protection #42
      appetite body #42
      transdermal gel #42
      location age #42
      dietary supplements life #43
      median weight #43
      desipramine patients #43
      5 induced #43
      sex location #43
      highdose interferon #43
      preliminary insights #43
      postsurgical #43
      baseline fatigue #43
      collaborative effort #44
      bupropion placebo #44
      pain reduction patients #44
      nonpain #44
      surveillance united states #44
      sensory symptoms #44
      trial benefit #44
      vaginal moisturizer #44
      disagreement #44
      chemotherapyinduced nausea vomiting #44
      weeks efficacy #44
      outcome gamma #44
      risk cipn #44
      objective tumor regression #45
      acute pain patients #45
      menogaril #45
      genitourinary syndrome menopause #45
      humans peripheral #45
      ginseng panax quinquefolius #45
      rash grade #45
      survivors colorectal cancer #45
      historic controls #45
      conclusion trial #45
      piroxantrone #45
      5 years incidence #45
      fisher tests #45
      adverse symptoms #46
      middle aged patient #46
      phase iii life #46
      epoetin alfa placebo #46
      putative mechanism #46
      megestrol acetate treatment #46
      nonpharmacological therapy #46
      radiotherapy randomized #46
      radiationinduced oral mucositis #46
      clinical problem #46
      study gaba #46
      current manuscript #46
      factor prognostic #46
      item measures #46
      longitudinal methods #46
      vaccines melanoma #46
      cisplatin neuropathy #46
      patients advanced adenomas #46
      acute skin toxicity #46
      chemotherapy antineoplastic #46
      randomized comparison #46
      iii colon cancer #46
      mascc #47
      dose paclitaxel #47
      neoplasms parenteral nutrition #47
      genetic predictors #47
      average pain #47
      cachexia female #47
      darbepoetin alfa patients #47
      differences pros #47
      bipn #47
      aged mometasone #47
      twopart #47
      screening setting #47
      oxybutynin #48
      physical examinations #48
      placebo gabapentin #48
      neck radiotherapy #48
      qol female humans #48
      menopause life #48
      genitourinary symptoms #48
      stratification factor #48
      nausea day #48
      patientclinician communication #49
      sham arm #49
      flie #49
      chemotherapy nausea #49
      female cancer #49
      receiving androgen #50
      pain numbness #50
      mastectomy pain #50
      hot flashes hfs #50
      cancer survivors fatigue #50
      replens #50
      placebos randomized #50
      antiserotonergic #50
      time conclusions #50
      cachexia #50
      models stage #50
      regional hypothermia #51
      patients 8 weeks #51
      cisplatin humans #51
      effective treating #51
      vomiting chemotherapy #51
      transdermal testosterone #51
      blinded placebo #51
      genitourinary syndrome #51
      patients cancer pain #51
      risk bone loss #52
      metaanalysis incidence #52
      treatment adt #52
      black cohosh #52
      aged orchiectomy #52
      trastuzumab orr #52
      management chemotherapy #52
      80k #52
      differences treatment arms #52
      potential adjuvant #53
      receiving radiotherapy #53
      nervous peripheral #53
      control nausea #53
      cancer venous #53
      toxicity time #53
      tamoxifen antineoplastic agents #53
      purposepatients #53
      pilot trial #54
      double‐blind trial #54
      20 data #54
      life topic humans #54
      blood testing #54
      recurrent disease #54
      antiemetics antineoplastic #54
      severe hot #54
      levetiracetam treatment #54
      standard placebo #54
      treatment months #54
      acupuncture cancer #55
      cancerdirected therapy #55
      fatigue inventory #55
      symptoms therapy #55
      scalp cooling #55
      cachexia therapy #55
      serial levels #55
      bupropion treatment #55
      treatment tobacco dependence #55
      symptoms hot #56
      undergoing chemotherapy #56
      adjuvant endocrine treatment #56
      diseases antineoplastic #56
      xaliproden #56
      carboplatin female humans #56
      time placebo #56
      12 courses #57
      placebo solution #57
      common terminology #57
      adjuvant colon #57
      benefit scale #57
      recurrence symptoms #57
      points placebo #58
      major bleeding enoxaparin #58
      completion adjuvant chemotherapy #58
      limited degree #58
      pain peripheral #58
      ferric gluconate #58
      skin dermatitis #58
      topical gel #58
      cachexia weight loss #58
      undergoing treatment #58
      compared oral #58
      quality life questionnaire #58
      weight appetite #59
      data understanding #59
      osteopaenia #59
      safety rivaroxaban #59
      coprescription #59
      chemotherapy cognitive #59
      ocular irritation #59
      patients hec #59
      chemotherapyinduced nausea #59
      placebo citalopram #59
      serotonergic effects #60
      patients mirtazapine #60
      anticonvulsants antidepressive #60
      study medication #60
      colonoscopically #60
      hb baseline #60
      lymphedema women #61
      doubleblind #61
      bleomycin patients #61
      3 randomized #61
      tamoxifen metabolism #61
      pipn #61
      paroxetine fluoxetine #61
      1 week treatment #61
      standard dosing #61
      cancer patients study #61
      sensitivity individuals #61
      topic surveys life #61
      caregivers pain #61
      emla cream #61
      chemotherapy dose #62
      venlafaxine placebo #62
      dermatological toxicities #62
      induced taste #62
      ocular toxicity #62
      fluorouracil induced #62
      recurrent disease patients #62
      pain bleeding #62
      alpha weight #62
      efficacy fluoxetine #62
      antibodies monoclonal carcinoma #63
      105 months #63
      lessen #63
      anorexia patients #63
      aged placebos #63
      patients disease recurrence #63
      integrative oncology #63
      prior chemotherapy regimen #63
      ncictc #63
      allelic variability #64
      patients cancer types #64
      versus placebo #64
      bupropion nicotine #64
      cyclohexanols #64
      carboplatin oxaliplatin #64
      rivaroxaban enoxaparin #64
      painful peripheral neuropathy #64
      improvement sexual function #64
      alleviate #64
      aged nausea #64
      incidence rash #64
      cyproheptadine #64
      treatment chemotherapy #64
      agents double #65
      75 daily #65
      efficacy toxicity #65
      patients minocycline #65
      survivorship issues #65
      patients comparisons #65
      administration paclitaxel #65
      validated patient #65
      appetite weight loss #65
      4 weeks week #65
      dalteparin treatment #65
      acetate therapy #66
      study gabapentin #66
      nicotine nasal #66
      food intake patients #66
      oncology clinical #66
      placebo months #66
      diseases neoplasms #66
      life topic #67
      clinician training #67
      target doses #67
      estrogen suppression #67
      qol fatigue #67
      subcutaneous dalteparin #68
      hec #68
      pilocarpine treatment #68
      cachexia weight #68
      patients randomized #68
      induced dermatitis #68
      46 95 #68
      prevention smoking #68
      hormonal therapies #68
      baseline study #68
      debilitating #69
      skin surveys #69
      gained weight #69
      vasomotor symptoms women #69
      ongoing loss #69
      fsfi score #69
      induced ovarian #70
      item score #70
      women ais #70
      surgery cancer #70
      development severity #70
      nonsignificant trends #70
      chemotherapy anemia #70
      multifactorial syndrome #70
      major bleeding apixaban #71
      infliximab combination #71
      week percentage #71
      incidence severity #71
      anthrapyrazole #71
      life referral #71
      weight compared #71
      effects ginseng #72
      trials planning #72
      systemic retinoids #72
      patients pilot #72
      cisplatin treated #72
      placebo patches #72
      oral drug administration #72
      humans lignans #72
      weeks placebo #73
      chemotherapy supportive #73
      prospective pilot trial #73
      ginseng treatment #73
      stage primary #73
      chemoprevention trial #73
      placebo #73
      ergotamines #73
      dronabinol #74
      anemia antineoplastic #74
      trial evaluating #74
      receiving chemotherapy #74
      qli #74
      rash #74
      women estrogen therapy #74
      fractional co2 laser #74
      rcts systematic reviews #74
      cancerrelated fatigue crf #75
      acid supplement #75
      prevention #75
      353 patients #75
      nervous diseases #75
      cycles cycle #76
      blind clinical #76
      acute skin #76
      weekly arm #76
      inhibitors tamoxifen #76
      breast cancer paclitaxel #77
      alliance patients #77
      tamoxifen postmenopausal #77
      dose 90 #77
      hospice staff #77
      anemia darbepoetin #77
      week p005 #77
      anorexia weight loss #77
      cancer randomized #77
      95 01 #77
      values data #78
      3 arm #78
      patients zoledronic acid #78
      female humans insurance #78
      tamoxifen postmenopausal women #78
      week schedule #79
      surgery year #79
      serum concentrations infliximab #79
      efficacy lamotrigine #79
      pain syndrome #79
      patients darbepoetin alfa #79
      vte recurrence #79
      symptoms sensitivity #79
      therapy antineoplastic #79
      life phase iii #80
      foot syndrome #80
      zoledronic acid treatment #80
      week 4 #80
      isoflavone supplements #80
      vomiting antiemetics #80
      time mastectomy #80
      patients treatment arms #81
      oral oncology #81
      guideline recommendation #81
      lowmolecular weight heparin #81
      period crossover #81
      patient qol #81
      study march #81
      backgroundchemotherapy #82
      paroxetine patients #82
      greater weight gain #82
      standard clinical #82
      suggestion #82
      bupropion smoking #82
      day weeks #83
      recommendations article #83
      orbital stability #83
      trpv1 trpa1 #83
      patients participating #83
      trpm8 trpa1 #84
      zinc sulfate #84
      cinv patients #84
      method female #84
      ice pack #85
      systematic reviews rcts #85
      neoplasm metastasis neoplasms #85
      cancer weight #85
      mayo clinic #86
      treatment nicotine dependence #86
      cryotherapy patients #86
      ttf survival #86
      receiving placebo #86
      baseline arms #87
      primary symptom #87
      nicotine nasal spray #87
      methodspatients #87
      incidence osteoporosis #87
      frequency severity #87
      week 5 #87
      pilot study safety #87
      therapyinduced #87
      life cachexia #87
      serum hepcidin levels #87
      integrative therapies #88
      acp documentation #88
      anecdotal reports #88
      cancer vte #89
      putative mediator #89
      iu daily #89
      treatment fatigue #89
      morphine pharmacokinetics #90
      clinical oncology asco #90
      male chemotherapy #90
      outcome venlafaxine #90
      endoxifen concentrations #91
      delayed cinv #91
      symptoms including #91
      iii efficacy #91
      arm treatment #91
      ncorp #91
      tolerated patients #91
      scores placebo #91
      patients paroxetine #92
      nerve pain #92
      cisplatin oxaliplatin #92
      completion chemotherapy #92
      patients upfront #92
      trials treatment #92
      ameliorating #93
      mometasone #94
      arm 3 #94
      duloxetine hydrochloride #94
      quiet stance #94
      apixaban dose #94
      breast cancer survivors #94
      1 primary #94
      anemic patients #94
      neoplasms quality life #94
      questionnaires survival #94
      patients appetite #95
      common symptoms #95
      cancerrelated pain #95
      alfa patients #95
      prevention management #96
      udi #96
      0 10 #96
      patients completion #96
      ccop #96
      mayo clinic rochester #96
      failure chemotherapy #96
      hlaa2 patients #96
      adjuvant therapy survival #97
      oral mucositis patients #97
      pyrexia #97
      acute vte #97
      paclitaxel patient #97
      alleviating #98
      15 points #98
      painful area #98
      identical placebo #98
      completed study #98
      text review #98
      treatment tolerability #98
      crnmb #98
      preliminary data #98
      agents paclitaxel #98
      fatigue insomnia #99
      5fu leucovorin #99
      induced esophagitis #99
      4 weeks baseline #99
      patient medical #99
      bcca #99
      topic cyclophosphamide #99
      pregnadienediols #99
      patient questionnaires #99
      5fluorouracil oxaliplatin #99
      difference incidence #99
      qlq #100
      clinician communication #100
      male sex factors #100
      oncology outpatients #100
      survival nsclc #100
      10 doses #100
      5 based #101
      oncology clinicians #101
      nortriptyline #101
      humans life #101
      antineoplastic agents life #101
      275 patients #101
      postresection #101
      lung cancer chemoprevention #101
      lidocaine lidocaine #101
      oncology asco #101
      placebo 1 year #102
      methods trial #102
      variance clinical trials #103
      reported effects #103
      purposeprevious #104
      3106 #104
      patients anorexia #104
      races ethnicities #104
      quality life data #104
      chemotherapy cycle #105
      leap #105
      patients 150 #105
      diseases treatment #105
      12 24 months #105
      phytogenic clinical trials #105
      compounds oxaliplatin #106
      dalteparin patients #106
      nutritional determinants #106
      infusion site #106
      stool samples patients #106
      months relapse #106
      dfmo #106
      trial studies #106
      neuropathy #106
      epoetin alfa patients #107
      anastrozole letrozole #107
      valeriana officinalis #107
      versus dexamethasone #107
      pain intensity ratings #107
      urogenital diseases #107
      cycle cycles #107
      humans menopause #107
      life topic severity #108
      week study #108
      women experience #108
      time toxicity #108
      relapse prevention #108
      breast cancer tamoxifen #108
      patients guideline #109
      mouthwash #109
      treatment cancer pain #109
      strong prognostic factor #109
      levocarnitine #109
      women vasomotor symptoms #109
      female urogenital #109
      patients cancer treatment #110
      clinic rochester #110
      oxaliplatin therapy #110
      combined paclitaxel #110
      life adverse events #110
      cmf chemotherapy #111
      egfr inhibitor #111
      prevention bone loss #111
      vomiting adult #111
      dosing schedules #112
      function suppression #112
      insomnia pain #112
      –iii #113
      vestibulitis #113
      functional iron deficiency #113
      adverse events ctcae #113
      treatment arms patients #113
      vaginal diseases #113
      visits patient #113
      colorectal neoplasia #113
      patients arms #113
      reassess #113
      agents hormonal #113
      cachexia humans #114
      single nucleotide variants #114
      qol patient #114
      hfsd #114
      months 3 #114
      alopecia patients #114
      diseases breast #114
      acitretin #114
      patients olanzapine #114
      therapy induced #114
      dietary lignans #114
      laser therapy lasers #115
      crci #115
      studies randomized #115
      patients anthracycline #115
      letrozole tamoxifen #115
      rivaroxaban venous #115
      combination nicotine #115
      treatment arm #116
      placebo postmenopausal women #116
      patients peripheral neuropathy #117
      nk1 receptor antagonist #117
      oral factor #117
      symptoms chemotherapy #117
      2007 guidelines #117
      induction ornithine decarboxylase #117
      appetite stimulant #118
      recurrence diagnosis #118
      oral antineoplastic agents #118
      trials conducted #119
      preventive therapies #119
      3915 #119
      patients weekly paclitaxel #119
      noradrenaline reuptake #119
      diseases pain #119
      trpa1 trpv1 #119
      olanzapine placebo #120
      definition classification #120
      750 day #120
      clinical histories #120
      treatment weeks #120
      resultswhile #120
      original report #120
      participants arms #120
      induced ocular #121
      hormonal agents #121
      patients cancers #121
      placebo double #121
      untoward #121
      postmenopausal postmenopause #121
      fullerton #121
      nervous agents #122
      cancer multiple #122
      oxaliplatin folfox #122
      cancer quality #123
      acute oral #123
      surgery analysis #123
      rolapitant #123
      stable dose #123
      skin pain #123
      netupitant #123
      objective review #123
      weeks 4 #123
      treatment letrozole #124
      survivors breast cancer #124
      patients diploid tumors #124
      neuropathic pain patients #124
      rivaroxaban compared #124
      isoflavones genistein #124
      pros baseline #124
      1 month patients #125
      90 dose #125
      week dose #125
      resultsfour #126
      factors odds #126
      neurotoxic agents #126
      patients physicians #127
      hormonal breast #127
      anorexia #127
      promising agents #127
      fsfi #127
      genetic quality #127
      recurrent adenomas #127
      diagnosis metastatic disease #127
      weight concerns #128
      alfa erythropoietin #128
      arms patients #128
      belladonna #128
      cancerassociated vte #128
      uncommon variants #128
      5 leucovorin #129
      agents neoplasms #129
      clinical trial patients #129
      resultsforty #129
      postural instability #129
      vomiting cinv #129
      neoplasms quality #129
      control arms #130
      serum baseline #130
      problem patients #130
      patientreported outcome #130
      cancer fatigue #131
      150 iu #131
      treatment toxicities #131
      function fsfi #131
      bmd tscore #131
      prognostic variables #131
      onycholysis #132
      efficacy vitamin #132
      cancerrelated symptoms #132
      pilot data #132
      neurotoxicity syndromes #132
      relapse smoking #132
      assessable #133
      topical treatment #133
      cachexia patients #133
      progress report #133
      5 placebo #134
      ganglion block #134
      ginseng panax #134
      symptom control #134
      endodermal sinus tumor #134
      cold hyperalgesia #135
      chemotherapy 5 #135
      cancers patients #135
      agents generation #135
      common adverse effects #135
      toxt #135
      150 women #135
      bmd postmenopausal women #135
      patientlevel pooled analysis #136
      weekly therapy #136
      bothersome #136
      symptomatic benefit #136
      npy levels #136
      painful neuropathy #136
      substantial benefit #137
      severe fatigue #137
      life physical function #137
      poor qol #137
      study trials #137
      percentage reduction #137
      stage cancer #137
      intrapatient #137
      agents bortezomib #137
      accrued #138
      grade stage #138
      hfs patients #138
      zoledronic #138
      therapy breast #139
      chemoprevention studies #139
      advanced lung #139
      incurable cancer #139
      factbr #139
      underwent mastectomy #139
      patients advanced cancer #140
      breast chest wall #140
      liquid suspension #140
      paclitaxel weekly #141
      oxaliplatin chemotherapy #141
      patients placebo #141
      financial concerns #142
      tamoxifen placebo #142
      disclose #142
      patients levetiracetam #142
      medicine clinical #143
      protocols breast #143
      fluorouracil 5 #143
      snv #144
      preoperative magnetic #144
      allopurinol placebo #144
      european organisation #144
      agents bone #145
      eortc qlq #145
      debilitating condition #145
      vaginal cytology #145
      fluorouracil humans #145
      evidence loe #145
      surgery type #146
      eligible women #146
      backgroundwomen #148
      volatile plants #148
      dietary counselling #148
      oral olanzapine #148
      numeracy #149
      desipramine treatment #149
      n201 #150
      adjuvant systemic #150
      predict recurrence #150
      venlafaxine treatment #150
      daily diaries #151
      women estrogen #151
      patients receive #151
      intravenous access #151
      response rate survival #151
      methodologic #151
      prior chemotherapy regimens #151
      multinational association #151
      balance impairments #152
      ovarian function suppression #152
      caa patients #152
      groups symptoms #152
      14 week #152
      tumor recurrence patients #152
      oral mucositis #152
      cramping #153
      80 dose #154
      carboplatin trastuzumab #154
      adjuvant systemic therapy #155
      dermatomes #155
      cindices #155
      life randomized #156
      combination chemotherapy cisplatin #156
      hyperalimentation #156
      infliximab 5 #156
      methods randomized #156
      mangafodipir #156
      integrated palliative #156
      vinblastine bleomycin #156
      fsds #156
      gait stability #157
      common terminology criteria #157
      breast cancer trastuzumab #157
      women breast carcinoma #157
      racially diverse #157
      oncology study #158
      study initiation #158
      vomiting nausea #158
      arm versus #158
      iii clinical #159
      physicians patients #159
      induced nausea #159
      survivors colorectal #159
      weekly doses #159
      chemotherapy breast cancer #159
      european organisation treatment #160
      chemotherapy quality #160
      stellate ganglion #160
      paclitaxel taxol #160
      cancer pain patients #160
      major problem #160
      treatment postmenopausal women #160
      estrogen depletion #161
      validity life #161
      women hormone therapy #161
      risk infertility #161
      data efficacy #163
      efficacy women #164
      neoplasms pain #164
      mometasone furoate #165
      cisplatin vinblastine #165
      current project #165
      skeletal events #166
      patients 1 month #166
      pharmacokinetic analyses #166
      osteoporosis prevention #167
      life topic surveys #167
      illness surveys questionnaires #167
      chemotherapy groups #168
      chemotherapy‐induced nausea #168
      anthracycline #168
      direct inhibitors #168
      patients adenomas #169
      432 patients #169
      menopause symptoms #169
      patients data #169
      dosing patients #169
      ixabepilone #170
      management chronic pain #170
      daily placebo #171
      rochester #171
      prospective clinical trials #171
      disease cmt #171
      global quality #171
      chemotherapy completion #172
      prestudy #172
      label pilot #173
      1 year therapy #173
      judicious #173
      hot flushes #173
      lamotrigine placebo #173
      impaired balance #173
      placebos #173
      pilot feasibility study #174
      prospective evaluation #174
      methylphenidate placebo #174
      diarrhoea patients #174
      phase iii trial #174
      physician order #175
      cancer cancer treatment #175
      decreased quality #175
      arthralgia #175
      male breast cancer #175
      baseline weight #176
      weeks women #177
      treatment 14 #177
      life assessments #177
      thirty percent #178
      bodyweights #178
      expected benefits #179
      life baseline #179
      bothered #179
      treatmentrelated toxicity #179
      bolus fluorouracil #179
      sufferer #180
      phase evaluation #181
      darbepoetin #182
      gain weight #182
      oxaliplatin 5fluorouracil #182
      escalations #182
      ginseng #182
      organisation treatment #183
      toxicity criteria #183
      peri postmenopausal women #183
      effects chemotherapy #184
      infliximab antibodies #184
      acute pain #184
      acetyll #184
      biostatisticians #184
      prognostic criteria #184
      tube primary #184
      received oral #184
      white smokers #184
      additional chemotherapy #185
      outcome measures life #185
      reported sexual #185
      arm volume #186
      treatment 4 weeks #187
      delayed nausea #187
      patients drug #187
      cinv #187
      treating #187
      tamoxifen letrozole #188
      week follow #188
      lessened #188
      management breast cancer #188
      strong prognostic #188
      reduction therapy #188
      troublesome #188
      adjuvant decision #188
      aching #189
      neoplasia female humans #189
      oxaliplatin dose #189
      aged nitriles #190
      protocol therapy #190
      survivors breast #190
      placebo study #190
      antiemetic regimens #190
      week 1 #190
      twentyfive patients #191
      cancer cancer survivors #191
      completed baseline #191
      aches #192
      aspirin incidence #192
      fortysix patients #192
      patients increases #192
      chronic lymphedema #192
      manuscript #192
      toxicity patients #192
      treatment cancer patients #192
      cimicifuga racemosa #193
      humans isoflavones #193
      assigned receive #193
      effective agents #194
      weekly trastuzumab #194
      25 women #194
      ornithine decarboxylase activity #195
      pain breast #195
      3 fatty #195
      weight loss patients #195
      resultsdata #196
      acids double #196
      palonosetron dexamethasone #197
      trial designs #197
      pituitaryadrenal axis #197
      surveillance strategy #198
      resultstwo #198
      toxicity profiles #198
      postmenopausal patients #198
      nicotine patch #199
      organization treatment #199
      women menopause #199
      patients letrozole #199
      delayed emesis #199
      accent #199
      culminates #199
      percent reduction #200
      adjuvant interferon #200
      oral glutamine #201
      menopause premature #201
      item responses #202
      primary goal #202
      treatment week #202
      imiquimod #202
      greater 5 #202
      treatment bmd #202
      hormonal treatments #203
      cancer anemia #203
      bmd postmenopausal #203
      plo #204
      composition cachexia #204
      pelvic radiation therapy #204
      treated placebo #204
      induced oral #205
      unwilling #206
      leucovorin patients #206
      chemotherapy drugs #206
      placebo 8 #206
      udi6 #206
      dalteparin #206
      pharmacologic interventions #207
      heat hyperalgesia #207
      mice cisplatin #207
      4 8 weeks #208
      humans leucovorin #208
      incurable #208
      reduced food intake #208
      chemotherapy #209
      hands patients #209
      5 daily #209
      methotrexate 5 #210
      controlled evaluation #210
      estrogen receptor modulators #210
      lamotrigine #210
      gel application #211
      vomiting patients #212
      initials #212
      diagnosis recurrence #212
      methodsthis #212
      regionally advanced #212
      trial vitamin #213
      docetaxel cyclophosphamide #213
      charcotmarietooth disease #213
      oncology practices #214
      dexamethasone control #214
      patient weight #214
      placebo 6 weeks #214
      december patients #215
      antiemetic therapy #215
      15 minutes #215
      oxaliplatin #215
      olanzapine 5 #215
      neoplasms cross #216
      prostate cancer survivors #216
      tamoxifen users #217
      women tamoxifen #217
      patients duloxetine #217
      women breast cancer #217
      gabapentin humans #217
      purposethe purpose #218
      10 daily #218
      current management #218
      placebo weeks #218
      hot #218
      —reply #218
      aprepitant #218
      nonmajor #218
      life humans #219
      palliative oncology #219
      transdermal fentanyl #219
      nmscs #219
      sexual symptoms #220
      sublingual administration #220
      nonabsorbable #220
      society clinical oncology #221
      painful peripheral #221
      moderate pain #221
      pregabalin patients #221
      ornithine decarboxylase odc #221
      relieving #222
      lymphedema patients #222
      primary breast cancer #222
      neoplasms palliative #222
      ginkgo biloba egb #222
      methylphenidate modafinil #222
      treatment postmenopausal #222
      prospective study women #222
      furoate #223
      randomized doubleblind study #223
      prevention patients #224
      99 months #225
      computerized physician #225
      quinquefolius #225
      partial mastectomy #226
      agent patients #226
      vaginal estrogen #226
      turmoil #227
      bupropion #227
      pain presence #227
      clinical situation #228
      trial #228
      secondary endpoint #229
      nondiploid #229
      200 iu #229
      antidepressive #230
      eating disorders humans #230
      placebo 10 #230
      akt inhibitor #230
      hospice patients #230
      editorials #230
      anthracycline cardiotoxicity #230
      cancer recommendations #230
      physicians quality #230
      vitamin effects #231
      rashes #231
      based adjuvant #231
      lightheadedness #232
      conclusionsthe #232
      time study #232
      handfoot syndrome #232
      cachexia cytokines #232
      nonpharmacologic #233
      fluoxetine paroxetine #233
      acute symptoms #234
      women hot #234
      4 doses #234
      thirty women #234
      treatment vte #234
      tamoxifen neoplasms chemotherapy #235
      relieve #235
      arm 95 #235
      375 day #235
      day response #235
      sucralfate #235
      effective treatments #236
      premenopausal patients #237
      placebo gel #237
      letrozole patients #238
      postoperative monitoring #238
      antiemetics #238
      survivors treatment #238
      incidence grade #238
      flash #238
      improved bioavailability #239
      nonpharmacologic interventions #239
      overexpressing metastatic #239
      chemotherapy placebo #239
      menopause middle #239
      adjuvant 5 #239
      methodswomen #239
      oncology clinic #239
      neoadjuvant therapy surgery #240
      oral complications #240
      cachexia syndrome #240
      treatment breast cancer #240
      independent tests #241
      stinging #242
      participants randomized #242
      small doses #243
      aged paclitaxel #243
      tetracycline #244
      epoetin alfa #245
      3 arms #245
      adjuvant oxaliplatin #246
      appetite stimulants #246
      common practice #246
      efficacy placebo #247
      cachexia cancer #248
      mouthwashes #248
      dysgeusia #249
      800 iu #249
      survivors adult #250
      loss bmd #250
      randomized sham #250
      item scores #250
      689 #251
      patients physical #251
      major problems #251
      topic vitamin #252
      coasting #252
      menopause women #252
      armodafinil #253
      primary point #253
      randomised studies #253
      moderate degree #254
      average intensity #254
      nasal spray #254
      recurrence registries #255
      chemotherapy breast #255
      longitudinal followup #256
      prospective clinical #256
      neoplasms randomized #257
      therapy women #257
      cancer treatment #257
      antidepressant #257
      pretreatment levels #258
      women treated #258
      dyspareunia #258
      new therapeutic approaches #258
      hydrochloride #259
      rigors #259
      tube cancer #260
      inhibitors treatment #260
      opioid doseresponse relationship #260
      repeated measures #261
      1 baseline #261
      common problem #261
      patients cancer #261
      patients ovarian cancer #262
      citalopram treatment #262
      chronic post #262
      management options #263
      dosage levels #263
      decision framework #263
      months treatment #263
      treatment oxaliplatin #264
      duloxetine placebo #264
      phytogenic #264
      hematinics #264
      recommendations quality #265
      outcome administration #265
      preoperative mri #266
      treatmentrelated deaths #266
      treatment cancer #267
      placebo 8 weeks #267
      substantiation #267
      paresthesia #267
      individual items #267
      surgery adjuvant #267
      impact quality #268
      adult cancer survivors #268
      208 patients #269
      nausea #270
      patients rash #270
      ginkgo biloba #270
      signaled #270
      estrogen antagonists #271
      patients octreotide #271
      moderate correlations #271
      80 90 #271
      control trials #272
      distressing #272
      score baseline #272
      dna test #272
      weekly #272
      treatment 95 #272
      bridged ring #272
      performance status patients #272
      placebo‐controlled trial #273
      abstinence rates #273
      sham treatment #274
      dryness #274
      oncology clinical trials #274
      gross disease #275
      induced cisplatin #275
      valeriana #275
      patients caa #276
      chemoprevention trials #277
      treatment breast #278
      perspiration #278
      therapeutic options #279
      biomarkers disease humans #279
      prominent #279
      patients symptoms #279
      cimicifuga #279
      patients hospice #279
      breast cancer outcomes #280
      cartilage patients #280
      patients frequency #280
      cholinergic antagonists #280
      individual patient #280
      doxorubicin cyclophosphamide #281
      psychometric testing #281
      zoledronic acid patients #281
      chamomile #282
      antidepressive agents #282
      stage colon #282
      greater severity #284
      women effects #284
      completed questionnaires #284
      smoking abstinence #285
      gabapentin treatment #285
      early discontinuation #286
      fatigue crf #286
      function quality #287
      female hormone #287
      acid adult #287
      paps #287
      weeks patients #287
      colorectal lung #287
      symptoms function #287
      hot flush #288
      aromatase inhibitor therapy #288
      life survival #290
      eligible patients #291
      qualitative approach #292
      discouraged #292
      common symptom #292
      clinical trial participation #292
      treatment target #292
      mucositis oral #293
      cbdca #294
      1636 #294
      pain symptoms #294
      weight gain patients #294
      monographs #295
      vinca alkaloids #295
      citalopram #295
      testosterone supplementation #295
      bone loss patients #295
      toxicity evaluation #296
      primary peritoneal cancer #297
      aspirin placebo #298
      patients entered #298
      questionnaires treatment #298
      neoplasms cyclophosphamide #299
      feet #299
      peripheral nervous #299
      radiation dermatitis #300
      hypothetical scenarios #300
      inhibitors ais #300
      shooting #301
      treated combination #301
      nogalamycin #302
      survival trials #302
      octreotide #302
      acute neurotoxicity #303
      treatment serum #303
      stage grade #303
      symptoms pain #304
      subscale scores #304
      nausea vomiting #304
      schedule female #305
      prime time #305
      complementary therapies #305
      placebo groups #305
      prospective clinical trial #305
      factg #306
      global quality life #306
      prochlorperazine #307
      inflammatory breast cancer #307
      placebo treatment #307
      shortread #307
      aromatase inhibitor #307
      drug embryo #308
      neoplasms chemotherapy #308
      apixaban #308
      aged cancer #308
      darbepoetin alfa #309
      zoledronic acid #310
      studies double #310
      individual subject #311
      lung docetaxel #311
      riskstratification #311
      cancer receiving #311
      advanced cancer #311
      testosterone placebo #312
      epoetin #312
      placebo‐controlled #312
      patients cycle #313
      musculoskeletal symptoms #313
      cancer adjuvant #314
      or10 #314
      syndrome aps #314
      operative chemotherapy #315
      new primary #315
      organoplatinum #316
      article evidence #316
      blinded #317
      bfi #317
      ambulatory patients #317
      double‐blind #317
      symptoms breast #317
      sesame oil #317
      rivaroxaban patients #318
      irox #319
      efficacy treatment #319
      informed decisions #321
      dietary counseling #322
      life differences #322
      thromboembolism anticoagulants #323
      glutamine humans #324
      smokers nicotine #324
      monthly intervals #324
      preventing #325
      breast radiotherapy #326
      nsclc chemotherapy #326
      compared baseline #327
      titrate #327
      patients ductal carcinoma #327
      continuation phase #328
      treatment 1 year #329
      vte cancer patients #329
      conducted evaluate #329
      patients resected #329
      lymphedema #329
      oral nutritional supplements #329
      antagonists female #329
      potential efficacy #330
      arms #330
      future clinical trials #330
      controlled clinical #330
      patients nasal #330
      polymerase inhibitor #331
      diagnosed primary #332
      lozenge #332
      cancer ontario #332
      placebo patients #334
      patients daily #334
      80 anemia #334
      time disease #335
      ongoing clinical #336
      paclitaxel therapy #336
      pain scale #336
      relative benefits #336
      128 patients #336
      sublingual #337
      adjuvant letrozole #337
      5 fluorouracil #337
      surveillance guidelines #338
      survival 5 years #338
      discernible #339
      flutamide #340
      order entry #340
      treatment proportion #341
      eligible participants #341
      patients 4 weeks #341
      mastectomy radiotherapy #341
      cancer cachexia #342
      fallopian tube cancer #342
      osteopenia osteoporosis #342
      tooth disease #343
      diseases quality #343
      society clinical #343
      pilot randomized #344
      epha5 #345
      skeletal neoplasms #345
      clinicians patients #345
      accruing #346
      mk2206 #346
      clinical problems #346
      adverse events groups #347
      therapy pain #347
      coumarin #347
      mucositis patients #348
      sham acupuncture #349
      antineoplastic therapy #349
      vast majority #350
      baseline quality #350
      induced acute #350
      adjuvant folfox #350
      treatment citalopram #351
      dehydroepiandrosterone dhea #351
      dose schedule #351
      study therapy #352
      paclitaxel #353
      response letter #353
      patientreported outcomes #353
      endodermal sinus #353
      letrozole #355
      cancer life #355
      risedronate #355
      pain baseline #356
      adjuvant colonic #359
      vomiting #359
      skin toxicities #359
      potential benefit #360
      wellknown #360
      clin oncol #360
      cryotherapy #360
      ductal situ carcinoma #360
      diaries #361
      began #361
      direct oral #362
      pelvic radiation #362
      pain measures #363
      ovarian suppression #363
      nonpharmacological #363
      cancer surveillance #363
      calculators #363
      flaxseed #363
      ovarian fallopian #365
      completing #365
      docetaxel paclitaxel #365
      local prognosis receptor #365
      cddp #365
      bioavailable testosterone #366
      optimal frequency #366
      management cancer #366
      patients delayed #366
      pain cancer #366
      scalp #367
      scale 0 #368
      5‐year #368
      weeks study #368
      scheduled #369
      aged neoplasms #369
      hrt risk #370
      cancer received #371
      skeletalrelated events #371
      gamma aminobutyric acid #372
      orally daily #372
      5fluorouracil 5fu #373
      skin toxicity #373
      symptoms patients #373
      irreversible damage #374
      ovarian failure #374
      resected stage #374
      paclitaxel dose #374
      clinical oncology #374
      ecogps #374
      −005 #375
      therapy based #376
      decreasing #376
      women breast #376
      blood test #377
      medroxyprogesterone acetate #377
      week patients #378
      drowsiness #378
      humans specificity #378
      polyneuropathy #378
      assessable patients #378
      nociceptors #379
      national cancer institute #380
      fura #381
      loss skeletal #381
      telerehabilitation #381
      4 treatment #382
      organoplatinum compounds #383
      leucovorin #383
      unacceptable toxicity #383
      trials involving #384
      disputes #384
      function pain #384
      402 #384
      adverse event #384
      patients capecitabine #384
      target dose #384
      conservation agents #385
      5fluorouracil leucovorin #385
      leptin patients #385
      density conservation #386
      fourths #386
      2 treatment #388
      androgendeprivation therapy #389
      glutathione gsh #390
      treatment women #390
      advanced adenomas #391
      aromatase inhibitors ais #392
      sexual desire #392
      adjuvant trials #394
      dying patients #394
      4 weeks #394
      early palliative #395
      life breast #396
      discontinuation rates #396
      humans mastectomy #397
      cytotoxics #397
      olanzapine #397
      performance score #397
      ring compounds #397
      1280 #398
      patients randomly #398
      paired tests #398
      life data #399
      questionnaires treatment outcome #400
      chemotherapy colorectal #400
      withdrew #400
      peripheral neurotoxicity #400
      intramuscular #400
      fatty acid supplementation #400
      assigned #401
      3 cohorts #401
      8090 #401
      estrogen receptors biomarkers #401
      entered #402
      evidencebased #402
      loe #402
      sadenosyllmethionine #403
      female humans life #403
      acid female #403
      5 weeks #405
      baseline demographics #406
      female fluorouracil #406
      responding patients #408
      cisplatin induced #409
      keratolytic #410
      patients 5fu #411
      life aged #411
      topic neoplasms #412
      female hemorrhage humans #412
      regimens patients #414
      ornithine decarboxylase #414
      placebo 2 #415
      based chemotherapy #415
      oxaliplatin based #415
      pain qol #415
      acetate #415
      carboplatin patients #416
      oncology neoplasms #416
      patient factors #416
      delayed #417
      platinum agents #417
      gabapentinoids #417
      prospective pilot #417
      receiving #418
      case series patients #419
      nighttime sleep #419
      0 4 #419
      adjuvant hormonal therapy #419
      metastatic breast cancer #419
      antiemetic prophylaxis #420
      controlled pilot #421
      tamoxifen women #421
      cancer purpose #421
      tcl1a #421
      study entry #421
      directed therapy #422
      severities #422
      fourth week #422
      selfreported symptoms #422
      pyridones #423
      5 trials #423
      arm 2 #423
      adequately #423
      neurophysiologic #424
      tamoxifen #425
      anastrozole #425
      androgen ablation #425
      ongoing clinical trials #426
      complementary alternative #426
      prevention vte #427
      baseline 6 weeks #427
      primary peritoneal #428
      treating patients #428
      gain adult #428
      greater percentage #429
      creatine #429
      desipramine #430
      adjectives #430
      detection colorectal #431
      laser therapy #431
      methodsa #431
      fatigue humans #431
      glycitein #431
      hgb #431
      contraindicated #431
      diploid tumors #432
      symptom management #432
      joint symptoms #433
      sunscreen #433
      antiseizure #433
      115 patients #434
      cancer tamoxifen #434
      resultsone #434
      purpose objectives #434
      oral calcium #435
      nutrition cancer #436
      pains #436
      topic treatment #436
      1157 #436
      olanzapine treatment #436
      clinical cancer #438
      absolute terms #438
      anthracyclinebased chemotherapy #438
      nodenegative breast cancer #439
      administration cutaneous #440
      postoperative follow #440
      neoplasms cancer #441
      diminish #441
      expected survival #441
      yoga #442
      vasomotor #442
      baseline 1 month #444
      hgpin #444
      life efficacy #445
      doxorubicin drug administration #445
      preoperative breast #445
      loss aged #445
      screening colorectal #445
      receive #445
      agents antineoplastic #446
      marie #446
      day dexamethasone #447
      treatment regimen #447
      acid aged #447
      patients weight #448
      2 months #448
      patients qol #448
      european organization #448
      climacteric #449
      estrogen therapy #449
      baseline patient #450
      premature discontinuation #451
      cancer symptoms #452
      baseline 4 weeks #452
      outline #453
      study feasibility #453
      arms arm #454
      nodepositive breast cancer #454
      dhea #455
      postmenopause #455
      geranium #456
      5fu patients #456
      axillary metastases #457
      diphenhydramine #458
      evaluate efficacy #459
      mucositis #460
      enforced #461
      patients venous thromboembolism #461
      questionnaires terminology #461
      6 weeks #462
      patients baseline #462
      cytokines patients #462
      helpful #462
      increased weight #463
      potential interventions #463
      therapy stage #464
      clin #468
      asco #468
      cancer institute #468
      lung humans #469
      referral centers #469
      radiation enteritis #469
      sexual distress #470
      consensus guideline #470
      esophagitis patients #471
      treatment options patients #471
      purposethis #471
      chemotherapy regimens #472
      new treatment #473
      subscale #474
      432 #474
      pilocarpine #474
      symptoms menopause #475
      groups 6 months #475
      hormonal replacement therapy #475
      uncertain #476
      preliminary studies #477
      single item #477
      appears #477
      placebo 24 weeks #478
      clinical decision making #478
      variables age #479
      onco #479
      95 placebo #479
      iii colon #479
      doubleblind study #479
      alopecia #480
      enrollment patients #480
      vitamin placebo #480
      osteoporosis osteopenia #481
      moderatetosevere #482
      crc 95 #482
      higher dose #483
      reluctance #484
      adjuvant therapy #484
      endpoints included #485
      neurotoxicity patients #485
      tpn #485
      locoregional disease #485
      cure #486
      655 #486
      blind #488
      taqman pcr #488
      induced neuropathic #489
      estrogen deprivation #491
      pain scores #491
      doselimiting toxicity #491
      cancer cardiovascular disease #492
      primary breast #493
      plant preparations #493
      combined modality treatment #493
      narcotics #494
      patients stage disease #495
      decarboxylase activity #498
      dropout rates #499
      patients breast cancer #500
      fentanyl humans #500
      “ ” #501
      received placebo #501
      placebo‐controlled study #502
      life questionnaires survivors #502
      kps #502
      pilot studies #502
      metastatic cancer #503
      mesonephroma #504
      loss patients #504
      chest ray #505
      awaited #506
      survival chemotherapy #509
      pain inventory #510
      smoking nicotine #511
      placebo trial #511
      preventative #512
      trials data #513
      breast diseases #513
      therapy aged #513
      flic #514
      advance planning acp #514
      nonmetastatic breast cancer #514
      evidencebased interventions #515
      premature menopause #516
      letrozole treatment #516
      women receiving #516
      serum albumin levels #517
      outcome antineoplastic #517
      acute diarrhea #519
      pain medications #520
      achievements #520
      cbcs #521
      eflornithine #521
      gamma aminobutyric #522
      pharmaceutic #522
      poorer quality life #523
      mastectomy middle #525
      symptoms fatigue #525
      chills #525
      resultsto #527
      adverse events placebo #528
      prophylactic therapy #528
      controlled crossover #528
      cmf #529
      phytogenic area #529
      abt888 #529
      patients clinical trial #529
      therapy prostate #530
      oncologists #531
      radiodermatitis #531
      centrally #531
      pregabalin #531
      patients vitamin #532
      iii trial #533
      30 minutes #534
      genitourinary #535
      patients evaluated #536
      medications treatment #536
      antineoplastic agents #537
      agents chemotherapy #538
      weeks therapy #538
      study week #538
      superficial bladder #538
      patients clinical trials #539
      terminally #540
      patients assigned #541
      pharmacologic #542
      pain patients #543
      dehydroepiandrosterone #543
      topic severity #543
      week 6 #544
      risedronic #544
      pain score #544
      329 #545
      592 #546
      peripheral #548
      patients scheduled #548
      unable #549
      bmd baseline #550
      receiving adjuvant #550
      differences study #551
      dabrafenib trametinib #552
      3 95 #552
      hypesthesia #553
      axonal transport #553
      adenomas patients #554
      leucovorin oxaliplatin #555
      dysplastic lesions #556
      co2 laser #556
      regular aspirin #556
      evaluable #556
      neoplasms drug #556
      abh #557
      300 day #557
      vasomotor symptoms #559
      emesis #560
      reported outcomes #560
      80000 #560
      rbc transfusions #560
      day treatment #561
      moisturizer #561
      methylphenidate #561
      mesna #562
      hands #564
      lmwh patients #564
      induced cold #565
      time detection #565
      method drug #565
      treatment periods #566
      trial data #566
      4 8 #567
      supportive cancer #567
      survival stage #567
      11 months #568
      adjuvant clinical trials #569
      calgb #569
      therapy primary #569
      scientifically #569
      decarboxylase odc #571
      lower dose #571
      topic treatment outcome #571
      bibliometric analysis #572
      paclitaxel patients #573
      topical capsaicin #578
      fluorouracil oxaliplatin #578
      patients candidates #580
      refute #580
      methods systematic review #580
      hwe #581
      treatment phase #581
      breakthrough pain #583
      paced #583
      paracentesis #584
      life questionnaire #584
      desvenlafaxine #585
      moderate correlation #585
      neoplasms nutritional #587
      drug toxicity #587
      paclitaxel carboplatin #588
      emotional functioning #589
      aged occult #589
      multiple cancers #589
      limited efficacy #589
      oxaliplatin patients #589
      muscle cramps #589
      aminobutyric #590
      osteopenia #590
      taxane chemotherapy #590
      acrin #591
      ablation therapy #592
      median time progression #592
      crossover trial #592
      platinum drugs #593
      chemotherapy benefit #595
      compounded #596
      pentoxifylline #596
      fatigue female #597
      sst2 #597
      exanthema #597
      radiotherapy breast #597
      topic depressive disorder #598
      multisite #598
      publication administration #599
      patients mastectomy #599
      initial surgery #599
      patients etanercept #600
      thromboembolism vte #600
      effects breast #600
      discretion #601
      1093 #601
      health providers #601
      statistically differences #601
      patient decision #601
      oral solution #601
      vte cancer #602
      prevention measures #602
      cfibers #603
      exposed patients #604
      anthracycline based #604
      cancer survivors #604
      toxicity profile #605
      endoxifen #607
      16 women #608
      chemotherapy administration #608
      toes #608
      iron supplementation #609
      management symptoms #609
      agents antidepressive #609
      agents tricyclic #611
      topic reproducibility #612
      pilot #613
      2 95 #613
      updated analysis #614
      montanide #615
      qol baseline #616
      animal data #616
      humans quality #617
      118 patients #617
      commonly #618
      appetite #620
      antacid #620
      aic #621
      persistent symptoms #621
      urinary frequency #621
      follow median #622
      itching #625
      analyzable #626
      gangliosides humans #626
      cisplatin etoposide #627
      life quality #630
      1 month #631
      iii patients #632
      authors knowledge #633
      biological targets #634
      mistletoe #634
      month patients #637
      female sexual function #638
      assessment cancer #640
      serum hepcidin #640
      dose placebo #640
      eligible #641
      poorer quality #642
      inhibitors breast #643
      hormonal aromatase #643
      prostatic intraepithelial #644
      placebo time #645
      multiple studies #646
      palliative quality #647
      nasal symptoms #647
      300 patients #648
      malignant melanomas #648
      syndrome acute #649
      symptoms #649
      method humans #651
      flushes #651
      sores #651
      doses patients #651
      appeared #652
      dose limiting #653
      opioid analgesic #653
      limiting toxicity #653
      patients 16 #655
      poms #657
      prior chemotherapy #658
      complete response patients #659
      grade glioma #660
      twentysix patients #661
      colorectal adenocarcinoma #662
      patients chemotherapy #662
      62 months #663
      95 − #665
      neoplasms patient #666
      active agent #666
      cancer prospective #666
      alternative treatments #666
      nonparametric surveys #667
      life radiotherapy #667
      levetiracetam #668
      cancer treatments #668
      treatment trials #669
      women chemotherapy #670
      paclitaxel docetaxel #671
      marie tooth #671
      axonopathy #674
      1822 #674
      pain adult #674
      p00004 #674
      maintenance disorders #675
      pharmacologic management #675
      racially #676
      induced cognitive #676
      5 consecutive #678
      patients standard #678
      controlled study #679
      routine follow #680
      reported outcome #681
      diethylstilbestrol #681
      purpose report #682
      study samples #684
      oncology practice #685
      popularly #685
      highdose melphalan #685
      deprivation therapy #686
      fluorouracil leucovorin #687
      therapy cancer #687
      charcot marie #688
      neurologic injury #688
      practice settings #688
      sulindac #688
      life survivors #692
      pharmacological targeting #692
      rescue medication #693
      guideline update #693
      phlebitis #694
      administration schedule #694
      randomized treatment #695
      based testing #698
      desmethyl #699
      potential benefits #699
      descriptive statistics #700
      versa #701
      appearing #702
      chemopreventive agent #704
      postmenopausal #704
      v30 #705
      medical oncologists #706
      effective interventions #707
      tens #709
      locoregionally advanced #710
      capecitabine patients #711
      erythropoiesis stimulating #712
      randomized studies #712
      160 #712
      tube neoplasms #714
      newer agents #714
      prevention cancer #715
      breast magnetic #716
      inflammatory breast #717
      lowmolecularweight heparin #717
      convened #719
      endorsement #719
      ameliorate #720
      data baseline #722
      erythropoietin female #722
      humans neoplasms #725
      6 months 95 #725
      cyclophosphamide methotrexate #725
      palliative medicine #725
      therapeutic equivalency #727
      physicians predictive #728
      4 hours #728
      joint pain #729
      patients radiation therapy #730
      induced human #731
      odc activity #731
      study treatment #731
      charcotmarietooth #732
      women undergoing #733
      nucleotide variants #734
      medroxyprogesterone #735
      vinca #735
      adjuvant clinical #736
      secondary prevention #737
      induced neurotoxicity #738
      chemotherapy women #738
      opd #739
      mirtazapine #741
      4 weeks patients #742
      prescribing practices #742
      locoregional therapy #742
      fist #744
      armamentarium #745
      women placebo #745
      baseline 1 year #745
      patients breast #747
      bone loss #748
      ecog #748
      trials patients #749
      chemotherapy initiation #749
      psychostimulant #750
      superficial bladder cancer #750
      alfa #750
      271 #750
      rand #752
      cervical dysplasia #752
      complementary medicine #753
      compared placebo #753
      oct2 #754
      radiation skin #754
      antigen levels #754
      4·2 #754
      46 #755
      secondary points #755
      trouble #755
      paclitaxel chemotherapy #755
      patients insomnia #756
      metastatic breast #757
      hepcidin levels #758
      rifngamma #759
      reduction pain #759
      local anesthetics #759
      prostate adenocarcinoma #760
      sulfasalazine #760
      additional data #762
      pain quality #763
      ambulatory setting #765
      occult blood #766
      seventy patients #766
      81 patients #766
      acid 4 #768
      neoplasms prospective #768
      medroxyprogesterone acetate mpa #768
      humans imidazoles #769
      baseline pain #769
      activity breast #770
      actual #770
      sensory neuropathy #771
      breast carcinoma ductal #772
      relatedness #772
      modified radical mastectomy #772
      sweating #772
      premenopausal women #773
      women enrolled #773
      primary endpoint #773
      keratinocyte growth factor #773
      patients colon #774
      10 day #774
      emla #774
      neoplasms breast #774
      fifty patients #774
      aged peripheral #775
      octreotide treatment #776
      acupuncture therapy #776
      oral administration #777
      257 #777
      gsm #778
      charcot #778
      p00002 #778
      137 patients #781
      severity patients #782
      menopausal symptoms #783
      agents phytogenic #784
      benefits patients #785
      skin conductance #785
      cutaneous administration #785
      prognostic survival #787
      management #788
      enoxaparin #788
      symptom experience #791
      anesthetics local #792
      women reported #793
      subsequent cycles #793
      colon rectal cancer #796
      baseline period #797
      estrogen levels #798
      potential treatments #798
      life outcomes #801
      neuralgia pain #801
      clinical questions #801
      erythropoiesisstimulating agents #802
      osteoporosis women #802
      randomized phase trial #804
      lack efficacy #804
      day 3 #804
      primary points #805
      glutathione #805
      effects patients #806
      double #806
      894 #807
      opioid analgesia #807
      continue #808
      80 antineoplastic #808
      3 day #808
      etoposide cisplatin #808
      placebotreated patients #808
      0025 #809
      complete response #811
      odc #812
      abrogate #812
      previous reports #816
      mild symptoms #817
      disease genes #818
      lorazepam #819
      agents clinical #820
      eastern cooperative #820
      etoposide patients #823
      randomly #824
      tolerated #826
      statisticians #826
      148 patients #827
      cancer control #828
      rasch model #828
      cancer phase #830
      placebo 6 months #830
      administration oral #830
      suggestive #830
      dabrafenib #832
      neoplasms bone #832
      humans medical #833
      subset analysis #833
      similarities differences #835
      366 #836
      advanced malignancies #836
      prognosis quality #837
      mandelic #837
      numeric #838
      eventual #844
      breast neoplasms #845
      adverse events aes #846
      herbal products #846
      p006 #847
      global qol #848
      142 patients #848
      detection rates #849
      toxicities #850
      eortc #850
      taxol #851
      prostate cancer patients #852
      stage ovarian #853
      n55 #853
      oncotype #853
      palliative services #855
      daily dosing #858
      assessment management #859
      taxoids #859
      vaginal bleeding #859
      published data #860
      stratification patients #860
      strongest #864
      etidronic #866
      placebo baseline #868
      unacceptable #868
      patients trial #868
      efficacious #873
      jellies #873
      peritoneal cancer #874
      treatment completion #875
      timepoints #878
      5ht3 #879
      nonpharmacological interventions #880
      phytogenic carcinoma #880
      symptomatic women #880
      midlife women #881
      study placebo #883
      450 #883
      antineoplastic #883
      monoclonal antineoplastic agents #885
      mitigates #889
      neurotoxic #889
      topic female #890
      monoclonal female humans #891
      data article #892
      concomitant chemotherapy #893
      caa #894
      cancer guidelines #894
      control arm #896
      completed #900
      oxy #901
      neoplasms hormone #901
      women hormone #902
      inconvenience #903
      percent #903
      nodal status #903
      nmsc #904
      provided #905
      00006 #905
      chemotherapy response #905
      survival surgery #905
      hospices #909
      increased risk death #910
      chemotherapeutic #910
      cancer studies #913
      national cancer #914
      weight maintenance #914
      norepinephrine reuptake #915
      life cancer patients #916
      paroxetine #916
      gynecomastia #918
      prospective pilot study #919
      cycle chemotherapy #920
      advanced cancer patients #921
      mouth mucosa #921
      evidence practice #923
      manuscripts #924
      population cohort #924
      illness female humans #925
      primary objectives #926
      chemotherapy study #927
      upper extremities #929
      oral dosing #929
      lasa #930
      oncol #931
      starting #932
      fluoxetine #933
      minocycline #935
      cytotoxic therapy #937
      day placebo #938
      electronic health record #939
      serotonin uptake #939
      visual analogue #940
      treatment symptoms #940
      138 patients #942
      advanced adenoma #943
      high‐risk #943
      uptake inhibitors #943
      patient population #944
      letter editor #944
      colorectal adenomas #944
      beckman #945
      gp100 #945
      iii topic #945
      1year survival #946
      fluorouracil #948
      arm patients #949
      natural menopause #951
      recurrence score #952
      compare #953
      jci #954
      orally #954
      participating centers #955
      evaluating #955
      cooperative oncology #957
      aloe vera #958
      adjuvant therapies #958
      hfs #958
      rheumatologic #958
      leukopenia #959
      erythropoietic #959
      moderately #961
      monoclonal carcinoma #962
      pjnk #963
      trpm8 #963
      received adjuvant #964
      serum cytokine #966
      menopause #968
      1160 #969
      mart1 #970
      table #972
      earlystage disease #972
      randomized pilot #973
      gluconate #976
      restarted #977
      olmsted county #977
      hypercalcemia #978
      1 10 #978
      mechanical allodynia #980
      1month #980
      2700 #982
      antidotes #984
      150 #984
      1 week #984
      patients venous #989
      threequarters #989
      adjuvant #992
      pain reduction #993
      multiple logistic regression #997
      analyses data #998
      mayo #1003
      bother #1003
      cancer chemoprevention #1005
      publication analgesics #1007
      71 #1010
      continued #1014
      patients metastatic disease #1015
      organ systems #1016
      neurocutaneous #1018
      anthraquinones #1019
      patients mri #1020
      reported pain #1021
      life symptoms #1023
      trial participation #1026
      145 patients #1027
      enteritis #1028
      fatigue patients #1028
      urogenital #1030
      delayed treatment #1031
      alternative treatment #1031
      evidence treatment #1037
      pill #1037
      ” “ #1038
      androgen deprivation therapy #1042
      validity responsiveness #1043
      prx #1044
      postural control #1044
      randomized trial patients #1046
      colorectal tumor #1047
      patients safety #1047
      prevention intervention #1047
      substantial #1050
      frey #1051
      nutritional supplementation #1051
      life #1053
      30 40 #1053
      postchemotherapy #1056
      doxorubicin female humans #1056
      minority #1057
      osteoporosis treatment #1059
      feeding eating #1059
      primary analysis #1059
      10 weeks #1060
      tricyclic #1061
      day study #1061
      fruitful #1063
      oncologist #1063
      prospective validation #1063
      endocrine resistance #1064
      347 #1064
      loss weight #1066
      ongoing studies #1066
      suggested #1069
      therapy #1069
      disappointing #1069
      metastatic lung #1070
      practical guidance #1070
      descriptive #1073
      tobacco dependence #1075
      monoclonal humans #1078
      nccn #1078
      concurrent chemotherapy #1078
      women treatment #1079
      placebo day #1080
      patients bone metastases #1081
      women received #1083
      advance planning #1084
      placebo participants #1085
      duloxetine #1089
      prompted #1089
      breast cancer recurrence #1089
      patients adjuvant therapy #1090
      low intermediate #1091
      prospective multicenter study #1092
      progestogens #1094
      postoperative surveillance #1095
      palonosetron #1095
      adult breast #1097
      25 day #1098
      intravenous iron #1099
      favor #1099
      agents treatment #1100
      functional ability #1100
      previous chemotherapy #1100
      54 #1103
      phytoestrogens #1103
      prospective trial #1106
      peripheral neuropathies #1108
      acknowledged #1110
      3 6 months #1112
      transdermal #1114
      randomized #1115
      1 year treatment #1116
      prevention trials #1119
      treatment life #1121
      life death #1122
      inhaler #1124
      cancer trials #1126
      interprofessional relations #1126
      dmc #1127
      unpleasant #1127
      prilocaine #1127
      based evidence #1128
      mexiletine #1129
      participants received #1131
      clinician #1133
      patients versus #1133
      sunscreening #1136
      lecithins #1137
      opioid therapy #1139
      25 micrograms #1139
      practice guideline #1140
      hormonal therapy #1140
      cancer #1141
      purposeto #1144
      inhibit #1144
      randomized crossover #1146
      egb #1146
      cancer pain #1146
      locoregionally #1147
      illness surveys #1148
      taste disorders #1149
      premature ovarian failure #1150
      shark #1150
      purpose determine #1150
      730 #1153
      nervousness #1153
      detrimental #1154
      hormonal #1154
      smoking prevention #1154
      flecainide #1157
      325 #1159
      481 #1161
      22 #1162
      rinse #1162
      doac #1163
      educate #1164
      purposethis study #1167
      toxicity assessment #1167
      comparative efficacy #1172
      ceramides #1173
      therapy estrogens #1174
      painful #1174
      intervention trials #1175
      receptor modulators #1176
      patients syndrome #1177
      clinical trial #1178
      inadequately #1179
      projects #1180
      lowest risk #1181
      chemotherapy regimen #1182
      chose #1184
      aged prostatic #1185
      growing population #1186
      physician patient #1187
      electrostimulation #1188
      prior treatment #1189
      international consensus #1189
      mastectomy breast #1190
      acetate treatment #1190
      usage #1193
      gained #1196
      estrogen replacement therapy #1197
      olmsted #1197
      diary #1197
      experiencing #1198
      alternative therapies #1200
      caregivers patients #1202
      male smokers #1204
      partial responses #1204
      552 #1204
      panax #1205
      clinical trials patients #1207
      magnesium #1208
      breast cancer #1212
      satisfied #1212
      induced skin #1213
      patients pts #1215
      611 #1215
      communication skills #1215
      likert #1217
      adjuvant endocrine #1218
      secondary endpoints #1219
      sexuality #1219
      precludes #1219
      8 week #1221
      higher numbers #1223
      phase clinical trial #1223
      limiting #1224
      editor #1227
      thighs #1227
      participants reported #1229
      organogel #1230
      8 weeks #1232
      primary melanomas #1232
      52 #1233
      n54 #1234
      discontinue #1235
      randomized phase #1235
      tricyclic antidepressants #1241
      clinical syndrome #1241
      baseline values #1245
      day 2 #1248
      symptoms diagnosis #1248
      review data #1248
      decided #1249
      etiologies #1250
      female sexual #1250
      postmenopausal women #1252
      bedtime #1252
      il1β tnfα #1253
      estrogens female #1255
      diarrhea patients #1257
      combination docetaxel #1258
      diphosphonates #1258
      thromboembolism patients #1258
      trametinib #1259
      hypochromic #1259
      patients 4 #1259
      kidney dysfunction #1260
      rasch #1260
      pain medication #1261
      neurologic humans #1263
      doubts #1263
      tumor promotion #1265
      dna ploidy #1265
      esophagitis #1266
      sae #1266
      protocols chemotherapy #1268
      magnesium oxide #1270
      phytotherapy #1271
      qol scores #1272
      drug double #1272
      short form36 #1273
      situ carcinoma ductal #1273
      preoperative chemotherapy #1274
      patients families #1274
      preclude #1276
      cutaneous melanomas #1278
      taxanes #1279
      tamoxifen patients #1279
      median ttp #1280
      dosing interval #1281
      heparin lmwh #1282
      label trial #1284
      male medication adherence #1285
      medical oncology #1286
      adjuvant tamoxifen #1287
      adjuvant therapy patients #1289
      opposed #1289
      cyclophosphamide doxorubicin #1289
      folfox #1291
      109 patients #1292
      cochran #1294
      acupuncture treatment #1294
      data clinical #1296
      prevalence severity #1296
      antimetabolites antineoplastic #1297
      neurosensory #1298
      neoplasms disease #1300
      emetic #1301
      women cancer #1303
      8 cycles #1307
      abstinent #1307
      stimulating agents #1309
      motion rom #1310
      survival 5 #1310
      critical review #1312
      sportdiscus #1313
      gynecologic cancers #1314
      melanoma antigen #1315
      biotech #1315
      gsh #1315
      breast biopsy #1317
      contacted #1318
      durations #1318
      etanercept #1320
      health‐related quality #1320
      oncology patients #1321
      chemotherapeutic agents #1321
      controlled #1321
      investigative #1321
      patients quality #1322
      pain interference #1322
      primary outcome measure #1322
      ointments #1323
      nerve damage #1326
      appetite loss #1327
      patient physician #1328
      life scores #1328
      agents colorectal #1329
      cardiac toxicity #1329
      life surveys #1337
      adjuvant breast #1339
      375 #1340
      published reports #1341
      evenly #1342
      2 week #1345
      ambulatory monitoring #1346
      breast cancer women #1347
      platinum compounds #1347
      colonoscopic #1350
      experienced #1350
      tibolone #1351
      karnofsky #1352
      cancer experience #1353
      benefit patients #1353
      malignant ascites #1354
      carcinoembryonic #1356
      period patients #1358
      eligibility criteria #1359
      wks #1360
      agents cancer #1367
      effects treatment #1368
      attribution #1369
      postural balance #1372
      continues #1376
      combination female humans #1377
      hopes #1379
      titrated #1381
      n32 #1382
      patients colon cancer #1382
      n29 #1382
      duplicates #1386
      mastectomy #1387
      hydrazines #1387
      snvs #1388
      patients 40 #1391
      femoral neck bmd #1396
      medical literature #1397
      ajcc #1399
      cancer adult #1400
      cancer therapies #1403
      pain neuropathic #1404
      somnolence #1406
      polyneuropathies #1407
      rifn #1407
      replete #1408
      physical activity level #1410
      treats #1411
      integrative medicine #1412
      fisher test #1415
      wilcoxon #1416
      viscum #1416
      combination chemotherapy #1417
      cessation treatment #1418
      quality life #1420
      treatment recommendations #1423
      noncompliance #1424
      sleep initiation #1424
      subjective symptoms #1424
      biloba #1425
      therapy initiation #1426
      methodsdata #1426
      prevent #1427
      cancer quality life #1427
      cytotoxic chemotherapy #1428
      hormonal treatment #1431
      aromatase #1431
      and or #1432
      weight heparin #1433
      5fu #1433
      radiation injuries #1434
      statistically difference #1434
      daily intake #1435
      primary objective #1437
      caloric intake #1439
      adults cancer #1440
      female humans illness #1442
      proctitis #1445
      goserelin #1445
      aminobutyric acid #1446
      ehrs #1447
      postacute #1447
      cancer clinical trials #1449
      incidences #1449
      assigning #1450
      coulter #1453
      patients ovarian #1454
      treatment pain #1454
      nccn guidelines #1454
      infliximab #1455
      cognitive testing #1456
      bruising #1457
      hrqol #1458
      63 #1459
      effective management #1461
      dna testing #1461
      individual patients #1461
      adjuvant treatment #1463
      aged quality #1466
      life cancer #1466
      network meta #1467
      discrepancies #1467
      haloperidol humans #1467
      crossover #1468
      nutritional support #1469
      locally advanced head #1469
      physical activity patients #1470
      recurrent vte #1475
      hormone dependent #1477
      life treatment #1477
      resultsa #1479
      substantial proportion #1479
      lower extremities #1483
      tumor promoter #1484
      oral aged #1484
      pik3ca mutation #1485
      aromatase inhibitors #1492
      nrs #1493
      cancer society #1494
      ongoing #1495
      systemic chemotherapy #1498
      mood states #1499
      planned #1500
      paclitaxel cisplatin #1501
      resultsafter #1501
      mpa #1509
      anti anxiety #1510
      colon cancer patients #1510
      perimenopause #1513
      gynecologic cancer #1513
      premalignant #1514
      neuropeptide npy #1518
      bowel function #1520
      hair loss #1523
      efficacy #1523
      biweekly #1523
      diagnosed cancer #1525
      p0024 #1525
      oncology #1526
      root ganglion #1526
      3 weeks #1528
      interfered #1530
      balanced #1532
      gastrointestinal toxicity #1533
      cck8 #1537
      cytotoxic agents #1537
      survivors #1538
      physical examination #1542
      cycle patients #1546
      warranted #1548
      guideline recommendations #1549
      tamoxifen treatment #1550
      treatment induced #1556
      adult cancer #1560
      blind randomized #1562
      male breast #1562
      pounds #1567
      transfusion requirements #1568
      design considerations #1569
      response rates #1572
      or1 #1574
      iii disease #1576
      pharmacologic treatment #1576
      5 day #1579
      bibliographies #1580
      crushed #1583
      rivaroxaban #1583
      patients small #1583
      rate survival #1584
      vaginal #1587
      prospective trials #1588
      postmenopausal breast #1589
      updates #1590
      image body #1593
      dissent #1593
      phase iii study #1595
      localized disease #1599
      trpa1 #1600
      stratification #1600
      therapy cyclophosphamide #1602
      aged cross #1603
      completion #1603
      advanced colorectal cancer #1604
      disagreements #1605
      modafinil #1606
      allopurinol #1608
      ≥70 #1611
      bid #1612
      dosing #1619
      aged antineoplastic #1620
      accrual #1623
      oncology nursing #1624
      970 #1624
      dna markers #1626
      cream #1627
      176 #1628
      prophylactic treatment #1629
      tumor type #1633
      227 #1634
      vte #1636
      upfront #1637
      potential channels #1642
      respiratory depression #1643
      combined modality therapy #1649
      cardiovascular toxicity #1650
      49 #1651
      2003 #1652
      controlled phase #1652
      monthly #1656
      cancer stage #1660
      current treatment #1661
      limited data #1663
      pelvic radiotherapy #1664
      referencing #1666
      breast cancer patients #1667
      populationbased cohort #1667
      evaluation female #1670
      treated breast #1676
      patient preference #1679
      therapy hrt #1680
      ovid medline #1682
      hb #1683
      agents carcinoma #1687
      blood tests #1689
      publication attitude #1691
      neoplasms practice #1693
      anticancer therapy #1693
      weight patients #1694
      stopping #1695
      percent patients #1695
      methyldopa #1696
      ≤2 #1696
      randomization #1698
      patients bone #1698
      nootropic #1698
      morpholines #1700
      symptom distress #1701
      patients control #1701
      endpoint #1703
      glutamine #1705
      enrolled patients #1705
      reported symptoms #1706
      study groups #1707
      chisquare #1708
      595 #1709
      chemotherapy patients #1709
      endocrine treatment #1711
      incorrectly #1714
      inhibitor therapy #1715
      crossover study #1716
      hyperalgesia male #1717
      antineoplastic agents carcinoma #1719
      interventions patients #1720
      human epidermal #1726
      effects cancer #1726
      referral consultation #1728
      selective estrogen #1728
      testosterone treatment #1729
      652 #1729
      nineteen #1730
      neuropathic pain #1731
      orchiectomy #1731
      lmwh #1738
      paucity #1740
      life questionnaires #1741
      p450 cyp2d6 #1746
      topical #1746
      ≥10 #1749
      oxcarbazepine #1749
      scores patients #1751
      fifty #1752
      recommendations patients #1753
      unique challenges #1754
      neoplasms early #1754
      insufficient evidence #1762
      treatment data #1762
      greater reduction #1762
      cramps #1764
      fall risk #1765
      massage #1766
      grade 2 #1766
      progression survival #1770
      anticoagulants doacs #1772
      urinary symptoms #1775
      performance status #1779
      95 0 #1781
      clinical endpoints #1781
      fingers #1784
      objective responses #1784
      lignans #1785
      behavioral interventions #1785
      pros #1787
      dizziness #1789
      facts #1790
      survival outcomes patients #1791
      anorectic #1791
      life assessment #1791
      drug therapy #1792
      rbc transfusion #1794
      transient receptor #1795
      alternative medicine #1796
      primary therapy #1796
      descriptive analysis #1798
      decision aids #1800
      investigator #1802
      treatment cycles #1803
      acetylcarnitine #1803
      severe toxicity #1804
      median survival time #1804
      supporting #1805
      premenopause #1807
      adjunct #1808
      analgesic efficacy #1811
      topic #1812
      16 patients #1813
      agents female #1813
      breast surgery #1816
      evidencebased recommendations #1818
      trpm #1818
      ql #1821
      receptor potential #1822
      cancer women #1823
      327 #1823
      evaluable patients #1825
      effective therapy #1825
      anxiety agents #1827
      humans neoplasm #1831
      ganglion neurons #1831
      longterm survival patients #1835
      neoplasms prognosis #1835
      suffering #1836
      menopausal transition #1837
      administration topical #1849
      active cancer #1850
      comprehensive cancer #1851
      months 12 #1851
      neuropathic #1853
      patients prognosis #1853
      dermatological #1853
      23 months #1853
      providers patients #1857
      initial dose #1858
      aged postmenopause #1858
      cancer types #1858
      rationale design #1863
      antimitotic #1864
      univariate analyses #1867
      antimetabolites #1871
      humans pain #1873
      europe female humans #1873
      secondary objective #1876
      continuing #1877
      vice #1878
      induced pain #1879
      resultsa total #1879
      antigen colorectal #1881
      analysis adult #1881
      musculoskeletal pain #1881
      leucovorin male #1886
      galvanic #1887
      weeks #1888
      15 weeks #1890
      keratinocyte #1891
      questionnaires time #1891
      schedules #1891
      mainstay #1892
      sexual functioning #1893
      hospice #1896
      triazoles #1897
      sensory motor #1898
      problematic #1899
      stellate #1899
      psqi #1903
      topic surveys #1910
      treatment modality #1911
      neuropeptide #1913
      evidence recommendations #1918
      serum cortisol #1922
      creams #1924
      unwanted #1928
      symptoms women #1933
      pain #1940
      prematurely #1946
      health personnel attitude #1946
      patients prostate cancer #1949
      5year followup #1950
      treatment trial #1951
      peritoneal neoplasms #1952
      imidazoles #1953
      cancer survivorship #1955
      diagnosed breast #1956
      cannabidiol #1964
      signed #1966
      nipple #1969
      primary aim #1971
      iii breast #1971
      warrant #1972
      articles #1974
      surveillance colonoscopy #1974
      initiating #1975
      clinical patients #1978
      estrogen replacement #1978
      hand foot #1979
      collaborative #1982
      intravaginal #1982
      dose melphalan #1983
      controlled trial #1985
      wasting syndrome #1989
      androgen antagonists #1994
      cancer patient #1994
      current treatments #2002
      stool samples #2004
      patients dose #2005
      effective therapies #2011
      dose reductions #2012
      gastrointestinal neoplasms #2017
      phytotherapy plant #2018
      form36 #2018
      fallopian tube #2019
      topic clinical trials #2022
      steroidal aspirin #2023
      perimenopausal #2025
      critics #2025
      neuromuscular diseases #2026
      cardiotoxicity #2029
      testing patients #2031
      patients arm #2032
      outpatient visits #2034
      doses #2036
      eortc qlqc30 #2038
      transcutaneous #2041
      exercise interventions #2042
      recurrence survival #2044
      dnr #2045
      functional impairment #2046
      breast cancer treatment #2047
      status patients #2056
      evidence base #2056
      concentration time #2058
      doxorubicin female #2059
      35 patients #2063
      antibodies monoclonal antibodies #2064
      head neck cancers #2065
      chest #2066
      relaxation therapy #2069
      cancer population #2069
      120 patients #2070
      contention #2073
      inhibitor treatment #2074
      hb level #2075
      safety pharmacokinetics #2075
      daily #2075
      50 reduction #2076
      vinblastine #2076
      nk1 #2077
      benefit #2080
      methysergide #2081
      20 day #2082
      younger women #2087
      iii #2087
      patients caregivers #2088
      nursing practice #2090
      advanced cancers #2090
      antidote #2090
      cco #2094
      major bleeding #2094
      weekly paclitaxel #2097
      66 years #2097
      anticonvulsants #2102
      density bone #2103
      mcg #2104
      mitomycins #2107
      therapy chemotherapy #2109
      eicosapentaenoic acid #2110
      orally administered #2111
      tmt #2111
      menopausal status #2113
      day 1 #2114
      65 #2115
      ≥2 #2121
      bmd lumbar spine #2121
      5fluorouracil #2122
      96 patients #2124
      treatment study #2124
      journals #2125
      hb levels #2126
      mildly #2126
      ttr #2127
      bpi #2128
      hormone concentrations #2129
      hepcidins #2130
      neoplasms clinical #2133
      osteolytic #2135
      concerned #2136
      secondary objectives #2136
      525 #2136
      egfr inhibitors #2136
      aggressive disease #2140
      qol #2142
      levamisole #2150
      tolerable #2153
      carcinoembryonic antigen #2154
      regimens #2157
      item #2158
      prt #2160
      preventive strategies #2161
      baseline #2166
      evidence efficacy #2166
      treatment acute #2169
      anemic #2169
      aloe #2175
      women #2177
      album #2179
      pain syndromes #2179
      worst #2179
      tosyl #2181
      physician #2182
      detailed description #2185
      fatigue pain #2188
      44 patients #2195
      nervous #2197
      severe symptoms #2204
      questionnaires survivors #2207
      dose intensity #2208
      455 #2208
      prescription drugs #2210
      age race #2210
      female head #2210
      1 7 #2212
      ensuing #2213
      hypnosis #2213
      weight loss #2214
      1–4 #2220
      recurrences #2220
      cmt #2224
      adenosyl #2225
      premenopausal #2226
      myalgia #2233
      osteonecrosis jaw #2235
      9 weeks #2235
      138 #2242
      60 minutes #2243
      adrenal axis #2247
      failed #2247
      patient populations #2251
      dermatologic #2256
      life severity #2257
      preliminary evidence #2262
      summarized #2265
      exercise female humans #2266
      clinically meaningful #2270
      patients metastatic melanoma #2271
      566 #2272
      differences patients #2273
      irritation #2277
      bioelectrical impedance #2284
      oophorectomy #2285
      1 year patients #2285
      occult #2288
      metastatic melanoma #2290
      osteoporosis postmenopausal #2291
      sloan #2292
      gastrointestinal cancer #2293
      likewise #2298
      800 #2299
      life illness #2301
      therapy adt #2301
      regular #2302
      dysfunction physiological #2303
      incisional #2308
      future trials #2309
      conclusionthe #2310
      polymerase inhibitors #2310
      recommendation #2311
      patch #2311
      cramp #2312
      genetic variations #2314
      therapeutic strategies #2320
      topic risk #2326
      baclofen #2327
      74 #2327
      weight breast #2328
      worse #2329
      mastectomy segmental #2333
      36 #2333
      burning #2333
      toxicity #2334
      modest #2334
      subcutaneously #2335
      receptor positive #2337
      exclusion criteria #2338
      week #2342
      opioid analgesics #2347
      society #2347
      improve quality #2349
      androgen deprivation #2349
      curve analysis #2352
      46 patients #2352
      endorsed #2357
      adult antineoplastic #2359
      cyp2d6 #2365
      density bmd #2365
      baseline treatment #2367
      increased risks #2367
      nonrandomized #2371
      669 #2373
      agent #2374
      bibliometric #2375
      rom #2378
      health practice guidelines #2379
      taste #2389
      cancer clinical #2390
      ornithine #2391
      treatment duration #2393
      difference 95 #2396
      justification #2397
      neoplasms survival #2399
      neurological complications #2400
      266 #2405
      counteract #2405
      titles #2406
      treatment baseline #2407
      inadequate #2407
      remaining patients #2412
      postural #2418
      rectal cancer patients #2419
      poor performance #2419
      ovid #2420
      documenting #2421
      5 patients #2425
      advanced prostate cancer #2425
      limited evidence #2426
      symptom scores #2426
      debate #2433
      761 #2436
      71 patients #2437
      practiced #2437
      estrogen deficiency #2439
      patients crc #2439
      acupuncture #2442
      response evaluation #2442
      outpatient treatment #2443
      phase trials #2449
      56 years #2452
      chemotherapy adjuvant #2453
      receptor antagonist #2460
      common cancers #2462
      iiic #2463
      common adverse #2464
      assessment scale #2469
      factor inhibitors #2469
      fallopian #2474
      207 #2474
      patients quality life #2477
      weight gain #2478
      bleomycin #2480
      guidelines patients #2481
      practical approach #2485
      network metaanalysis #2491
      crossed #2493
      approached #2494
      melanomas #2495
      raloxifene #2496
      discontinuing #2497
      6 patients #2502
      sexual function #2507
      ginkgo #2510
      locoregional #2510
      61 #2510
      patients colorectal cancer #2519
      children cancer #2524
      topic clinical #2526
      venous thromboembolism #2527
      regimen #2531
      cooperative #2537
      amitriptyline #2542
      asked #2542
      radiation induced #2544
      rescue #2545
      treatment methods #2556
      12 24 #2556
      carryover #2557
      symptom #2558
      galectin3 #2562
      mandated #2564
      randomised clinical trial #2567
      telopeptide #2567
      nitriles #2568
      reuptake #2570
      treatment selection #2570
      earlystage breast cancer #2573
      stage small #2573
      conjunctivitis #2574
      secondary analyses #2592
      trials #2592
      ideally #2595
      carboplatin #2597
      effects drugs #2598
      2 cycles #2602
      erbb2 receptors #2608
      parenteral #2610
      arm #2612
      pruritus #2614
      patient education #2617
      outcome united #2624
      antineoplastic combined #2624
      consented #2626
      apr #2626
      suspicious #2627
      dorsal root #2629
      symptoms quality #2629
      life hrqol #2631
      increased likelihood #2639
      managing #2642
      prefer #2644
      remedy #2648
      55 #2649
      races #2657
      0001 patients #2657
      thromboembolism #2657
      attenuate #2662
      scores #2663
      total parenteral nutrition #2663
      lasted #2667
      basal cell #2670
      testosterone #2672
      cancer outcomes #2673
      imprecise #2675
      comparable #2676
      poorer survival #2677
      symptoms treatment #2685
      817 #2686
      prescribed #2687
      prevention interventions #2692
      statistically #2696
      randomized controlled #2699
      direct oral anticoagulants #2701
      prevalence smoking #2705
      impotence #2707
      advanced colorectal #2711
      data synthesis #2713
      primary lung #2717
      myelosuppression #2724
      1000 #2735
      01 #2741
      modestly #2745
      chemotherapy protocols #2745
      thermal hyperalgesia #2748
      multiple factors #2749
      acp #2749
      patients pain #2750
      topic drug #2752
      efficacies #2753
      taxane #2758
      advanced breast #2760
      male medical #2761
      ttf #2762
      250 #2764
      neurotoxicity #2769
      pyrazoles #2774
      male neoplasms #2775
      1 4 #2775
      237 #2776
      breast carcinoma #2777
      convenience sample #2780
      selfreport #2781
      syndrome aged #2788
      cryosurgery #2789
      pooled data #2790
      paraneoplastic syndromes #2790
      neoplasia #2791
      undergone #2792
      adverse #2793
      ascites #2794
      isoflavones #2794
      agents #2797
      complete data #2799
      thrice #2801
      nv #2801
      doacs #2802
      acid epa #2806
      cox model #2812
      additional studies #2813
      shortness #2814
      continuous infusion #2815
      preferred #2817
      neurofeedback #2823
      750 #2827
      breast #2834
      sexual health #2837
      muscle weakness #2840
      1 3 #2842
      opioids #2844
      meeting #2844
      38 #2845
      primary outcomes #2845
      cancer aged #2854
      n31 #2857
      cohen #2857
      linseed #2859
      breakthrough #2859
      pharmacogenomic #2860
      neoplasms #2860
      sham #2861
      statistical methods #2866
      breaths #2867
      activity level #2867
      anticipate #2869
      purposethe #2869
      covariate #2870
      fertility preservation #2875
      surveillance patients #2876
      5 years patients #2886
      task force #2886
      ellipse #2893
      survival dose #2895
      p04 #2895
      decarboxylase #2912
      functional assessment #2915
      endodermal #2917
      packyears #2918
      screening tests #2920
      measurable #2922
      p0002 #2927
      placebo response #2930
      prior #2931
      condylomata #2931
      phase clinical #2933
      p008 #2941
      topic design #2945
      identifier #2949
      review articles #2949
      dosing regimens #2949
      colonoscopy colorectal #2951
      auc #2954
      laser treatment #2955
      utility #2956
      week 12 #2961
      2 groups #2962
      humans infusions #2963
      hirsutism #2966
      combined chemotherapy #2969
      search terms #2971
      curable #2974
      chest wall #2975
      intraepithelial neoplasia #2977
      prophylactic #2982
      placebo difference #2983
      questionnaires #2985
      eicosapentaenoic #2986
      calculator #2988
      testimony #2989
      stopped #2990
      calories #2991
      started #2991
      severity symptoms #2995
      positive breast #2998
      fatigue #3000
      resected #3004
      long acting #3010
      n5 #3012
      objective response #3012
      topically #3013
      time progression #3014
      discomfort #3014
      pathologic complete response #3019
      patients 5 #3022
      mianserin #3026
      bone fractures #3029
      ifosfamide #3033
      nci #3034
      skeletal muscle mass #3038
      her2 status #3041
      reuptake inhibitors #3041
      dermatoses #3042
      placebo week #3052
      sided #3053
      relief #3058
      risk colorectal #3058
      dukes #3058
      tumor activity #3066
      curve auc #3067
      outcome measure #3067
      264 #3068
      clonidine #3069
      malignancy #3071
      hyperhidrosis #3072
      ctx #3074
      sternal #3076
      histograms #3092
      sexual dysfunction #3097
      nicotine dependence #3098
      loss adult #3099
      intergroup #3103
      patients day #3107
      tumor grade #3108
      cancer female humans #3111
      vera #3111
      bmd #3111
      66 #3116
      neurokinin1 #3121
      26 #3121
      reversing #3135
      cognitive dysfunction #3139
      schedule #3143
      12 weeks #3144
      treatment oral #3146
      life measures #3147
      clinical stage #3150
      trpv1 #3154
      infusions intravenous #3155
      randomized controlled study #3161
      χ2 #3165
      subsequent development #3166
      strongest association #3168
      lifestyle factors #3178
      phase 3 #3180
      reasonable #3181
      systematic literature search #3183
      current approaches #3185
      supportive #3185
      leuprolide #3186
      relevant articles #3188
      617 #3189
      intravenous #3190
      wore #3192
      cannabinoids #3193
      64 #3196
      podophyllotoxin #3197
      abstracted #3201
      menopausal #3208
      case reports #3210
      constellation #3218
      42 #3222
      intervention trial #3225
      joint committee #3225
      nonsmallcell lung cancer #3226
      39 #3226
      cochrane central register #3231
      pain perception #3235
      enrolled #3238
      breathing #3239
      medical record #3240
      paraneoplastic #3245
      itch #3260
      therapy combination #3260
      intervention patients #3263
      designed #3264
      oral mucosa #3264
      236 #3266
      disagree #3269
      prior studies #3269
      treatment efficacy #3270
      n30 #3271
      5 10 #3272
      skin biopsies #3278
      supplementary #3279
      finished #3282
      expert panel #3284
      root ganglia #3287
      2030 #3287
      80 antibodies #3288
      lymphoma patients #3290
      695 #3290
      885 #3290
      previous analyses #3291
      576 #3294
      understudied #3296
      0026 #3303
      neuralgia #3313
      suffer #3314
      undertook #3316
      resection colorectal #3319
      impression #3320
      treatment placebo #3320
      electronic health #3321
      chlorhexidine #3322
      prostate cancer risk #3328
      acuminata #3334
      171 #3334
      risk vte #3339
      systemically #3350
      platinum based #3352
      terminology #3356
      erythema #3358
      historic #3360
      female breast #3365
      breast prostate #3368
      doubt #3370
      bone metastases #3370
      thirty #3374
      preclinical studies #3375
      relapse free #3380
      chemoprevention #3386
      acute chronic #3392
      equivalency #3395
      advanced prostate #3396
      iii trials #3399
      answers #3400
      preceding #3406
      oral #3408
      lymph node excision #3411
      prostatic neoplasms #3415
      delaying #3417
      anilides #3418
      severity #3422
      delineated #3425
      axillary lymph #3426
      administering #3437
      npy #3438
      higher scores #3444
      screening methods #3446
      012 #3446
      subsequent #3452
      aminoquinolines #3460
      64 patients #3463
      utilizing #3463
      sprays #3464
      listed #3468
      survival benefits #3468
      pts #3468
      chemotherapy radiation #3471
      anthracyclines #3471
      multicenter randomized #3473
      lidocaine #3475
      lower rate #3477
      mailed #3479
      cross validation #3480
      cessation smoking #3481
      3 6 #3484
      attempt #3489
      antidepressants #3490
      intent #3495
      reviewing #3499
      ctc #3500
      malignant disease #3501
      #3505
      chemotherapeutic agent #3512
      recommend #3524
      allodynia #3529
      carries #3539
      metastatic disease #3544
      points #3545
      opiates #3559
      stage breast #3561
      148 #3565
      faced #3566
      patients metastatic #3574
      survival women #3583
      phase topic #3583
      correlational #3583
      135 #3586
      carboplatin paclitaxel #3586
      oestrogen #3587
      chemotherapy cycles #3588
      patients experiences #3588
      treatment decisions #3595
      211 #3596
      gold standard #3607
      objective measures #3608
      life qol #3608
      periodically #3610
      thiotepa #3615
      stage iiia #3618
      oral adult #3619
      ≥30 #3620
      benefits risks #3620
      survival cancer #3620
      therapeutic benefit #3623
      improvement quality #3629
      antacids #3630
      29 patients #3631
      survivals #3634
      racial differences #3639
      complete responses #3648
      patients adjuvant chemotherapy #3650
      ordinal #3650
      colon cancer #3650
      adjuvant chemotherapy patients #3652
      ≥18 years #3655
      parp inhibitor #3660
      bodymass #3661
      34 patients #3666
      acid antagonists #3674
      673 #3682
      sigmoidoscopy #3682
      preceded #3685
      proportion #3686
      580 #3686
      aps #3688
      thirty patients #3689
      cardio #3690
      chemotherapies #3695
      redness #3700
      moxibustion #3702
      options #3705
      electron rats #3706
      relapsefree survival #3707
      study evidence #3708
      cancer chemotherapy #3712
      annually #3714
      instructed #3716
      adjuvant chemotherapy #3718
      5000 #3719
      exception #3721
      911 #3725
      breast tissue #3731
      impressive #3738
      combination female #3741
      foams #3742
      randomized clinical trial #3742
      practicing #3743
      anabolic #3746
      late effects #3752
      lymphatic vessels #3754
      weight status #3758
      longterm survival #3768
      menopausal women #3774
      symptom severity #3782
      vertigo #3788
      adversely #3789
      cancer drugs #3795
      compassionate #3800
      567 #3801
      hormone replacement therapy #3804
      external beam #3805
      sixth #3806
      600 #3807
      terminal #3811
      anesthetics #3811
      hormone replacement #3811
      colchicine #3815
      phase trial #3816
      centric #3817
      etoposide #3822
      pain control #3825
      cancer prostate #3830
      ploidies #3831
      intramuscularly #3834
      patients experienced #3834
      136 #3839
      16 weeks #3839
      patients moderate #3843
      cutaneous #3846
      trpv #3847
      contraindications #3847
      blinding #3854
      seventy #3854
      patients grade #3855
      sharks #3855
      internally #3858
      23 #3861
      treatment metastatic #3861
      04 #3866
      futility #3867
      786 #3875
      individually #3880
      queried #3882
      flushing #3886
      midwestern #3888
      adenomas #3895
      compelling #3897
      dfs survival #3905
      modulators #3906
      received chemotherapy #3909
      sponsored #3917
      bone turnover #3919
      24 weeks #3921
      hyperactivation #3922
      keywords #3927
      vte patients #3928
      therapies #3933
      myoclonus #3940
      publication clinical trials #3940
      discontinued #3942
      grade 1 #3945
      61 patients #3947
      bf #3950
      food drug administration #3951
      difficulty #3953
      colorectal #3955
      inhibitors female #3956
      prostate carcinoma #3961
      capsaicin #3969
      manifested #3970
      study drug #3973
      25 #3975
      accidental #3976
      pain severity #3977
      adenosine triphosphate #3980
      pluronic #3983
      20 #3988
      30 years #3991
      toxic effects #3993
      449 #3994
      weight #4002
      lasting #4002
      370 #4004
      gait #4005
      sideeffects #4006
      692 #4008
      kras mutations #4014
      surgery radiation #4018
      estrogenic #4023
      audio #4034
      patients intervention #4034
      year patients #4039
      lumbar spine #4044
      thirteen patients #4047
      tid #4052
      prostatic #4062
      erythropoietin #4062
      nonusers #4066
      flax #4068
      conjunction #4069
      cancer therapy #4069
      516 #4075
      intravenously #4077
      extremities #4084
      strong evidence #4087
      meaningful #4099
      revisions #4102
      rose #4108
      2–4 #4116
      iii study #4120
      bone neoplasms #4124
      dermatitis #4125
      noninfiltrating #4126
      favoring #4126
      sphase #4131
      documentation #4132
      7 months #4134
      topic practice patterns #4138
      definitions #4138
      tablets #4138
      femoral neck #4139
      malignant melanoma #4139
      269 #4143
      combination therapy #4144
      mbc #4157
      interleukin6 il6 #4159
      4 months #4164
      326 #4175
      effective #4194
      noxious #4196
      10 months #4199
      calcium vitamin #4201
      cancer bone #4210
      depressants #4210
      undertaken #4211
      2006 #4220
      treatment option #4223
      twothirds #4232
      18 months #4236
      platinumbased chemotherapy #4238
      drug response #4250
      quinazolines #4254
      anemia patients #4256
      contraindication #4258
      neoplasms colorectal #4258
      treatment discontinuation #4268
      serially #4268
      cation channels #4271
      58 patients #4278
      2 4 #4283
      survival quality #4284
      bone density #4284
      day #4285
      inconsistencies #4289
      utilized #4289
      colorectal neoplasms #4297
      rheumatism #4301
      node negative #4307
      aged breast #4313
      bioavailable #4314
      chemotherapy treatment #4323
      reductions #4326
      prednisolone #4326
      vast #4327
      bone diseases #4330
      primary endpoints #4331
      healthy women #4331
      reply #4340
      firstline chemotherapy #4343
      treatment studies #4355
      equally #4357
      institute #4359
      neoplasms combined #4359
      participated #4360
      detrimental effects #4367
      outcome data #4368
      3 months #4373
      sleeping #4376
      discontinuation #4381
      preliminary #4385
      carcinoma ductal #4389
      time surgery #4393
      therapies patients #4394
      judgment #4395
      12 week #4396
      drug combinations #4402
      repeatedly #4402
      hyperalgesia #4411
      grouping #4414
      minnesota #4415
      purpose #4417
      #4424
      evaluate #4425
      1015 #4427
      14 months #4429
      balance #4430
      80 breast #4431
      studies colorectal #4431
      low doses #4436
      drg neurons #4437
      pain relief #4438
      documented #4440
      relevant studies #4445
      day patients #4446
      improve patient #4446
      summarize #4450
      clinical predictors #4455
      clinical parameters #4460
      humanized antineoplastic #4464
      pain measurement #4465
      80 #4465
      fecal #4466
      clinical practice guidelines #4490
      05 #4494
      risk breast cancer #4499
      humans lymph #4501
      received #4504
      drug administration #4505
      stimulants #4510
      axillary #4521
      5 #4523
      daily activities #4523
      sedation #4529
      ductal breast #4530
      ganglion #4530
      gynecologic #4530
      disease recurrence #4531
      cancer methods #4534
      hematology #4535
      disabling #4536
      stimulant #4536
      sphingolipids #4537
      natural #4537
      drug effects #4540
      diarrhea #4540
      journal #4544
      impairments #4546
      3 4 #4550
      ganglia spinal #4552
      continuation #4558
      outcome measures #4561
      financial #4562
      rescue therapy #4564
      clinical #4564
      376 #4567
      rbc #4569
      reliability validity #4575
      4 #4575
      successes #4577
      single blind #4583
      tumor regression #4587
      explore #4588
      risk bleeding #4591
      hydroxytryptamine #4591
      mmf #4592
      cumulative #4604
      tenderness #4606
      115 #4609
      longer duration #4612
      chemopreventive #4617
      emphasizes #4620
      neoplasms dna #4626
      throat #4633
      caf #4636
      patients increase #4642
      daily dose #4647
      neuropathies #4647
      6 12 #4647
      tumor recurrence #4653
      1 study #4661
      data studies #4662
      96 #4664
      adpribose #4665
      dose chemotherapy #4665
      increased incidence #4669
      treatments #4674
      qol patients #4679
      vitality #4683
      peaked #4684
      hazards #4689
      deprivation #4691
      29 #4693
      secondary analysis #4699
      treatment survival #4701
      dose #4704
      low dose #4708
      dose reduction #4712
      reference lists #4722
      preliminary study #4733
      #4734
      mediastinum #4734
      assessment tool #4740
      phase 2 trial #4741
      vigor #4751
      percentage patients #4752
      cgy #4762
      efficacy tolerability #4773
      analysis neoplasm #4783
      recommended #4785
      adt #4790
      invasive breast cancer #4792
      353 #4795
      proven #4798
      corticosteroid #4806
      009 #4806
      tears #4810
      538 #4810
      evaluations #4813
      circulating concentrations #4817
      cancer compared #4818
      improved quality #4818
      acetylcysteine #4821
      capecitabine #4829
      musculoskeletal #4830
      symptom burden #4836
      multicenter #4836
      carcinoma small #4837
      bridged #4837
      seer program #4841
      tubulin #4841
      aes #4846
      60 #4848
      55 patients #4854
      receipt #4857
      381 #4861
      patients recurrence #4868
      patients prostate #4870
      individual patient data #4876
      amines #4886
      neck neoplasms humans #4890
      048 #4901
      receptor egfr #4904
      fisher #4910
      crc patients #4911
      lastly #4917
      systemic therapy #4921
      harms #4922
      platinum #4924
      stage iiib #4925
      abstinence #4926
      unfavorable #4927
      existed #4928
      basal cell carcinoma #4933
      ≥1 #4937
      727 #4942
      coadministration #4946
      sensitization #4956
      screening tool #4956
      9 months #4960
      plethora #4970
      subsequently #4974
      eligibility #4975
      equivocal #4980
      cancer background #4981
      optimal management #4983
      depot #4989
      deep vein thrombosis #4992
      cumulative dose #4996
      recurrence free #4997
      exercise intervention #5003
      lessons #5005
      metastatic prostate #5016
      situ carcinoma #5017
      based cohort #5018
      combined treatment #5027
      routine clinical #5028
      biphasic #5029
      multicenter trial #5039
      initiate #5045
      sedative #5055
      actively #5058
      missing data #5060
      favorably #5071
      osteoporosis #5073
      physical symptoms #5075
      3 trials #5076
      methotrexate #5077
      karnofsky performance #5084
      genistein #5084
      study incidence #5086
      phenobarbital #5091
      100 patients #5098
      342 #5099
      pyrimidinones #5104
      version #5104
      bortezomib #5105
      cisplatin treatment #5106
      published #5116
      skin neoplasms #5121
      ntprobnp #5124
      conventional chemotherapy #5126
      physical therapy #5131
      reducing #5131
      120 #5141
      topical application #5142
      indomethacin #5143
      medicine humans #5149
      higher rate #5154
      women early #5155
      lower rates #5157
      bisphosphonates #5165
      resolve #5169
      prognostic #5176
      analysis randomized #5177
      compiled #5181
      cycle #5186
      antiinflammatory agents #5187
      supplement #5201
      thalidomide #5207
      30 patients #5214
      references #5218
      cisplatin #5225
      april #5231
      medications #5239
      identical #5243
      dying #5243
      randomised controlled trial #5244
      humans lung #5249
      article #5249
      insomnia #5255
      patients time #5257
      conventionally #5257
      mitoxantrone #5265
      progestins #5266
      resectable #5269
      low molecular #5270
      caring #5270
      negative impact #5277
      health disparities #5278
      sed #5291
      undergo #5306
      gynecology #5309
      parenteral nutrition #5310
      vaporizers #5317
      cancer prevention #5319
      conflicting #5325
      pelvic #5326
      ineligible #5327
      404 #5333
      alkaloids #5335
      anticipated #5335
      administered #5339
      methods design #5344
      patient data #5349
      monophenol #5351
      perceived #5359
      sensation #5359
      current practice #5361
      colorectal cancers #5362
      answered #5376
      neurologists #5377
      346 #5385
      adenosylmethionine #5393
      isotretinoin #5394
      declining #5396
      judged #5403
      responding #5412
      study women #5421
      stage iii #5423
      officinalis #5423
      33 #5425
      colonic polyps #5444
      axilla #5468
      57 #5470
      manner #5473
      p0006 #5481
      minutes #5482
      baseline characteristics #5486
      health records #5490
      pufas #5492
      based interventions #5496
      167 #5504
      preclinical models #5506
      methylases #5508
      ovary #5512
      thromboembolic events #5518
      patient demographics #5521
      neoplasms humans #5525
      410 #5535
      pooled #5548
      medical conditions #5556
      03 #5571
      cancer center #5573
      ready #5580
      acne #5582
      routine clinical practice #5583
      stage patients #5590
      dropped #5593
      002 #5594
      current literature #5598
      patient quality #5604
      woman #5605
      41 #5611
      polyps #5620
      carnitine #5623
      enteral #5633
      treatment approaches #5638
      sensory #5638
      new therapies #5642
      lung carcinoma #5642
      0007 #5648
      concurrent #5672
      treatment regimens #5676
      guideline #5679
      constipation #5683
      sf36 #5684
      n6 #5687
      standard chemotherapy #5688
      neuromodulation #5689
      50 #5693
      dexamethasone #5694
      renewed #5694
      desire #5695
      preserve #5696
      online #5699
      patients therapy #5701
      nonsignificant #5703
      multiplied #5704
      raise #5705
      cancer type #5708
      androgen #5716
      trials rcts #5722
      complete #5730
      specialist #5730
      dna content #5733
      serial #5736
      provider #5761
      tumor stage #5762
      interruption #5762
      tumor breast #5762
      total score #5766
      impair #5770
      versus #5773
      chance #5779
      mucous #5783
      carcinoma situ #5783
      nicotine #5783
      exploratory study #5790
      node excision #5795
      345 #5805
      higher doses #5806
      395 #5814
      vitamin #5817
      systemic effects #5827
      patients aspirin #5828
      patient experience #5830
      4 5 #5837
      cancer breast #5842
      leukocyte count #5850
      intermediate risk #5852
      selfreported #5855
      patients survival #5857
      stools #5858
      subgroups patients #5873
      405 #5877
      interfere #5877
      excitatory amino #5883
      enrollment #5886
      neoplasm recurrence #5887
      exercises #5888
      totally #5898
      response relationship #5899
      potential mechanisms #5909
      3 #5910
      0 1 #5917
      trastuzumab #5925
      alternating #5926
      gel #5930
      acids omega3 #5935
      humans injections #5940
      pooled analysis #5946
      dysplastic #5947
      questionnaires adult #5952
      treatment toxicity #5954
      previous #5955
      treatment failure #5964
      symptoms depression #5967
      returned #5979
      confounding #5990
      analogue #5995
      devoted #5996
      evaluation studies #5997
      239 #5997
      icd9 #6000
      sectional survey #6002
      validated #6007
      serum patients #6010
      insulinlike growth factor #6013
      1977 #6013
      prognostic indicator #6018
      minute #6019
      descriptions #6019
      worsened #6026
      sentinel node #6028
      0013 #6041
      chemotherapy radiotherapy #6041
      grade 3 #6042
      243 #6045
      new evidence #6049
      month #6052
      institutional #6061
      syndrome #6065
      protective agents #6066
      caution #6067
      stool #6070
      480 #6082
      subscales #6083
      approved #6097
      aspect #6098
      20 years #6102
      43 #6104
      hormone therapy #6108
      increment #6109
      tests prognosis #6116
      spitzer #6118
      conducted #6120
      randomized controlled trial #6125
      routes #6128
      surviving #6156
      antiepileptic #6164
      kilogram #6167
      endpoints #6173
      inception #6184
      skin diseases #6188
      241 #6189
      omega3 #6193
      selective serotonin #6195
      boronic #6199
      intraepithelial #6204
      16 #6215
      900 #6218
      female #6221
      central venous #6229
      combination treatment #6232
      62 #6234
      epa #6239
      randomized clinical trials #6242
      invasive breast #6249
      patients colorectal #6253
      treated mice #6255
      exploratory #6257
      58 #6258
      asymptomatic patients #6260
      metastasis neoplasm #6261
      receptors progesterone #6265
      historically #6269
      palliative #6270
      protocols #6275
      disclosure #6280
      psychotropic drugs #6280
      ease #6282
      2000 #6283
      xerostomia #6284
      followup patients #6293
      innovations #6299
      scopus #6300
      insignificant #6302
      benzhydryl #6302
      survival female #6312
      328 #6314
      chi2 #6320
      prospective #6330
      lobular #6343
      counseling #6344
      59 #6346
      rigorous #6347
      clinically #6350
      endocrine therapy #6365
      aged #6372
      fentanyl #6372
      2007 #6385
      venous thromboembolism vte #6385
      infusions #6393
      epidermal growth #6393
      breadth #6395
      physicians #6402
      cronbach #6404
      narcotic #6407
      vitro model #6413
      early intervention #6424
      sexes #6425
      initial treatment #6426
      endocrinology #6432
      2 3 #6433
      pittsburgh #6439
      psychotropic #6439
      multinational #6440
      entire #6440
      361 #6445
      counts #6446
      soybeans #6449
      sex hormones #6452
      logs #6453
      congeners #6455
      quality #6458
      termed #6470
      75 #6471
      intraluminal #6471
      life health #6478
      n16 #6481
      treatment guidelines #6482
      patients 2 #6485
      time diagnosis #6486
      mcf7 cells #6496
      records #6498
      abcb1 #6499
      ≥18 #6501
      usual patients #6512
      disease stage #6515
      adenoma #6520
      complementary #6521
      consultation #6524
      guidance #6531
      iu #6533
      ranked #6536
      developments #6540
      transfusions #6551
      004 #6552
      tumor location #6554
      86 #6567
      0004 #6575
      analog #6576
      53 #6591
      abstracts #6593
      baseline patients #6598
      initiated #6602
      acting #6604
      colonic neoplasms #6605
      pyrazines #6608
      hemoglobins #6612
      l3 #6612
      287 #6614
      decisions #6614
      fourth #6615
      phase #6617
      02 #6618
      surveys questionnaires #6621
      hrt #6622
      curative resection #6623
      familiar #6641
      pellet #6646
      guidelines #6646
      crf #6648
      patients health #6651
      hormone receptor #6651
      courses #6664
      randomized controlled trials #6666
      emerging evidence #6681
      osseous #6682
      physical health #6683
      tools #6685
      figure #6689
      dex #6691
      caloric #6694
      erectile dysfunction #6694
      develops #6696
      neoplasm metastasis #6699
      radiotherapy chemotherapy #6702
      hypothesized #6702
      ketamine #6710
      colorectal cancer patients #6717
      consecutive #6717
      interprofessional #6728
      detailed #6731
      testicular cancer #6743
      score #6745
      295 #6750
      quit #6751
      replacement therapy #6751
      difference #6763
      grade #6770
      lower incidence #6773
      true #6776
      ocular #6783
      prevents #6784
      titration #6787
      pain management #6793
      frequently #6801
      search strategy #6801
      longest #6801
      chart review #6802
      rounds #6804
      344 #6806
      hepcidin #6809
      controlled studies #6810
      fulfilled #6810
      participating #6811
      mice treated #6818
      detect #6826
      ovarian function #6841
      treatment advanced #6842
      integrative #6851
      early treatment #6853
      exercise therapy #6861
      classification #6874
      inventory #6877
      narrative #6879
      drg #6883
      routinely #6887
      new drugs #6889
      secondary #6891
      concerns #6896
      strength muscle #6898
      differ #6903
      277 #6904
      serum concentrations #6912
      tumor formation #6917
      5 ht #6918
      controversial #6930
      summarizes #6932
      mass loss #6941
      factors breast #6942
      cbd #6942
      iiib #6944
      laparotomy #6953
      diarrhoea #6955
      tartrate #6960
      quarter #6970
      skin temperature #6981
      regressions #6981
      ais #6986
      quiet #6990
      calorie #6990
      wearing #6990
      definition #6994
      35 #6994
      seer #7001
      promise #7002
      patients developed #7006
      1 year #7011
      initially #7015
      women study #7019
      hemorrhage humans #7020
      breast cancers #7030
      051 #7045
      metaanalyses #7049
      animal doseresponse relationship #7050
      neoplasms risk #7063
      patients 1 #7067
      interested #7067
      50 patients #7068
      31 #7083
      screening middle #7089
      total #7097
      overview #7098
      asian patients #7111
      neu #7113
      approval #7114
      97 #7121
      neoplasms treatment #7122
      polyadp #7124
      neoplasms female #7130
      prostate cancer #7130
      261 #7131
      female gastrointestinal #7143
      strengthened #7144
      neuroprotection #7147
      833 #7154
      therapy humans #7165
      estrogens #7171
      appropriateness #7179
      breast cancer risk #7187
      expect #7188
      pik3ca #7201
      confirm #7211
      uncontrolled #7220
      estrogen #7228
      entity #7234
      discusses #7238
      agents steroidal #7255
      203 #7262
      questionnaire #7264
      ameliorates #7264
      chosen #7266
      popularity #7283
      additionally #7295
      outpatients #7296
      neoplasms primary #7296
      cinahl #7333
      node biopsy #7334
      increased survival #7336
      10 #7340
      aged anti #7343
      stages #7347
      evaluates #7353
      superficial #7353
      radiotherapy adjuvant #7358
      prognosis prospective #7361
      firstline therapy #7376
      epo #7378
      eating #7379
      short #7384
      square distribution #7390
      47 #7393
      noradrenergic #7407
      rfs #7416
      curative #7416
      esr1 #7417
      radiotherapy #7433
      genital #7435
      emphasis #7436
      receptor agonists #7436
      confirmatory #7436
      naphthalenes #7437
      cancer treated #7438
      established #7449
      25 patients #7456
      clinical evaluation #7467
      199 #7478
      1st #7482
      058 #7484
      prognosis proportional #7488
      wasting #7488
      treatment strategy #7489
      bolus #7496
      genetic factors #7499
      metastatic colorectal #7501
      gonadotropin #7504
      259 #7507
      november #7509
      dysplasia #7523
      transaminases #7524
      objectively #7526
      melanoma patients #7528
      cancer vaccines #7531
      infertility #7534
      investigators #7534
      october #7539
      tumor colorectal #7541
      local neoplasm #7543
      315 #7558
      primary treatment #7559
      adequacy #7564
      concurrently #7578
      kaplanmeier method #7583
      intraductal #7586
      00001 #7589
      patients head #7594
      grades #7605
      single dose #7607
      tretinoin #7608
      discussions #7609
      chronic pain #7615
      coumarins #7616
      gain #7620
      opinions #7621
      interval #7624
      ploidy #7624
      receptor antagonists #7632
      receptor erbb2 #7633
      pharmacists #7641
      local neoplasms #7642
      sequelae #7645
      metastatic colorectal cancer #7656
      clinical benefit #7666
      retinoids #7678
      corticosteroids #7684
      visits #7691
      longterm effects #7695
      evident #7696
      1 day #7699
      monitored #7699
      026 #7710
      publication biomarkers #7713
      surveys #7725
      021 #7725
      recurrence #7726
      risk breast #7728
      thrombophilia #7734
      administration #7744
      washout #7744
      onethird #7749
      nicotinic #7751
      rank #7758
      cancer recurrence #7763
      independent predictors #7776
      omega3 fatty #7779
      treatment time #7780
      serotonergic #7785
      pathophysiology #7796
      negative effects #7805
      14 #7807
      ovarian neoplasms #7811
      erectile #7812
      clinicians #7820
      gonadal #7839
      12 months #7842
      swallowing #7843
      subcutaneous #7855
      pain intensity #7856
      patient centered #7866
      thiophenes #7869
      0 #7876
      hemoglobins humans #7892
      statistic #7900
      physical function #7917
      impacted #7927
      ago #7927
      40 #7933
      dysfunctions #7950
      androgens #7955
      5year survival #7956
      comparing #7956
      advanced #7957
      generally #7963
      305 #7965
      ductal carcinoma #7968
      #7972
      actuarial #7973
      055 #7975
      individualized #7981
      collect #7982
      situation #7983
      female genital #7985
      062 #8006
      278 #8020
      noninferiority #8032
      powered #8051
      preclinical #8062
      intractable #8063
      genders #8063
      colorectal cancer crc #8064
      45 #8065
      208 #8069
      105 #8086
      sixteen #8088
      humans longitudinal #8090
      relating #8096
      expand #8099
      resultant #8100
      trial background #8102
      occurred #8107
      irrespective #8127
      analgesics opioid #8128
      5 years #8132
      reduce #8141
      receptors estrogen #8142
      methodswe #8150
      entering #8154
      translational #8164
      facilitating #8173
      dose escalation #8185
      specific antigen #8189
      edetic #8191
      ondansetron #8204
      withdrawal #8206
      tnf alpha #8213
      cancer detection #8218
      popular #8220
      b4 #8224
      mild #8234
      spearman #8242
      regard #8249
      patients adult #8249
      committees #8252
      stage #8255
      parp #8258
      dietary supplements #8265
      treated #8266
      modalities #8269
      tobramycin #8285
      antitumor activity #8287
      neoplasms male #8289
      patient groups #8315
      201 #8324
      estradiol #8325
      risk cancer #8327
      triazines #8331
      wellbeing #8341
      sertraline #8344
      concern #8345
      cell lung #8349
      pubmed #8352
      patient treatment #8362
      pharmacogenetics #8372
      year follow #8372
      calcium #8389
      clinical activity #8395
      choose #8397
      6 cycles #8403
      predisposing #8405
      costly #8417
      preparations #8422
      undergoing #8422
      neck neoplasms #8435
      expense #8447
      married #8448
      detecting #8460
      testing #8465
      underestimate #8466
      composition body #8478
      37 #8482
      3 trial #8482
      eruptions #8486
      oncologic #8488
      neuromuscular #8489
      clinical experience #8509
      39 patients #8527
      respond #8553
      cyclophosphamide #8562
      253 #8570
      average #8576
      020 #8587
      stratified #8596
      exists #8598
      ttp #8610
      standard therapy #8620
      81 #8624
      015 #8629
      estrogen receptors #8637
      morphine #8637
      cancer female #8639
      remain #8643
      fda #8646
      legs #8657
      initial #8658
      relative risks #8659
      practitioners #8676
      functional status #8679
      syndrome patients #8684
      6 months #8685
      egfr #8692
      grip #8695
      single nucleotide polymorphisms #8700
      notable #8700
      molecular markers #8705
      threatening #8705
      loss #8714
      aged 80 #8715
      selfreports #8722
      leptin #8728
      32 patients #8731
      colorectal cancer #8743
      drug #8748
      perspectives #8751
      majority #8756
      illustrates #8757
      inhibitors #8764
      repeated #8765
      123 #8769
      2001 #8774
      survivorship #8779
      066 #8786
      aged models #8792
      real #8800
      mouth #8800
      prospective randomized #8808
      providers #8813
      question #8814
      advanced stage #8823
      accumulating #8842
      groups patients #8847
      ferric #8858
      uremic #8865
      concomitant #8886
      highrisk #8893
      enteral nutrition #8908
      publication aged aged #8919
      predefined #8929
      supplemental #8938
      negatively #8961
      017 #8966
      145 #8971
      ovaries #8984
      demographics #8989
      ribose #8990
      28 patients #8996
      2 study #9000
      acceptability #9006
      dna neoplasm #9008
      304 #9013
      lung neoplasms #9014
      analyses #9017
      bivariate #9019
      favored #9020
      longer #9020
      300 #9035
      18 #9037
      literature #9043
      223 #9060
      vagina #9062
      analgesics #9073
      women risk #9074
      116 #9084
      venous #9089
      275 #9107
      consisted #9112
      medical treatment #9114
      70 #9117
      instability #9124
      oral anticoagulants #9131
      referred #9132
      286 #9133
      gene expression profiling #9135
      rated #9162
      232 #9167
      1987 #9170
      103 #9180
      germ cell #9183
      erbb receptors #9195
      feeling #9196
      moderate #9197
      embryonal #9202
      erythropoiesis #9216
      12 patients #9228
      predict #9230
      approaches #9232
      320 #9249
      psycinfo #9250
      update #9253
      incidence #9265
      eighteen #9277
      stimulate #9281
      manifestation #9291
      primary #9292
      administrative #9293
      greater risk #9301
      favorable #9308
      hypnotics #9310
      94 #9317
      systematic literature #9317
      possess #9332
      15 #9332
      participant #9336
      grip strength #9341
      metastatic #9361
      lives #9367
      cycles #9371
      mechanisms action #9383
      acceptable #9383
      ambulatory #9385
      drug female #9385
      postulated #9389
      177 #9431
      82 #9435
      28 #9436
      consisting #9437
      neurologic #9443
      definitive #9454
      partial response #9454
      abdomen #9468
      3 groups #9499
      death patients #9509
      ophthalmic #9514
      recurrence patients #9518
      serving #9539
      cancer crc #9542
      500 #9542
      006 #9545
      065 #9547
      jaw #9565
      decisionmaking #9568
      imbalance #9575
      melphalan #9579
      similarities #9580
      add #9583
      sentinel lymph #9619
      68 #9624
      progesterone receptor #9627
      addressed #9641
      oral cavity #9657
      prednisone #9662
      electroacupuncture #9668
      publications #9669
      referrals #9677
      items #9695
      p0004 #9696
      fell #9698
      149 #9702
      nerve injury #9707
      adenocarcinoma aged #9733
      logistic regression analysis #9737
      smokers #9746
      cope #9749
      erbb #9762
      experts #9767
      carcinoma patients #9777
      sleep disorders #9784
      food intake #9785
      monoclonal humanized #9791
      priority #9791
      0002 #9797
      remission induction #9812
      exercise female #9831
      trends #9835
      7 #9836
      patient age #9855
      saponins #9856
      palliation #9857
      neuroprotective agents #9871
      clinical outcomes patients #9872
      avoid #9872
      95ci #9875
      goals #9882
      bleeding #9884
      axonal #9897
      illness #9909
      89 #9921
      injections #9941
      zinc #9942
      mitigate #9952
      provision #9954
      variety #9963
      telephone #9968
      recurrence rates #9969
      education topic #9980
      88 #9985
      behavioral therapy #9988
      ethics #9991
      400 #9997
      growing #9999
      square #10005
      reactions female #10007
      prescribing #10007
      advanced disease #10009
      dosedependent manner #10013
      exist #10016
      art #10020
      bone resorption #10023
      progressed #10053
      women health #10061
      autonomic #10070
      ortho #10071
      reason #10076
      percentages #10095
      candidates #10096
      exceptions #10097
      76 #10099
      node dissection #10100
      il1β #10101
      criterion #10109
      disease adult #10113
      56 #10120
      predictive factors #10154
      preference #10168
      micronutrients #10188
      categorized #10215
      measures #10218
      monoamine #10221
      12 #10224
      40 patients #10233
      demonstrate #10251
      lack #10261
      curve #10266
      guideline adherence #10267
      256 #10271
      developed #10274
      achieving #10279
      caused #10317
      higher incidence #10325
      sarcomas #10341
      epidermal #10345
      variables #10354
      bone mineral density #10369
      anemia #10385
      cell transplant #10386
      morning #10392
      survival dfs #10400
      changed #10400
      3 5 #10407
      142 #10413
      141 #10436
      smoking cessation #10437
      chart #10440
      041 #10450
      revised #10485
      24 hours #10489
      lvef #10497
      masked #10500
      syndromes #10508
      mineral density #10522
      longitudinal studies #10522
      effort #10550
      instruments #10555
      154 #10558
      define #10560
      650 #10565
      surveillance #10571
      persisted #10581
      elucidate #10582
      informed #10584
      trend #10585
      months 95 #10586
      encountered #10600
      667 #10608
      fewer #10613
      counselling #10617
      doxorubicin #10617
      academic #10623
      include #10636
      concert #10640
      european society #10663
      histories #10672
      curative intent #10673
      upper extremity #10688
      vitamins #10697
      examinations #10703
      treatment chronic #10721
      prognostic significance #10733
      median followup #10743
      tests #10751
      edema #10753
      anticoagulants #10757
      enter #10757
      fat mass #10763
      iiia #10779
      median duration #10779
      patients response #10788
      induction chemotherapy #10795
      60 years #10802
      182 #10803
      clinic #10803
      columbia #10805
      73 #10812
      insufficient #10814
      rcts #10818
      internal consistency #10826
      21 #10828
      advisory #10839
      noradrenaline #10843
      recurrent #10863
      randomised controlled #10873
      determine #10873
      hydroxy #10874
      neck cancer #10884
      clinicaltrialsgov #10885
      nighttime #10888
      felt #10892
      held #10899
      1 patient #10911
      9 patients #10922
      limited #10928
      occurring #10934
      supplements #10937
      kits #10950
      head neck cancer #10956
      cognition disorders #10958
      start #10961
      retrospective review #10966
      failure #10978
      needed #10981
      squamous cell carcinoma #10982
      registry #10999
      physiology #11017
      155 #11028
      030 #11031
      agents drug #11051
      rationale #11080
      ascertained #11084
      interventions #11094
      soft tissue #11097
      smoking #11105
      international society #11105
      3 years #11121
      043 #11122
      editorial #11123
      years diagnosis #11128
      sleep wake #11133
      practice guidelines #11135
      sick #11135
      091 #11146
      decrease #11150
      extensive #11160
      head neck #11164
      reduces #11166
      127 #11168
      subclinical #11185
      decreases #11199
      progesterone #11207
      facilitate #11216
      gamma #11222
      2004 #11246
      secondary outcome #11250
      anticoagulation #11251
      1983 #11257
      survival #11259
      prostate #11267
      contributed #11278
      cognitive behavioral #11279
      diploid #11281
      therapy neoplasm #11287
      snps #11295
      closer #11307
      reviews #11329
      benzimidazoles #11334
      vincristine #11361
      168 #11373
      thrombocytopenia #11377
      129 #11387
      affect #11397
      radiation therapy #11423
      subgroup analyses #11428
      apparent #11439
      clinical signs #11439
      point #11449
      rating scale #11457
      78 #11468
      092 #11469
      label #11482
      2 trial #11486
      patients patient #11493
      multidimensional #11498
      alive #11501
      caregivers #11509
      235 #11509
      recombinant human #11530
      6 #11541
      130 #11548
      lymphatic metastasis #11549
      040 #11553
      helps #11582
      computerized #11583
      109 #11585
      enhancing #11586
      20 patients #11588
      analgesic #11591
      humans mass #11616
      incontinence #11617
      opioid #11645
      benefits #11651
      pulmonary embolism #11652
      minimal #11660
      peritoneal #11670
      028 #11674
      gefitinib #11675
      adenocarcinoma adult #11688
      camptothecin #11691
      body image #11717
      docetaxel #11732
      sarcopenia #11745
      lumbar #11751
      small cell #11764
      rheumatic #11765
      comparisons #11767
      nerves #11789
      reduction #11791
      oxidative damage #11822
      aged postoperative #11823
      128 #11825
      resultsthe #11835
      risk recurrence #11837
      definite #11855
      024 #11855
      neoplasms cell #11862
      interim #11864
      hematologic #11897
      investigation #11910
      testicular #11913
      cured #11926
      haloperidol #11938
      pelvis #11956
      thirteen #11969
      humanized #11970
      ≥3 #11995
      referral #11997
      1998 #11997
      involving #11999
      90 patients #12014
      24 patients #12015
      humans #12017
      negative breast #12030
      effectively #12047
      thirds #12053
      single nucleotide #12063
      muscarinic #12067
      triphosphate #12068
      committee #12069
      rating #12071
      bone mineral #12074
      #12078
      toxic #12079
      cumulative incidence #12103
      greater #12144
      expectancy #12147
      dosage #12148
      rectal cancer #12163
      119 #12183
      104 #12187
      unadjusted #12191
      validity #12205
      aspirin #12207
      deoxycytidine #12226
      alternatively #12248
      believed #12251
      malignant #12268
      peri #12270
      sodium channel #12270
      2 weeks #12279
      disease specific #12302
      igf #12308
      compliance #12317
      categories #12322
      cognitive #12338
      terms #12340
      grading #12342
      classic #12345
      tolerability #12360
      sexual #12361
      psychometrics #12376
      27 #12378
      adjuvants #12396
      falls #12402
      searched #12414
      relapse #12415
      qualitative study #12416
      sentinel #12421
      p21ras #12426
      1 2 #12446
      anticancer drugs #12449
      science #12462
      drug humans #12482
      90 #12485
      predictive #12492
      194 #12495
      embase #12496
      transfusion #12502
      consistency #12511
      reasons #12523
      prognostic factor #12536
      mitomycin #12540
      010 #12573
      predictors #12577
      bladder cancer #12581
      explored #12591
      bioavailability #12611
      sleep #12615
      attempts #12621
      test #12626
      psychometric #12641
      therapeutic approaches #12642
      supports #12643
      fourteen #12657
      rank test #12657
      recommendations #12691
      problem #12710
      2013 #12714
      patient outcome #12719
      reliability #12747
      translated #12749
      stiffness #12752
      crc #12777
      missed #12783
      develop #12817
      023 #12853
      segmental #12865
      cancer nsclc #12868
      patients surgery #12874
      statistics #12876
      subject #12882
      ice #12886
      normal tissue #12931
      interviewed #12944
      inform #12945
      irreversible #12946
      poorer #12947
      coded #12950
      184 #12952
      single agent #12954
      scale #12961
      univariate #12983
      monoclonal antibodies monoclonal #13009
      193 #13020
      n4 #13025
      defining #13026
      cancers #13041
      ovariectomy #13045
      paired #13049
      future #13082
      humans logistic #13082
      suggests #13099
      longterm followup #13101
      pharmacotherapy #13121
      trial comparing #13126
      gains #13129
      alter #13132
      aged neoadjuvant #13151
      inflammatory cytokines #13153
      demographic #13159
      originally #13160
      cox regression #13163
      responsiveness #13183
      44 #13192
      tpa #13230
      multiple myeloma #13238
      humans lymphatic #13262
      epidemiologic #13262
      21 patients #13267
      longitudinal data #13270
      myeloma #13286
      racial #13299
      requiring #13322
      outpatient #13334
      symptomatic #13346
      cognitive function #13351
      hours #13376
      steroidal #13380
      pg #13393
      measure #13408
      formal #13409
      therapeutic potential #13414
      intermediate #13433
      muscle mass #13492
      ductal #13505
      eventually #13506
      randomised trial #13513
      attending #13528
      psychometric properties #13563
      discriminate #13564
      pharmacological #13578
      typically #13588
      diminished #13609
      improves #13630
      agonists #13630
      196 #13634
      skin cancer #13649
      tended #13650
      frequency #13652
      participants #13674
      infective #13701
      hypothesis #13703
      tested #13723
      attempted #13739
      initiation #13758
      distress #13778
      foods #13785
      severe #13795
      192 #13800
      clinical manifestations #13803
      marked #13813
      18 years #13813
      conditional #13831
      018 #13858
      colonic #13890
      solid tumors #13891
      negative patients #13900
      march #13918
      lymphatic #13928
      sleep quality #13935
      mechanisms underlying #13938
      102 #13944
      p00001 #13946
      focus #13988
      aged muscle #13991
      conducting #13996
      estimate male #13999
      igf1 #14032
      calcitonin #14038
      head #14056
      eastern #14057
      lung cancer #14080
      substances #14080
      0001 #14090
      respondents #14106
      skin #14109
      169 #14117
      breast cancer cells #14121
      physiologic #14122
      antagonist #14137
      led #14139
      risk death #14180
      her2 #14186
      modality #14195
      protective #14195
      risk developing #14199
      etiology #14201
      189 #14202
      cytotoxic #14234
      demonstrating #14236
      124 #14251
      life style #14259
      suboptimal #14279
      states aged #14282
      careful #14282
      cetuximab #14293
      hypothesize #14318
      efficacy safety #14319
      32 #14329
      recurrence risk #14331
      analysis performed #14341
      instance #14341
      virtually #14371
      188 #14375
      clinical impact #14379
      cessation #14403
      alpha2 #14412
      144 #14420
      produces #14420
      4 patients #14436
      extremity #14440
      nodal #14440
      transitional #14454
      stat #14456
      178 #14484
      1997 #14487
      distant metastases #14504
      trial registration #14517
      2008 #14518
      8 #14521
      univariate multivariate #14524
      nsclc #14525
      erbb2 #14544
      gm #14553
      035 #14567
      year survival #14570
      heavily #14577
      iron #14583
      34 #14587
      prospectively #14607
      episodes #14626
      09 #14626
      007 #14634
      tumor response #14639
      hypothetical #14647
      additional #14648
      initial diagnosis #14674
      estrogen receptor #14679
      prophylaxis #14686
      5 year #14689
      dermal #14710
      008 #14729
      adult #14729
      menstrual #14740
      examine #14743
      practice #14751
      reflecting #14758
      neoplasm #14762
      15 years #14762
      neoplasm staging #14774
      interferons #14781
      clarify #14785
      health professionals #14804
      erlotinib #14821
      asian #14838
      relevant #14863
      peer #14921
      1990 #14930
      cancer cases #14942
      incorporate #14956
      emerged #14959
      cancer diagnosis #14977
      median #15008
      colorectal carcinoma #15030
      cognitive decline #15047
      07 #15052
      premature #15064
      overexpressing #15067
      expected #15111
      september #15115
      proportions #15119
      011 #15123
      medical #15125
      2 #15153
      clear #15163
      p004 #15169
      colonoscopy #15187
      assessments #15187
      odds ratios #15193
      replacement #15198
      ganglia #15220
      specific #15227
      portion #15240
      intervals #15241
      acute #15247
      agreed #15266
      subjective #15290
      area #15293
      subgroups #15325
      achieved #15344
      proliferative #15352
      routine #15362
      releasing hormone #15390
      131 #15404
      197 #15404
      072 #15431
      070 #15436
      december #15459
      investigate #15464
      reports #15470
      51 #15487
      race #15509
      education #15510
      1 #15515
      medication #15554
      basis #15598
      standard #15614
      life expectancy #15626
      ranging #15639
      safely #15648
      estimate #15652
      male #15673
      survival benefit #15674
      24 months #15681
      criteria #15693
      502 #15702
      measuring #15712
      animals antineoplastic #15714
      individual #15716
      offered #15728
      updated #15749
      option #15749
      colon #15751
      period #15756
      nutrition #15780
      antagonists #15789
      globulin #15792
      quartile #15810
      nonparametric #15815
      kappa #15831
      rate treatment #15867
      societies medical #15873
      local #15882
      glandular #15882
      87 #15905
      focused #15931
      pharmacokinetics #15932
      longitudinally #15937
      dfs #15988
      phenomenon #16013
      usa #16013
      roughly #16039
      distant metastasis #16044
      squared #16045
      improvement #16107
      118 #16114
      079 #16120
      february #16127
      naïve #16154
      decision #16179
      95 patients #16188
      analysis survival #16209
      161 #16209
      drug interactions #16211
      lung #16212
      081 #16213
      supported #16222
      neoadjuvant #16222
      162 #16223
      serotonin #16242
      cold #16243
      cation #16245
      cochrane library #16265
      93 #16278
      alternatives #16284
      exceeded #16313
      colleagues #16319
      detection cancer #16320
      neurotransmitter #16320
      channel blockers #16348
      supplemented #16355
      papillomavirus #16362
      14 patients #16380
      excision #16385
      releasing #16393
      kras #16396
      neoplasm grading #16407
      progressively #16413
      0006 #16416
      diagnostic imaging #16418
      improvements #16418
      osteonecrosis #16452
      scales #16460
      30 #16525
      protect #16536
      declined #16537
      ranged #16562
      black #16565
      support #16576
      population surveillance #16580
      improving #16587
      13 patients #16588
      condition #16625
      systematic review metaanalysis #16649
      radiation #16657
      understand #16705
      male neoplasm #16705
      tumor size #16709
      treat #16715
      mucosa #16717
      broader #16719
      broadly #16748
      082 #16750
      106 #16760
      10 years #16780
      post operative #16791
      mimic #16818
      studying #16832
      demonstrated #16842
      bayes #16878
      safety #16885
      major #16886
      rarely #16886
      maintained #16890
      inpatient #16921
      aware #16924
      drugs #16939
      67 #16962
      depletion #16977
      sex #16982
      hormone #16988
      confer #16998
      hemoglobin #17005
      125 #17019
      maximum #17031
      muscles #17039
      investigating #17045
      issues #17053
      neoadjuvant therapy #17063
      genotype humans #17068
      publication adaptation #17073
      84 #17091
      directed #17099
      diseasefree survival #17162
      iron deficiency #17162
      disseminated #17164
      utilize #17166
      feasible #17197
      energy intake #17217
      inconsistent #17247
      mineral #17315
      088 #17335
      valid #17344
      tnfα #17364
      percentage #17396
      interleukin6 #17416
      raf #17421
      describing #17520
      centered #17529
      neck #17557
      functioning #17582
      locally #17585
      physical activity #17586
      survival outcomes #17596
      traditional #17602
      fact #17609
      original #17648
      080 #17655
      2019 #17720
      current evidence #17735
      log #17761
      adding #17766
      unrelated #17776
      carcinogenesis #17789
      lactic #17816
      impairment #17825
      assayed #17837
      decreased #17874
      confirms #17879
      094 #17886
      examination #17892
      graded #17909
      meta #17936
      monoclonal antibodies #17955
      200 #17981
      minimum #18048
      clinical presentation #18052
      structured #18083
      primary prevention #18124
      48 #18131
      primary tumors #18132
      formulated #18148
      il6 #18159
      metastasis male #18162
      bone #18174
      medline #18185
      uncommon #18193
      mass screening #18244
      80 biomarkers #18256
      critically #18295
      assessing #18322
      retinoic #18359
      hazards models #18394
      reporting #18396
      healthrelated quality #18416
      relationships #18418
      respective #18423
      carry #18439
      humans intestinal #18447
      096 #18450
      83 #18485
      staging prognosis #18489
      consistently #18499
      akt #18504
      adjustment #18519
      equal #18526
      2 years #18534
      maintain #18583
      negligible #18617
      nutritional #18643
      003 #18655
      address #18711
      raised #18739
      3 patients #18741
      meier estimate #18762
      kaplan meier #18769
      mucosal #18825
      promising #18832
      highlighted #18856
      includes #18858
      098 #18862
      chronic diseases #18875
      poor #18878
      hormones #18887
      tailored #18923
      status #18942
      united states #18948
      pyridines #18950
      serum #18956
      orr #18990
      histologic #19009
      stimulating #19056
      dysfunction #19111
      meier #19125
      cohort #19137
      inhibitor #19177
      mood #19177
      #19195
      excessive #19215
      irinotecan #19250
      agents apoptosis #19258
      consensus #19281
      accepted #19282
      candidate #19292
      recombinant proteins #19298
      recorded #19302
      ovarian #19337
      metaanalysis #19377
      newly #19381
      staging #19391
      global #19431
      evidenced #19433
      fats #19483
      inflammatory agents #19496
      proportional hazards #19507
      prone #19520
      asymptomatic #19544
      surgically #19614
      hospitalized #19617
      pretreated #19680
      degree #19687
      predicted #19728
      adaptation psychological #19769
      emotional #19779
      making #19782
      humans kaplan #19803
      scored #19840
      kaplan #19866
      neoplasms carcinoma #19874
      3 year #19944
      1995 #19991
      procedures #20019
      2002 #20057
      cervical #20082
      tumor necrosis factor #20104
      observational studies #20128
      randomised #20168
      mediator #20189
      beneficial #20254
      24 #20258
      patients risk #20262
      maximal #20273
      log rank #20282
      small #20300
      endocrine #20301
      rates #20333
      involves #20398
      allcause mortality #20422
      exploring #20500
      assess #20503
      adjusting #20553
      successful #20677
      usual #20690
      women aged #20722
      95 confidence interval #20729
      invasiveness neoplasm #20747
      addressing #20782
      19 #20821
      concluded #20831
      july #20847
      node #20854
      finding #21019
      remaining #21031
      relationship #21070
      collected #21085
      male mass #21107
      reliable #21137
      year #21139
      january #21202
      statistical #21265
      1999 #21287
      absence #21319
      mri #21400
      comparison #21403
      extended #21420
      proportional #21490
      feasibility #21521
      rectal #21541
      prognosis #21551
      gradually #21576
      implementing #21589
      models male #21936
      improved #21939
      death #21941
      apply #21969
      morbidity #22004
      intervention #22038
      insulin growth #22054
      verbal #22139
      10 patients #22157
      urinary #22186
      combination #22213
      authors #22223
      2005 #22223
      alterations #22302
      aimed #22386
      predictive tests #22416
      event #22426
      fibroblast #22446
      reviewed #22573
      status humans #22597
      elevated #22633
      frequent #22673
      setting #22759
      cox proportional #22797
      malignancies #22798
      allocated #22808
      95 #22862
      imaging mri #23033
      diverse #23033
      superior #23111
      post #23144
      selected #23153
      june #23240
      surgical resection #23266
      aged neoplasm #23452
      persistent #23460
      term #23463
      represent #23526
      antibodies monoclonal #23543
      comprehensive #23553
      continuously #23560
      remained #23674
      classified #23739
      body #23757
      strong #23813
      monoclonal #23861
      physical #23883
      gastrointestinal #23900
      exclude #23924
      2011 #23997
      2017 #23997
      severely #24141
      median follow #24342
      partial #24353
      abnormal #24383
      systemic #24466
      recruited #24477
      general #24560
      dietary #24683
      1996 #24713
      carcinoma #24787
      susceptible #24878
      providing #25068
      acids #25078
      consistent #25119
      implemented #25293
      attributed #25373
      17 #25476
      early #25506
      markedly #25526
      inhibition #25536
      free #25571
      lymph #25627
      international #25729
      regional #25737
      sought #25746
      selective #25748
      0003 #25751
      single #25859
      mechanism #26084
      unclear #26339
      putative #26419
      surgery #26438
      13 #26589
      unknown #26785
      electronic #26810
      predisposition disease #26997
      accompanied #26998
      multiple #27050
      follow studies #27065
      polymorphism single #27142
      united #27151
      histologically #27323
      inherited #27404
      neoplasm proteins #27717
      prognosis retrospective #27768
      systematic #27775
      functional #27808
      0005 #28001
      predisposition #28007
      preoperative #28036
      skeletal #28185
      longitudinal #28189
      estimated #28229
      leads #28238
      missing #28264
      acid #28356
      anti inflammatory #28360
      correlate #28365
      larger #28581
      sex factors #28629
      causing #28688
      sensitivity #28740
      vary #28851
      11 #28869
      matched #28979
      represents #29258
      detection #29343
      active #29413
      differentiate #29510
      objectives #29543
      completely #29721
      factual #29750
      databases factual #29793
      varied #30036
      excluded #30077
      quantified #30091
      occurs #30143
      adjusted #30189
      logistic #30241
      underlying #30508
      allowed #30520
      national #30765
      odds #30909
      001 #30996
      regression #31005
      unchanged #31053
      separately #31068
      characterize #31283
      recombinant #31415
      adolescent #31473
      dose dependent #31787
      age #31875
      lacking #31939
      attenuated #31971
      lower #32078
      correlated #32273
      postoperative #32309
      negative #32666
      growth factor #33089
      positive #33861
      understood #33957
      confirmed #33982
      reduced #34048
      implicated #34054
      confidence #34153
      defined #34517
      occur #34659
      requires #35112
      directly #35347
      followup #36532
      diagnosed #36787
      suggesting #37604
      remains #37899
      multivariate #38132
      independent #38886
      measured #38991
      proto oncogene #39186
      proto #39814
      biomarkers tumor #39899
      examined #40295
      retrospective studies #42973
      underwent #43365
      95 confidence #44196

       

      Prominent publications by Charles L Loprinzi

      KOL-Index: 16482

      Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.

      Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.

      Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...

      Kjent for Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events
      KOL-Index: 16399

      Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...

      Kjent for Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed
      KOL-Index: 13693

      PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.

      PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...

      Kjent for Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline
      KOL-Index: 13389

      BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...

      Kjent for Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice
      KOL-Index: 13187

      PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.

      PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...

      Kjent for Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate
      KOL-Index: 12870

      To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...

      Kjent for Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake
      KOL-Index: 12824

      PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.

      PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...

      Kjent for Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis
      KOL-Index: 12701

      OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.

      METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...

      Kjent for Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase
      KOL-Index: 12639

      BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.

      METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...

      Kjent for Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma
      KOL-Index: 12619

      BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.

      OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).

      DESIGN: Blinded, multicenter, cross-sectional study.

      SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.

      PARTICIPANTS: 4482 ...

      Kjent for Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity
      KOL-Index: 12464

      PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.

      PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...

      Kjent for Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year
      KOL-Index: 12354

      PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...

      Kjent for Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment
      KOL-Index: 12321

      BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...

      Kjent for Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo

      Nøkkelpersoner for Hot Flashes

      Toppkols i verden
      #1
      Charles L Loprinzi
      hot flashes breast cancer megestrol acetate
      #2
      Robert R Freedman
      hot flashes core body temperature vasospastic attacks
      #3
      Debra L Barton
      hot flashes breast cancer newer antidepressants
      #4
      Jeff A Sloan
      hot flashes lung cancer medical students
      #5
      Paul J Novotny
      hot flashes lung cancer physical activity
      #6
      Janet S Carpenter
      hot flashes breast cancer menopausal symptoms

      Charles L Loprinzi:Ekspertvirkning

      Konsepter somCharles L Loprinzihar direkte innflytelse:Hot flashes,  Breast cancer,  Megestrol acetate,  Peripheral neuropathy,  Scrambler therapy,  Phase iii,  Newer antidepressants,  Hot flash.

      Charles L Loprinzi:Kol Impact

      Konsepter relatert til arbeidet til andre forfattere somfor which Charles L Loprinzi har innflytelse:Breast cancer,  Hot flashes,  Adjuvant chemotherapy,  Quality life,  Weight loss,  Oral mucositis,  Neuropathic pain.


       

      Tools

      Er dette profilen din? manage_accounts Krev profilen din content_copy Kopier url code Legg inn lenke til profilen din


      Mayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: cloprinzi@mayo.edu. | Mayo Clinic, R

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL gir ikke medisinsk råd, diagnose eller behandling.